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ABSTRACT
Many believe that vaccines are the intervention with the greatest chance of reducing the 
worldwide burden of malaria. Irradiated sporozoites protect against subsequent malaria 
challenge, and a vaccine that mimics this stage might be effective. CD4 and CDS T cells 
are thought to be crucial in protection, but studies of T cell immunity in malaria exposed 
donors are hampered by widespread nonresponsiveness, to malaria antigens. Most studies 
of natural T cell immunity measured lymphoproliferation alone, but I found that if 3 T cell 
assays were employed simultaneously (proliferation, overnight IFN-y ELISPOT, and IFN-y 
ELISPOT after 14 days culture), that T cell reactivity to circumsporozoite protein (CS) 
was considerably higher than when using proliferation alone. Responses to individual 
epitopes failed to correlate over the 3 assays, suggesting that they detect different memory 
T cell subsets. I investigated the nature of responder cells in the 3 assays, and found ex- 
vivo ELISPOT responses were mediated by CCR7* and cultured ELISPOT by CCR7+ cells. 
I also found a CD4+CD38+ T cell subset that suppressed lymphoproliferation, and might 
contribute to malaria immunosuppression.
The immunodominant T cell epitope regions of CS are highly polymorphic, and I found 
that altered peptide ligand antagonism operated for variants of a CD4 T cell site. Less 
polymorphic antigens might be better vaccine candidates, one promising candidate being 
thrombospondin related adhesive protein (TRAP). I mapped novel CD4 T cell epitopes in 
TRAP, 16 of which were conserved. I found differences in TRAP T cell reactivity between 
East and West Africans, and adults and children, which is important since these
populations will be recipients of future malaria vaccines. I investigated whether IFN-y 
ELISPOT responses to TRAP correlated with protection, since IFN-y is thought to be the 
mechanism by which T cells exert their protective effect, but no protection was found.
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CHAPTER 1
INTRODUCTION
i . i
MALARIA PERSPECTIVE
Two major breakthroughs in malaria research more than a century ago led to the award of 
Nobel Prizes. One to Alphonse Laveran for his discovery that malaria is caused by a 
protozoan parasite in the blood (Laveran, 1880), and another to Sir Ronald Ross who 
found that malaria is transmitted by mosquitoes (Ross, 1897). Despite such seminal 
discoveries over 100 years ago, we are still not winning the battle against this worldwide 
tyrant. One third of the world’s population remains exposed to the risk of malaria, and 
hundreds of millions of clinical cases occur each year. The vast majority of disease and 
death occurs in sub-Saharan Africa (WHO, 1992), where it is estimated that malaria is 
responsible for up to 2 million deaths a year, mainly in children (WHO, 1995).
Resistance to antimalarial drugs has now been described to almost all those available 
(White, 1998), and continues to increase. Newer treatments are more expensive, and there 
is little impetus for drug companies to invest in developing drugs that will be affordable in 
developing countries. Anophelene mosquito resistance to commonly used insecticides 
precludes the use of large scale vector control programmes, once thought to be an effective 
strategy for malaria control. Permethrin treated bednets are highly effective in reducing 
childhood mortality, however the long term sustainability of such programmes is debatable 
(Snow et a l, 1997). These factors, compounded by inadequate infrastructure and resources 
for delivery and monitoring of control measures, highlight the difficulties involved in the 
fight to control this parasite.
Alternative solutions must be sought, and many believe that malaria vaccines may be the 
intervention with the greatest chance of reducing the worldwide burden of this disease. 
(Doolan and Hoffman, 1997, Kwiatkowski and Marsh, 1997, Miller and Hoffman, 1997).
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Intense research efforts have been made in the last 15 years towards this ultimate goal. The 
studies in this thesis aimed to further our understanding of the development and nature of 
natural immunity in malaria exposed individuals, which in turn might improve the design of 
future malaria vaccines.
1.2
MALARIA LIFE CYCLE (Figure 1.1)
The infected female anophelene mosquito injects the infective sporozoites from her 
salivary glands into the host blood stream at the time of taking a blood meal. It is estimated 
that the mean number of sporozoites injected at any one time ranges between 10 and 100 
(Rosenberg et a l, 1990, Ponnudurai et a l, 1991). These pass to the host liver within 
minutes, and 5-10% of the initial innoculum successfully penetrate hepatocytes and begin 
dividing (Ferreira et a l, 1986a). They form pre-erythrocytic schizonts in which up to 
30,000 daughter cells called merozoites develop. After a minimum of 5% days for P. 
falciparum the merozoites lyse the hepatocytes and enter the red blood cells within the 
hepatic sinusoids (Nardin and Nussenzweig, 1993). The stage from sporozoite inoculation 
to release into the blood stream comprises the pre-erythrocytic stage of infection.
The blood stage commences with the entry of merozoites into host red blood cells. Here 
they divide to become schizonts containing 10-30 merozoites, which subsequently rupture 
and release merozoites into the blood, each of which is capable of entering a host red blood 
cell. This asexual stage leads to an exponential increase in parasites, with up to 10 fold 
increases in parasitaemia every 48 hours. It is the intermittent release of merozoites from 
infected red blood cells which gives rise to the symptoms, and is responsible for the 
cyclical pattern of disease. After a variable period of infection, a small proportion of 
merozoites enter the sexual stage by differentiating into gametocytes within red blood cells 
as male (micro-) gametes and female (macro-) gametes. If ingested by a feeding mosquito, 
they enter the mosquito midgut where they mature and fuse to form zygotes.
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Figure 1.1
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Zygotes develop into ookinetes which invade midgut epithelial cells and develop into 
thousands of sporozoites. These enter salivary glands from whence they transmit infection 
when the mosquito feeds on a human host (Sinden et a l, 1996).
1.3 
MALARIA VACCINES
Malaria vaccines may be broadly divided into 3 main groups according to the parasite stage 
they are targeted at: pre-erythrocytic stage, blood stage and sexual stage. Different antigens 
are expressed at each of these stages, and an effective vaccine may need to combine 
antigens from each stage. Many conventional vaccines against infectious diseases use live 
attenuated or inactivated organisms. This strategy is not applicable to malaria vaccine 
design since it is not logistically possible to produce sufficient attenuated organisms. The 
rapid development of molecular technology and genome mapping in recent years has 
opened up the possibility of constructing malaria epitope and antigen based vaccines, and 
the race is now on to develop a recombinant vaccine that works.
1.3.1 
Pre-erythrocytic Stage Vaccines
The rationale for development of pre-erythrocytic stage vaccines is based upon early 
observations in the murine model and humans that injection with radiation attenuated 
sporozoites can induce sterile protection against subsequent malaria challenge 
(Nussenzweig et a l, 1969, Clyde et a l, 1973, Clyde et a l, 1975, Rieckmann et a l, 1979). 
Irradiated sporozoites develop only partially inside hepatocytes (Sigler et a l, 1984), and 
do not mature fully or produce blood stage infection. The protection is not strain specific, 
and lasts at least nine months in humans (Hoffman et a l, 1996). Sporozoite production on 
a large scale is not feasible, but a vaccine that mimics the sporozoite effect is thought to be 
an achievable goal.
It is probable that irradiated sporozoites induce immunity against hundreds or thousands 
of antigens, which may explain why protection is heterologous in nature. Extensive efforts
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have focused on identifying the antigenic targets at the pre-erythrocytic stage, and 
characterising the nature of the protective immune response. Numerous pre-erythrocytic 
antigens have now been identified, although most effort has focused on just one pre- 
erythrocytic antigen called the circumsporozoite (CS) protein. As new pre-erythrocytic 
antigens emerge, and new vaccine strategies are developed, the possibility of developing an 
effective vaccine against this stage increases.
A fully effective pre-erythrocytic vaccine, that prevents the development of the 
symptomatic blood stage, might be highly suitable for the non-immune traveller. However, 
such a vaccine might not be suitable for naturally exposed donors in areas of intense malaria 
transmission, where adults are semi-immune. A totally effective pre-erythrocytic vaccine 
would prevent the development of this natural immunity, and if pre-erythrocytic 
immunity waned with time, a vaccination programme could paradoxically lead to an 
increase in the incidence of severe disease and death. However, a partially effective pre- 
erythrocytic vaccine might reduce the number of parasites reaching the blood stage, thus 
reducing the parasite burden, and possibly reducing mortality as a result of decreased 
parasite loads, whilst allowing immunity to develop.
1.3.2
Blood Stage Vaccines
The blood stage is able to progress exponentially in the unprotected host, leading to the 
symptoms of fever and rigors, and later more serious complications such as anaemia, coma, 
renal failure and death. Many of the life threatening complications are thought to be due to 
sequestration of the parasite in tissue microvasculature where they cause obstruction and 
destruction due to the release of harmful cytokines and inflammatory mediators.
Vaccines designed against the blood stage aim to prime the individual against blood stage 
antigens in an attempt to contain the disease and prevent exponential parasite growth. The 
primed response can then be boosted by infection, thereby controlling disease progression 
before more serious complications develop. This would be rather like the state of natural
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immunity which develops in those who are exposed throughout their lives, since they often 
carry blood stage parasites, but have no symptoms of disease. The goal of a blood stage 
vaccine would thus to be to prevent disease rather than infection. Unfortunately there has 
been reluctance to invest money into blood stage vaccine development for use in humans 
because they do not provide sterile protection, and are of little use to the “at risk” traveller. 
There is little commercial interest in a vaccine designed exclusively for use in the 
developing world, and hence little motivation to take such products to human trials.
Early experiments demonstrated that monkeys immunised with P. knowlesi merozoites in 
complete Freund’s adjuvent can rapidly clear homologous and heterologous blood stage 
challenge (Mitchell et a l, 1975). Blood stage protection is mainly antibody mediated, but 
both IFN-y production and T cell proliferation in response to blood stage antigens are also 
associated with protection (Miller et a l, 1998, Good et a l, 1998). Numerous antigens are 
expressed throughout the blood stage of infection and have differing roles in the life cycle. 
Obvious targets are those expressed on the merozoite surface, and those released by the 
merozoite during red blood cell invasion (attachment, orientation and penetration). The 
most intensively studied blood stage vaccine candidate is merozoite surface protein-1 
(MSP-1) which is the major surface protein on the merozoite (Holder and Freeman, 1982, 
Holder and Blackman, 1994). Antibodies against a specific region of MSP-1 have been 
shown to correlate with protection against clinical episodes of malaria in naturally exposed 
donors (Egan et a l, 1996).
Parasitisation of red cells leads to a change in the antigens expressed on the red cell surface 
and the red cell structure (Crandall and Sherman, 1994). Infected red cells bind to the 
endothelium in a receptor-specific manner to prevent them from being killed on passing 
through the spleen. P. falciparum erythrocyte membrane protein 1 {Pf EMP1) is the 
molecule primarily involved in binding to vascular endothelium, and would seem to 
represent an ideal vaccine candidate antigen. Unfortunately the parasite has developed an 
extraordinary capacity for phenotypic variation of P/EMP1 with up to 150 copies per 
parasite genome (Su et a l, 1995, Smith et a l, 1995). Reactivity in naturally exposed donors
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to P/EMP1 is variant specific, and while this huge variation provides an excellent immune 
escape mechanism for the parasite (Bull et a l, 1998), it makes P/EMP1 a less than ideal 
vaccine candidate. Since the variant gene family that encodes P/EMP1 has been cloned 
(Baruch et al., 1995, Su et a l, 1995), the hope is to find relatively conserved regions to 
which Abs might be induced. The transitory nature of expression of many of these ligands 
make them less than ideal as vaccine candidates, and no protein has yet been identified that 
is continually expressed on the surface of merozoites and involved in signalling.
Patarroyo and colleagues developed a vaccine called SPf66 comprised of 3 putative blood 
stage antigen peptides and the NANP peptide from the circumsporozoite protein 
(Patarroyo et a l, 1987). Studies in Columbian adults and children (Valero et a l, 1993) and 
in Tanzanian children (Alonso et a l, 1994) suggested that the vaccine can prevent 
approximately one third of clinical episodes of malaria, but subsequent field trials in The 
Gambia, Thailand and Tanzania failed to substantiate these protective effects in children 
(d'Allesandro et a l, 1995, Nosten et a l, 1996, Acosta et a l, 1999).
1.3.3 
Sexual Stage Vaccines
Antibodies are generated against gametocyte antigens during the course of natural infection 
(Graves et a l, 1990), and it is possible to immunise the mammalian host against the sexual 
stage (Carter and Chen, 1976, Gwadz, 1976). Sexual stage or transmission-blocking 
vaccines contain gamete, zygote and ookinete surface proteins and ookinete secreted 
proteins. They induce Abs that are ingested by the mosquito with the blood meal and 
prevent the development of the sexual stages, thus arresting the parasite life cycle within 
the mosquito. Infected humans produce Abs to a 230 kDa gametocyte antigen which has 
been correlated with suppression of inactivity in mosquito feeding experiments (Quakyi et 
al, 1987), but whether this response reduces malaria transmission in the field is not 
known.
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These vaccines will not prevent the disease process in the person being vaccinated, but will 
block the transmission of parasite from the infected host. As such they are described as 
altruistic vaccines, and are aimed at reducing malaria within the community with no benefit 
for the individual recipient. They could be used to prevent the spread of parasites that are 
drug resistant, or for epidemic control in areas of unstable transmission. They might also be 
useful in eradication programmes in small communities or islands where transmission rates 
are low, probably in combination with other strategies such as insecticide programmes. 
Some argue that sexual stage vaccines might also be of benefit in high transmission areas 
since the reduction in transmission intensity might have a similar impact on morbidity and 
mortality to that seen following the implementation of bednet control programmes (Alonso 
etal., 1991, Snow et a l, 1999).
1.3.4
Malaria Vaccine Field Trials
The final stage in testing a candidate vaccine will require field trials in malaria endemic 
regions to look for protective efficacy. The design and implementation of such studies is 
fraught with problems. Most of the countries where malaria is a major health problem are 
very poor, with little health surveillance infrastructure for assessment of outcomes. 
Transmission blocking vaccine trials are severely limited by the fact that they need to be 
tested in isolated communities where the influx of new mosquitoes is absent. An ideal site 
would be an archipelago of small islands, although the results of such a trial may not be 
relevant to mainland Africa where the malaria burden is greatest.
The design of the trial is the next problem, and even the definition of end points has proved 
challenging. Pre-erythrocytic vaccines, which are intended to arrest development before the 
blood stage, are relatively straightforward to assess compared to blood stage vaccines 
which are designed to reduce the blood stage disease severity. If someone has symptomatic 
malaria then one is ethically obliged to treat them, and thus it is impossible to assess the 
disease prevention efficacy of a blood stage vaccine in the field. Defining a case of malaria 
has proved more difficult than it might at first seem since asymptomatic parasitaemia is
common in high transmission regions, and an episode of fever may be due infection other 
than malaria, even in parasitaemic individuals. The definition of a clinical episode must be 
tailored according to the local epidemiological circumstances (Smith et al., 1994). There is 
the issue of how to assess one of the most important outcomes of vaccine implementation, 
namely the impact on mortality. This requires very large numbers of volunteers, and 
cannot be assessed very easily in a closely monitored population who will be treated each 
time they are found to have symptomatic disease.
The finding that permethrin-impregnated bednets reduce mortality despite an unchanged 
infection rate (Alonso et a l, 1991) highlights the complexity of assessing the impact of 
intervention measures. This is further complicated by the fact that different levels of 
transmission are associated with different patterns of disease (Marsh, 1992, Miller et a l, 
1994, Snow et a l, 1997). Thus, in areas of intense transmission (>100 infectious bites / 
individual per yr), such as parts of Kenya, the major manifestation of severe malaria is 
severe anaemia seen mainly in the first few years of life. In areas of lower transmission 
(<15 infectious bites / individual per yr), such as The Gambia, cerebral malaria in 2 to 4 
year old children is more common. There are concerns that a reduction in the transmission 
rates due to vaccination might even increase the mortality, since there is evidence that 
malaria mortality is lower in high transmission areas (Snow et a l, 1997).
Despite these difficulties, several vaccine candidates have been tested in field studies. The 
only malaria vaccine candidate to reach phase III trials to date is SPf66 (Valero et a l, 1993, 
Alonso e ta l,  1994, dAllesandro e ta l, 1995, Nosten et a l, 1996), and Phase I, Ha and lib 
trials of the candidate vaccine RTS,S are ongoing in The Gambia (Doherty et a l, 1999).
1.4 
PRE-ERYTHROCYTIC ANTIGENS
The studies described in this thesis are of pre-erythrocytic T cell responses, and thus the 
other stages of malaria infection will not be discussed further. The fact that sporozoite 
immunisation is not strain specific, and is efficacious in all humans who receive an optimal
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dose, suggests that the immune response is directed against multiple pre-erythrocytic 
antigens / epitopes. Hence considerable efforts have been made to identify new parasite 
proteins expressed at the pre-erythrocytic stage of infection, which might be incorporated 
into vaccine constructs to enhance the immunogenicity.
Precisely how pre-erythrocytic antigens are recognised by the immune system is not 
completely understood. Sporozoites are injected by the bite of a female Anopheles 
mosquito and quickly localise to the liver sinusoids. Here they must cross the endothelium 
into the space of Disse before entering hepatocytes. Some studies suggest that sporozoites 
are arrested by Kupffer cells in the liver, although the evidence for this is contradictory 
(Sinden and Smith, 1982, Meis et a l, 1983, Hollingdale, 1988, Vreden, 1994). A major role 
for Kupffer cells is unlikely since sporozoites interact poorly with Kupffer cells in vitro 
(Seguin et al., 1989), and Kupffer cell depletion has little effect on sporozoite infectivity in 
vivo (Vreden, 1994). An interaction between sporozoites and macrophages has been 
suggested, and phagocytosis by macrophages may be involved in induction of protective 
immunity at this stage (Danforth et a l, 1980, Vanderberg et a l, 1990).
Sporozoites bind directly to liver cells via two main sporozoite antigens called 
circumsporozoite (CS) protein (Pancake et a l, 1992, Frevert et a l, 1993) and 
thrombospondin related adhesive protein (TRAP) (Müller et a l, 1993, Robson et a l, 
1995) (Figures 1.2A and B). Binding is probably mediated by interactions between region 
II of these antigens and sulphatides (Cerami et a l, 1992b, Cerami et a l, 1992a, Pancake et 
a l, 1992, Frevert et a l, 1993, Müller et a l, 1993), and antibodies to the binding sites 
would provide an ideal site for host immune attack. Invasion occurs apically by 
invagination of the hepatocyte cell membrane to form a parasitophorous vacuole (Aikawa 
e ta l,  1984), and involves the release of substances from the sporozoite rhoptries (Aikawa 
et a l, 1984). Indeed invasion probably involves a cascade of interactions between 
sporozoite and host molecules (Hollingdale et a l, 1993).
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Shortly after invasion the sporozoite starts to break down to create a uninucleated 
trophozoite, the so called exoerythrocytic (EE) form, situated inside the parasitophorous 
vacuole membrane (PVM) (Aikawa et a l, 1984). As the trophozoite develops into the 
mature liver stage schizont, parasite antigens are inserted into the PVM, which forms deep 
invaginations (Atkinson et a l, 1992) particularly adjacent to the parasite nucleus 
(Hollingdale, 1988). Some parasite proteins are also found in the cytoplasm of the infected 
hepatocytes (Hollingdale, 1988, Charoenvit e ta l,  1995). There has been just one report of 
the presence of parasite antigens on the surface of hepatocytes (Rénia et a l, 1990), 
suggesting that antigen presentation does not occur on the surface of the hepatocyte. 
Precisely how pre-erythrocytic antigens are processed and presented to T cells thus 
remains unclear. Many pre-erythrocytic antigens have now been characterised and the main 
ones are discussed below.
1.4.1
Circumsporozoite Protein (CS) (Figure 1.2A)
Circumsporozoite (CS) protein was the first pre-erythrocytic Ag to be identified as a 
target of protective immune responses (Yoshida et a l, 1980), and is certainly the most 
extensively studied. It is the most abundantly expressed Ag on the surface of sporozoites 
(Nussenzweig and Nussenzweig, 1985), and is also found on the micronemes (Fine et al, 
1984, Aikawa et a l, 1990). CS protein is involved in the binding to and invasion of target 
cells (Cerami et a l, 1992a, Pancake et a l, 1992, Frevert et a l, 1993), is shed on entering the 
hepatocyte when the sporozoite invades, and is present on the EE parasite membrane and 
PVM. There is no evidence for transcription, translation or expression of CS protein 
within hepatocytes, and in fact some data suggests the contrary (Atkinson et a l, 1989).
CS protein genes of the different Plasmodium species {Plasmodium falciparum, P. berghei, 
P. cynomolgi, P. knowlesi, P. vivax, P. yoelii etc.) encode proteins of similar structures 
(Figure 1.2A) but limited homology at the nucleotide and amino acid level (Santoro et a l, 
1983). CS proteins have a hydrophobic leader sequence, followed by a central region of 
tandem repeats which are particular to the species.
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Two regions, designated region I and region II, flank the amino and carboxy regions 
respectively of the repeats, and are highly conserved between Plasmodium spp. Region I 
contains basic amino acids and has been implicated in the process of sporozoite/hepatocyte 
recognition (Aley et a l, 1986). Region II contains the sulphatide binding motif (Cerami et 
a l, 1992b, Pancake et a l, 1992, Müller et a l, 1993, Sinnis et a l, 1994) that has been found 
in a growing number of adhesive proteins involved in cell-cell and cell-matrix interactions 
(Lawler and Hynes, 1986, Klar et a l, 1992, Leung-Hagesteijn et a l, 1992). The remaining 
carboxy-terminus of CS protein contains most of the T cell epitopes, which are discussed 
later (Good et a l, 1988d). In the case of P. falciparum these regions are highly 
polymorphic (de la Cruz et a l, 1987, Good et a l, 1988c, Good et a l, 1988d, de Groot et 
a l, 1989), which complicates the use of CS protein in malaria vaccines.
1.4.2
Thrombospondin Related Adhesive Protein (TRAP) (Figure 1.2B)
Thrombospondin related adhesive protein (TRAP) (Robson et a l, 1988), also known as 
sporozoite surface protein 2 (SSP2) (Rogers et a l, 1992), is located in micronemes and 
secretory organelles of sporozoites, and is released onto the sporozoite surface upon 
contact with target cells (Gannt et a l, 2000). TRAP is involved in the gliding motility of 
sporozoites (Sultan et a l, 1997), and their attachment to and entry into hepatocytes 
(Müller et a l, 1993, Robson et a l, 1995). It is also present at the liver stage (Aikawa et al, 
1990), where it is expressed for the first 4 days of infection (Rogers et a l, 1992). TRAP 
may also be expressed at low levels by erythrocytic stages of some strains of P. falciparum 
(Robson e ta l,  1988).
The TRAP family of proteins consists of distinct domains (Figure 1.2B), although the 
precise structure of the molecule has yet to be determined. There is a hydrophobic leader 
sequence, then a conserved motif, followed by a region called the ‘A domain’ (or I domain, 
aa 48-241) which exhibits sequence similarity with a group of proteins including the 
integrins (Let et a l, 1995). Next is a sulphatide binding domain which contains the 
conserved peptide sequence motif (EWSPCSVTCG, aa 249-258) that is found in region II
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of all CS proteins (Dame et a l, 1984, Amot et a l, 1985, Eichinger et a l, 1986, Galinski et 
al, 1987, Lal et a l, 1987b), and a variety of other adhesive proteins such as 
thrombospondin (Lawler and Hynes, 1986) and properdin (Goundis and Reid, 1988). 
Proteins and synthetic peptides containing this sequence bind a variety of sulphated 
glycoconjugates, in particular glycosaminoglycans (GAGs) such as heparin sulphate or 
heparin (Holt et a l, 1989, Sun et a l, 1989, Prater et a l, 1991, Müller et a l, 1993), 
suggesting that this motif confers specific binding properties. TRAP also contains the cell- 
recognition signal RGD (aa 307-309) which is characteristic of many adhesive 
glycoproteins and involved in cell recognition, and an IQQ motif (aa 76-78) which has been 
implicated in cross-linking to factor VIII. The analogous proteins in Eimeria spp. and 
Cryptosporidium parvum are very similar in these 2 regions, and it has been suggested that 
these molecules are involved in the signalling process related to invasion. These are 
followed by the transmembrane domain (aa 512-540 of PfTRAP) and cytoplasmic tail (aa 
541-574) at the carboxy-terminus.
P/TRAP is polymorphic (Robson et a l, 1990, Robson et a l, 1998), although less so than 
CS protein. All nucleotide changes occurring outside the conserved sulphatide binding 
domain result in amino acid changes, and the high ratio of coding to non-coding changes 
implies that these mutations are a direct response to immune selection pressure (Robson et 
ai., 1990). The majority of mutations occur within the ‘A domain’, and few mutations are 
predicted to lead to structural or functional changes (Robson et a l, 1998). However, they 
could alter antigenicity and thereby provide a mechanism of immune evasion by the 
parasite. The same point mutations are found in parasites from different geographic 
locations (Robson et a l, 1998), which may be a reflection of structural constraints which 
limit the repertoire of variants found. Alternatively these mutations may have arisen at a 
bottleneck during evolution before spread to different parts of the world, although 
phylogenetic data for TRAP suggest that it is still evolving (Robson et a l, 1998).
Natural immunity to TRAP has not been studied in detail despite the interest in it as a 
vaccine candidate. The CTL epitopes identified to date are distributed in different regions
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of the molecule, are all conserved, and natural responses occur at very low precursor 
frequencies (Aidoo et a l, 1995, Doolan et a l, 1997, Plebanski et a l, 1997a). No CD4 
epitopes had been identified in TRAP at the time of commencing this thesis.
1.4.3
Other Pre-erythrocytic Antigens 
LSA-1
LSA-1 was the second protein identified in infected hepatocytes (Guérin-Marchand et al,
1987). Expression is detected throughout liver schizogeny and increases as maturation 
progresses, suggesting active synthesis (Fidock et a l, 1994b). It is present in the 
parasitophorous vacuole, and may adhere to merozoites (Fidock et a l, 1994b). The protein 
contains a large central repeat region that is variable in length, and is flanked by relatively 
invariant regions (Fidock et a l, 1994b, Yang et a l, 1995).
PfEXP-1
The mouse homologue of P. falciparum exported protein-1 (P/EXP-1) is P. yoelii HEP 17 
(PyHEP17). The genes for both proteins have now been cloned, revealing striking 
homology between them. A mAb to PyHEP17 (NYLS3) recognises infected hepatocytes 6 
hours after sporozoite invasion, and also recognises ring forms and trophozoites of infected 
erythrocytes (Charoenvit et a l, 1995). During the liver stage PyHEP 17 can be found in 
abundance on the surface of the parasitophorous vacuole and in the cytoplasm. The mAb 
is able to eliminate P. yoe/n-infected but not P. 6erg/zez-infected hepatocytes from in vitro 
culture (Charoenvit et a l, 1995). The pattern of expression of PyHEP17 and P/EXP-1 is 
very similar (Sanchez et a l, 1994).
SALSA
SALSA was identified by screening a set of 120 DNA clones expressing pre-erythrocytic 
antigens against human sera that strongly recognised native proteins on the sporozoite 
surface and in liver stages, but did not recognise CS protein or LSA-1 (Marchand and 
Druilhe, 1990). SALSA is present on sporozoites and is actively synthesised and 
expressed in the liver stage. No homology has yet been found between SALSA and any 
other human or rodent Plasmodia spp.
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STARP
The sporozoite threonine- and asparagine-rich protein (STARP), cloned by Fidock and 
colleagues in 1994 (Fidock et a l, 1994a), is present on all sporozoites of P. falciparum 
(Fidock et a l, 1994c) in an unusual nonhomogeneous distribution. The gene was identified 
using the same method as for SALSA detailed above (Marchand and Druilhe, 1990). 
Immunofluorescence studies support the presence of STARP at the liver stage. The 2-kb 
gene encodes a mosaic of multiple motifs and tandem repeats. Many repetitive and non 
repeat regions are conserved (Fidock et a l, 1994c), and DNA hybridization and probing 
reveals similar conserved genes for P. yoelii and P. berghei, but no homology with P. vivax. 
LSA-3/RESA
LSA-3 or RES A (ring-infected erythrocyte surface antigen) is an abundant 205-kDa protein 
expressed at sporozoite, liver and blood stages, with the same distribution as LSA-1 during 
the liver stage. The gene shows polymorphism in the number of repeats, but not sequence. 
Heat shock proteins
Two members of the heat shock protein family have been cloned from P. falciparum, 
namely hspVO (Bianco et a l, 1986, Yang et a l, 1987) and a glucose regulated protein 
GRP78 (Kumar et a l, 1988, Kumar and Zheng, 1992). They are expressed following 
invasion of hepatocytes (Kumar et a l, 1993), but not by sporozoites themselves. P/hsp70 
was localised in the nuclei and cytoplasm of EE parasites, and GRP78 was found in their 
nuclear membranes and endoplasmic reticulum (Kumar et a l, 1993). P/hsp60 has now been 
cloned and is implicated in protective yÔ T-cell responses (Tsuji et a l, 1994).
CSP-2
Sera and a mAb from sporozoite immunised mice recognise a 42/54-kDa antigen designated 
CS protein 2 (CSP-2) localised to the PVM o f P. falciparum and P. berghei EE forms (Sina 
et a l, 1995). CSP-2 has not yet been cloned.
Blood Stage Antigens Expressed in Hepatocytes
Several blood stage antigens are first expressed in infected hepatocytes including P/MSP-1, 
P/EMP2 and rhoptry antigen 1. Their significance as targets of immunity at the liver stage 
has not been established.
16
1.5 
ANTIBODIES & PRE-ERYTHROCYTIC IMMUNITY 
1.5.1 
Antibodies in Animals
Early studies of Ab mediated immunity at the pre-erythrocytic stage of infection focused 
on responses to CS protein. Initial observations in the P. berghei model of rodent malaria 
showed that antibodies alone against CS protein could confer protection (Yoshida et a l, 
1980), and many groups have since demonstrated protective anti-CS Abs in the mouse 
(Potocnjak et a l, 1980, Egan et a l, 1987, Tam et a l, 1990). The immunodominant B cell 
epitope in CS protein recurs in tandem and is highly conserved within each Plasmodia 
species (Godson et a l, 1983, Dame et a l, 1984). However, antibodies are not an absolute 
requirement for protection since p-suppressed (B cell deficient) mice immunised with 
irradiated sporozoites are still protected against challenge (Chen et a l, 1977). There is 
limited data suggesting that antibodies attack antigens present within infected hepatocytes. 
This has been shown for Abs against the heat shock proteins (Rénia et a l, 1990) and 
PyHEP17 (Charoenvit ef a l, 1995). Antibodies may also develop to exoerythrocytic (EE) 
merozoite antigens, and these in turn may block the invasion of red blood cells after 
merozoites are released from hepatocytes.
1.5.2 
Antibodies in Humans
Nardin and colleagues demonstrated in 1997 that naturally exposed humans have Abs 
against sporozoites (Nardin et a l, 1979). There is evidence for a protective role for anti-CS 
Abs in humans (Clyde et a l, 1975, Hoffman et a l, 1986, Schofield et a l, 1987c, Riley et 
a l, 1990), although several studies have now demonstrated that protection does not 
correlate with anti-CS antibody levels in individuals living in high malaria transmission 
regions (Riley et a l, 1990, Hoffrnan et a l, 1987). Antibodies to the extracellular domain of 
TRAP may inhibit infectivity of sporozoites (Müller et a l, 1993), but a more recent study 
suggests that this is not the case (Gannt et a l, 2000). Partially protective antibody 
responses to TRAP have been demonstrated in humans (Scarselli et a l, 1993), and while it
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is probable that anti-TRAP Abs play a role in protection against malaria, field studies 
suggest that they are unlikely to induce sterile immunity.
1.5.3
Antibody Inducing Vaccines In Animals & Humans
Anti-CS Ab inducing vaccines had variable success in the murine model (Egan et al., 1987, 
Lal et al., 1987a, Zavala et al., 1987), although one study showed unequivocal protection 
(Zavala et a i, 1987). Initial attempts to develop an anti-sporozoite vaccine in humans 
focused on inducing Ab responses to CS protein. These first-generation malaria vaccines 
looked promising in preliminary trials since two of four volunteers with the highest anti-CS 
Ab levels were completely protected (Ballou etal., 1987, Herrington et a i, 1987), although 
only two out of nine individuals vaccinated were protected overall. Several studies have 
now demonstrated that protection does not correlate with anti-CS antibody levels in 
volunteers immunised against CS protein (Stoute et a l, 1997). In fact no vaccine has been 
reliably able to induce sterile immunity in humans based on the induction of anti-CS 
antibodies alone (Nardin and Nussenzweig, 1993, Stoute et a l, 1997, Good et a l, 1988a, 
Herrington et a l, 1991).
The protective effect of immunising with irradiated sporozoites vanishes if the sporozoites 
are irradiated too heavily. This suggests that sporozoites invade the hepatocytes in order 
to elicit protective immunity, and that immunological functions other than Ab production 
are involved in protection. Moreover, B cell deficient irradiated sporozoite immunised mice 
are able to spontaneously clear malaria parasites and resist infection (Chen et a l, 1977). 
Nevertheless, a pre-erythrocytic vaccine is likely to include Ab inducing B cell epitopes, 
and thus optimal Ab induction remains an important goal. As adjuvents and vaccine 
constructs become more immunogenic, very high Ab levels look achievable and are certain 
to contribute to protection. The CS protein based vaccine RTS,S/SBAS2 has now been 
shown to induce high anti-CS Ab levels both in naïve volunteers and naturally exposed 
populations (Stoute et a l , 1997, Doherty et a l, 1999).
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1.6
CD8+ T CELLS & PRE-ERYTHROCYTIC IMMUNITY
Precisely how antigen is processed and presented for class I recognition at the pre- 
erythrocytic stage of infection is not fully understood. Nearly all nucleated cells express 
MHC class I, so if infected can present Ag to CD8+ T cells. MHC class I can be expressed 
on the surface of hepatocytes, although only one study has demonstrated surface 
expression of a liver stage antigen (Rénia et a l, 1990). The possible role of Kupffer cells 
lining the liver sinusoids, and macrophages, in processing and presentation of sporozoite 
derived antigens has been discussed above. Liver endothelium and circulating dendritic cells 
may also play a role in class I restricted antigen processing and presentation of liver stage 
antigens.
1.6.1
IFN-y Mediated Cytotoxicity
The “classic” pathways of CD8+ T cell mediated cytotoxicity involve either the release of 
perforin / granzyme, or an interaction between the target cell surface receptor called Fas 
(CD95) and it’s ligand on the effector cell called Fas ligand (CD95L). Both pathways lead 
to apoptosis and target cell death (Kâgi et a l, 1994, Lowin et a l, 1994). However, 
protection can be independent of conventional cytotoxic mechanisms. Thus, sporozoite 
immunisation of perforin and Fas deficient knock out (KO) mice induces protection against 
P. berghei infectious sporozoite challenge. (Renggli et a l, 1997). It is now believed that 
IFN-y mediated cytotoxicity is the most important means of cytotoxic elimination of 
infected hepatocytes.
IFN-y has been shown to inhibit the development of EE forms parasites both in vitro and 
in vivo in the murine and simian models (Ferreira et a l, 1986b, Schofield et a l, 1987a, 
Mellouk et a l, 1991), and the protective immunity conferred by irradiated sporozoite 
immunisation can be abrogated by injection of anti-IFN-y mAbs (Maheshwari et a l, 1986, 
Schofield et a l, 1987c). Hepatocytes possess tens of thousands of IFN-y receptors, and it
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is assumed that IFN-y binds to these receptors rendering the hepatocyte incapable of 
supporting the growth of malaria parasites (Sarkar and Gupta, 1984).
IFN-y is thought to exert its protective effect via the induction of reactive nitrogen 
intermediates, in particular nitric oxide (NO). Addition of different inducible nitric oxide 
synthase (iNOS) inhibitors both in vitro and in vivo reverses the protection generated by 
attenuated sporozoites (Mellouk et a l, 1991, Nüssler et a l, 1993, Seguin et a l, 1994, 
Klotz et a l, 1995). Nitric oxide mediated antiplasmodial activity can be demonstrated in 
vitro in both murine and human hepatocyte cultures (Mellouk et a l, 1994). Mice treated 
with anti-IFN-y mAb prior to sporozoite challenge failed to produce iNOS in their livers, 
suggesting that the induction of NOS is IFN-y dependent (Seguin et a l, 1994). Inducible 
nitric oxide synthase expression in livers following sporozoite challenge is limited to 
infected hepatocytes, and depends on the persistence of irradiated parasites within the 
hepatocytes (Klotz et a l, 1995, Scheller and Azad, 1995). Mice lacking the IFN-y receptor 
(IFN-yR0/0) are not protected by a single injection of P. yoelii irradiated sporozoites, 
whereas wild type mice are protected and express high levels of iNOS mRNA in their liver 
(Tsuji et a l, 1995). However, a second injection restored protection suggesting that other 
mechanisms may also play a role in protection at the pre-erythrocytic stage.
Both CD4 and CD8 T cells are thought to mediate their protective effect via the 
production of IFN-y. T cell responses against malaria are generally a (3 T cell mediated, but 
yô T cells can also have significant activity against infected hepatocytes (Tsuji et a l, 1994, 
Langhome e ta l,  1995, Rzepczyk et a l, 1997). Natural killer (NK) cells might also have a 
protective effect (Doolan and Hoffman, 1999), although their precise role remains unclear. 
Despite the evidence suggesting a protective role for IFN-y mediated T cell responses, few 
studies of T cell immunity at the pre-erythrocytic stage have assessed for IFN-y 
production and protection. One study found a protective effect for cultured IFN-y 
responses against LSA-1 derived peptides (Luty et a l, 1999), but no studies have assessed 
for protective efficacy in the field using assays that detect rapid IFN-y release by 
ELISPOT assay.
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1.6.2
CDS T Cells in Animals
Early experiments suggested that pre-erythrocytic immunity is dependent on CD8+ T 
cells. Treatment of sporozoite-immune mice with anti-CD8 Ab abrogates their immunity 
(Schofield eZ a/., 1987c, Weiss eZ<2/., 1988), and protective immunity was lost following in 
vivo depletion of CD8+ T cells, but not CD4+ T cells (Schofield et al., 1987c, Weiss et ai, 
1988). CS protein specific CD8+ T cell clones have since been shown to mediate protective 
immunity in mouse models of malaria, even to a single CTL epitope (Romero et al., 1989, 
Weiss etal., 1992). Mice immunised with irradiated P. berghei sporozoites and challenged 
with live sporozoites produce parasite-specific CD8+ T cell-dependent inflammatory 
infiltrates in their livers (Hoffman et al, 1989a). Spleen cells from these mice eliminate 
infected hepatocytes from hepatocyte cultures that are free of Kupffer cells, in a class I 
MHC-dependent and species specific manner (Hoffman et al, 1989a, Hoffrnan et al, 
1990) suggesting that Plasmodium antigens on the surface of infected hepatocytes are 
recognised by T cells leading to killing.
Adoptive transfer experiments demonstrate that CTL against a single 9mer CTL epitope in 
CS protein can confer protection against sporozoite challenge (Romero et al, 1989, 
Romero et al, 1990, Rodrigues et al, 1991, Weiss et al, 1992). Adoptive transfer of a 
CD8+ CTL clone against PySSP2/TRAP protected 100% of mice against challenge 
(Khusmith et al, 1994). Transfer of CD8+ T cell clones 3 hours after sporozoite challenge, 
at a time when the parasites have already entered hepatocytes, can still prevent 
development of blood stage infection (Rodrigues et a/., 1991, Khusmith et al, 1994). There 
is also experimental evidence for a protective role for CTL directed against other pre- 
erythrocytic antigens including LSA-1 and PyHEP17 (EXP1) (Hollingdale et al, 1990, 
Atkinson et al, 1992, Charoenvit et al, 1995).
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1.6.3
CD8+ T Cells in Humans
Sporozoite immunised human volunteers have CD8+ T cell-dependent, peptide specific 
cytolytic activity against a CTL epitope region of CS protein which is homologous to a 
CTL epitope 1st identified in mice (Malik et a l, 1991). Malaria exposed Australians, and 
lifelong exposed Kenyans, were subsequently shown to have peptide specific CD8+ T cell- 
dependent CTL against a similar epitope region of CS (Doolan et a l, 1991, Sedegah et al, 
1992). Several HLA restricted CD8+ T cell epitopes have since been identified in CS, 
TRAP, LSA-1 and STARP in naturally exposed donors from The Gambia (Hill et al, 
1992b, Aidoo et a l, 1995) and Burkina Faso (Blum Tirouvanziam et a l, 1995). Eleven 
novel HLA-A2 restricted epitopes in SSP2 / TRAP were identified in studies of volunteers 
immunised with irradiated sporozoites (Wizel et a l, 1995a, Wizel et a l, 1995b). These 
volunteers had direct cytotoxic activity without the need for in vitro re-stimulation, thus 
demonstrating the presence of circulating activated CTLs against a P. falciparum antigen 
for the first time.
1.6.4
CTL Inducing Pre-erythrocytic Vaccines in Animals
CTL responses are HLA class I restricted, therefore sufficient antigens or epitopes would 
need to be incorporated in a vaccine to cover the range of HLA types present in the 
population to be vaccinated. Indeed, different vaccines may be required for different ethnic 
groups where HLA types vary widely. Stimulation of adequate CTL responses is the next 
logistic problem. Strategies conventionally employed, such as the use of attenuated 
organisms are not practical in the case of malaria, and the current focus of attention is on 
molecular techniques.
A considerable number of CD8+ T cell inducing vaccines have been tested in the mouse 
model of malaria including oral recombinant salmonella (Sadoff et a l, 1988), recombinant 
vaccinia (Satchidanandam et a l, 1991) and pseudorabies (Sedegah et a l, 1990) based 
vaccine constructs expressing CS protein. Most early studies using these constructs failed
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to induce protective CTL, although oral recombinant salmonella achieved 50-75% 
protection against P. berghei challenge (Sadoff et a l, 1988). Immunisation of mice with 
plasmid DNA encoding either CS protein, PyHEPl? or TRAP (SSP2), induced 50-90% 
protection in certain mouse strains, but not in others in a number of separate studies 
(Sedegah et a l, 1994b, Doolan et a l, 1996, Wang et a l, 1998). There are concerns about the 
long term safety of DNA vaccines (Hedstrom et a l, 1990, Mor et a l, 1997), although trials 
in animal models show a good safety record, and human trials have commenced.
Vaccines consisting of combinations of antigens generally give better protection than 
constructs based upon one antigen alone. For example, the combination of transfected P815 
cells expressing P. yoelii CS protein and PySSP2 / TRAP gave full protection (Khusmith et 
al, 1991), and a combination of 2 DNA vaccine constructs encoding PyCS and PyHEPl7 
was more effective than either construct alone (Doolan et a l, 1996). Priming mice with a 
recombinant influenza virus expressing a P. yoelii CS CD8+ T cell epitope, and boosting 
with recombinant vaccinia expressing the whole of P. yoelii CS, increased protection to the 
60% level (Li et a l, 1993). Regimes involving a DNA prime and MVA boost (Schneider et 
al, 1998), or Ty particle prime and MVA boost (Plebanski et a l, 1998), have since 
induced complete protection. Protection in the latter study was highly correlated with the 
induction of high numbers of IFN-y secreting CD8+ T cells detected by ELISPOT assay.
1.6.5 
CTL Inducing Pre-erythrocytic Vaccines in Humans
Over the last 5 years a number of CTL inducing vaccines for use in humans have been 
constructed. These include an oral recombinant salmonella expressing CS protein 
(Gonzalez et a l, 1994), hepatitis B particles carrying part of CS protein (Gordon et a l, 
1995), and attenuated vaccinia expressing several liver stage antigens (Ockenhouse et al, 
1998). Each of these constructs induced CD8+ CTL in certain donors, although only the 
hepatitis B construct showed significant protection in 2 out of 8 volunteers who received a 
certain formulation (Gordon e ta l,  1995).
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There is optimism that DNA vaccination will be a suitable means of inducing protective 
CTL (Hoffman et a l, 1998), and clinical trials are ongoing. It is more likely however that 
methods designed to optimise the DNA vaccination will ultimately be employed such as 
prime-boost strategies which have proved so effective in murine models (Plebanski et a l, 
1998, Schneider et a l, 1998, Sedegah et a l, 1998). Modified vaccinia Ankara (MVA) is a 
highly attenuated strain of vaccinia which was used extensively in humans as past of the 
smallpox eradication campaign, with no serious adverse effects (Mayr et a l, 1978). This 
seems an excellent candidate for use in prime-boost strategies, although many other CTL 
inducing vaccine constructs might be considered including Ty particles (Weber et a l, 1995) 
and adenovirus (Fender et a l , 1997).
A widely applicable CTL inducing vaccine construct would require epitopes or antigens 
recognised by individuals with a variety of HLA types (Doolan et a l, 1996). Use of the P. 
falciparum CTL epitopes reported to date together as a string could provide coverage of 
over 75% of European and West African individuals (Aidoo et a l, 1995). Problems such as 
antigenic polymorphism (Doolan et a l, 1992) and altered peptide ligand antagonism 
(APL) (Gilbert et a l, 1998) must also be overcome in the choice of epitopes and antigens 
(see below).
1.7
CD4+ T CELLS & PRE-ERYTHROCYTIC IMMUNITY
For more than a decade pre-erythrocytic vaccine development focused on the induction of 
high levels of Abs and CD8+ T cells. There is now increasing evidence that CD4+ T cells 
also play an important protective role, which may be as potent as CD8 mediated 
protection. The precise nature of CD4 T cell induced protection is not understood. MHC 
class II is mainly present on the surface of APCs, including Kupffer cells, but needs to be 
induced. It may also be induced and expressed by hepatocytes. IFN-y can induce class II 
expression by endothelial cells, and this may play a role in class II mediated immunity in 
malaria. CD4+ T cells that are remote from the infected hepatocyte might be activated by
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sporozoite derived antigens, or antigens secreted by hepatocytes. These activated CD4+ T 
cells might release cytokines such as IFN-y and kill the parasite infected hepatocytes.
1.7.1
CD4+ T Cells in Animals
The first CD4+ T cell responses to a pre-erythrocytic antigen were described for the P. 
berghei model in 1977 (Spitalny et a l, 1977). Murine studies subsequently showed that 
there is an immunodominant T cell antigenic region on CS protein, denoted Th2R (aa 326- 
343) which falls in a polymorphic domain (Good et a l, 1987). Adoptive transfer of a 
CD4+ cytolytic T cell clone recognising a sporozoite antigen (not CS protein) from 
sporozoite immunised mice confers protection against sporozoite challenge (Tsuji et al, 
1990). CD4+ T cells directed against P. yoelii CS protein have been shown to recognise CS 
protein peptides on the surface of infected hepatocytes, eliminate infected hepatocytes in 
culture, and confer protection in adoptive transfer experiments (Rénia et a l, 1991, Rénia et 
al, 1993, Takita-Sonoda et a l, 1996). The majority of studies demonstrating CD4+ T cell 
activity at the pre-erythrocytic stage of infection in mice have been to CS protein, although 
a more recent study demonstrated CD4+ T cell activity against a P. yoelii 17-kilodalton 
hepatocyte erythrocyte protein (Charoenvit et a l, 1999).
1.7.2 
CD4 T Cells in Humans
The seminal study mapping human CD4 T cell epitopes in CS protein was performed by 
Good and colleagues using PBMC from naturally exposed West Africans (Good et a l, 
1988d). They tested for lymphoproliferative responses to 29 overlapping 20mer synthetic 
peptides spanning the whole of CS protein. Three immunodominant domains denoted 
ThlR (aa 301-320), Th2R (aa 326-345) and Th3R (aa 361-380) were found within the 
highly polymorphic carboxy-terminus of CS protein. One of these domains overlapped the 
mouse T cell helper epitope region Th2R (aa 326-343), identified in studies as a helper 
epitope for P. falciparum anti-CS Ab production (Good et a l, 1987). Indeed, the human
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CD4+ T cell epitope regions in the carboxy-terminus of CS seem to correspond with those 
found in the murine model (Dontffaid et a l, 1988).
Sinigaglia and colleagues identified another immunodominant region in CS protein denoted 
CS.T3 (aa 379-398) (Sinigaglia et a l, 1988a). They selected 3 peptide sequences (CS.T1, 
CS.T2, CS.T3) predicted to contain T cell epitopes, and tested for lymphoproliferative 
responses in 16 malaria exposed (Ivory Coast) and 6 malaria naïve individuals. Nine of the 
16 malaria exposed individuals responded to CS.T3, and all 3 peptides induced responses 
in some donors. T cell clones to CS.T3 were derived from one of the responders, and the 
cells were found to be CD4 CD8", and required specific class II haplotypes for effective 
antigen presentation (Sinigaglia et a l, 1988a). Three of the CS.T3 clones recognised P/CS 
protein purified from sporozoites. Four of the 6 malaria naïve donors also responded to at 
least one peptide. This might be explained by the presence of cross-reactive epitopes with 
other microorganisms arising at these regions of the CS protein.
Field studies in Kenyans showed that lymphoproliferative responses to two T cell epitope 
regions in the carboxy-terminus of CS protein (aa 361-380; aa 371-390), the former being 
the Th3R epitope, significantly correlate with resistance to re-infection with malaria 
(Hoffman et a l, 1989b). However the numbers were very small in the non-parasitaemic 
group, and the evidence for protection is not compelling. Riley and colleagues assessed 
lymphoproliferative responses to 3 polymorphic strains of the Th2R and Th3R regions of 
CS protein in 391 Gambian children aged 3 to 8 years. They were unable to confirm the 
protective effect of the Th3R epitope observed by Hoffrnan and colleagues, but did find a 
protective association between lymphoproliferation to this epitope at the beginning of the 
transmission season and subsequent susceptibility to infection among those children with 
high anti-CS Ab levels (Riley e ta l,  1990). Thus, seropositive children who did not become 
infected had a higher mean proliferative response to the Th3R region than seropositive 
children who did become infected.
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CD4+ CS-specific CTL have also been demonstrated in sporozoite immunised humans 
(Moreno et a l, 1991, Moreno et a l, 1993). These studies identified DR1-, DR4-, DR7- 
and DR9-restricted distinct T cell epitopes within aa 326-345 of P. falciparum CS protein, 
all of which have been cloned. CD4+ T cell clones from these studies specifically lysed 
autologous B cells pulsed with a synthetic peptide representing the C-terminal region of 
CS protein (Moreno et a l, 1991). CD4 epitope regions have now been identified in several 
other pre-erythrocytic antigens including LSA-1 (Fidock e / <3/., 1994b, Krzych et a l, 1995, 
Yang e ta l,  1995), LSA-3 (BenMohammed e ta l,  1997), and SALSA (Bottius et a l, 1996). 
No CD4 T cell epitopes have been identified within TRAP, despite the fact that this is 
currently considered a good vaccine candidate antigen.
1.7.3
Thl and Th2 CD4+ T Cell Dichotomy
CD4+ T cells can be broadly divided into 2 functional groups named T helper type 1 (Thl) 
and T helper type 2 (Th2) (Mosmann and Coffman, 1987, Mosmann and Coffman, 1989), 
although other subgroups are now known to exist (Groux et a l, 1997). These 2 groups are 
characterised by distinctive patterns of cytokine release, and different immunological 
functions (Figure 1.3). Thl CD4+ T cells produce cytokines such as IFN-y, IL-2 and 
TGF(3; whereas Th2 CD4+ T cells are typified by the production of IL-4 and IL-5, with 
other cytokines such as IL-10 and IL-13 also commonly produced. Thl cytokines activate 
cytotoxic, inflammatory and delayed hypersensitivity reactions. By contrast Th2 cells 
encourage Ab production, particularly IgE, and are associated with regulation of Ab and 
allergic responses. Cytokines from Thl cells inhibit Th2 cells, and vice versa, and thus 
most CD4 T cell responses settle into a Thl or Th2 type pattern. This Thl/Th2 
dichotomy depends on a number of factors including antigen dose, local cytokine profile, 
and activation of co-stimulatory molecules.
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Figure 1.3
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CD4 T cells can be broadly divided into Thl and Th2 types, each with distinct effector functions. 
Thl type cytokines include IFN-J, TNF-fi, IL-3 and 1L-12. Th2 type cytokines include IL-4, IL-5, 
IL-6, IL-10 and IL-13.
The protective CD4+ T cell response at the pre-erythrocytic stage of malaria infection is 
thought to be mediated by the Thl type cytokine IFN-y. The evidence that IFN-y is 
responsible for T cell mediated cytotoxicity in protection at the pre-erythrocytic stage of 
malaria infection was discussed earlier in relation to CD8+ T cells (section 1.6.1). The same 
mechanisms are thought to be responsible for CD4+ T cell mediated protection against 
malaria. Thus, IFN-y release by Thl type CD4+ T cells leads to induction of reactive 
nitrogen intermediates, in particular nitric oxide (NO), via the nitric oxide synthase 
pathway, which in turn kill the infected hepatocytes. However, there is a fine balance 
between the production of a protective inflammatory response, and that response being 
destructive (Hirunpetcharat e ta l,  1999).
Administration of recombinant IL-12, another Thl type cytokine, to mice and rhesus 
monkeys provides 100% protection against sporozoite challenge with P. yoelii and P. 
cynomolgi respectively (Sedegah et a l, 1994a, Hoffman et a l, 1997). The protection in 
mice is entirely eliminated with mAb to IFN-y, and is eliminated in 50% of mice by 
administration of an iNOS inhibitor. It is thought that IL-12 induces T cells and NK cells 
to produce IFN-y, which induces infected hepatocytes to produce the NO that kills 
developing parasites (Sedegah et a l, 1994a).
There is evidence that Th2 type responses play a regulatory role at the blood stage of 
malaria infection (Troye-Blomberg et a l, 1990, Stevenson and Tam, 1993, Taylor- 
Robinson et a l, 1993, al-Yaman et a l, 1997), but few studies have assessed for the 
production of Th2 type cytokines at the pre-erythrocytic stage of malaria infection in 
animals (Rénia et a l, 1993, Takita-Sonoda et a l, 1996) or humans (Doolan et a l, 1994, 
Kurtis et a l, 1999). The inhibitory effects of the Th2 type cytokine IL-6 on intrahepatic 
development of human and murine parasites have been reported (Pied et a l, 1991), and 
high levels of peptide specific IL-6 production to CS protein is observed in naturally 
exposed donors from Papua New Guinea (Doolan et a l, 1994). An inverse correlation 
between IFN-y and IL-6 production was noted in this study, which is typical of the 
Thl/Th2 dichotomy discussed above.
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Th2 type CD4+ T cell clones can eliminate liver stage parasites in vitro and in vivo in the 
mouse model of malaria (Rénia et al., 1993). Th2 type CD4+ T cell clones can also provide 
protection against murine P. c. chabaudi infection in adoptive transfer experiments, 
probably via the enhancement of IgGl production (Taylor-Robinson et a l, 1993). Th2 
type T cells may also have a regulatory role by downregulating the Thl type IFN-y 
mediated inflammatory response. A role for IL-10 producing cells at the pre-erythrocytic 
stage of infection remains controversial . IL-10 downregulates Thl type responses 
(Mosmann and Moore, 1991), and thus while it may prevent the induction of protective 
responses, it may also control the pro-inflammatory response leading to host tissue 
damage (Kurtis et a l, 1999, Li et a l, 1999). Thus, although Th2 type CD4+ T cell 
responses have been described at the pre-erythrocytic stage, the main bias is towards a 
protective Thl type response characterised by the production of IFN-y. Indeed, the 
contribution of Th2 type responses to pre-erythrocytic stage immunity in humans remains 
poorly characterised.
1.7.4 
CD4 T Cell Inducing Vaccines in Animals
BALB/C mice immunised with a multiple antigen peptide known to contain a protective 
CD4+ T cell epitope from P. berghei CS protein were protected against subsequent 
sporozoite challenge (Migliorini et a l, 1993). Several further studies have similarly shown 
CD4+ T cell peptide specific protection following immunisation with CS derived peptides 
(Takita-Sonoda et a l, 1996, Charoenvit et a l, 1999). A vaccine based upon an 18 amino 
acid peptide from PySSP2/TRAP in an anionic polymer adjuvent provides 100% 
protection in A/J mice, but little protection in 2 other strains (Wang et a l, 1996). The 
immunity is eliminated by in vivo addition of anti-CD4 Abs, but not anti-CD8 Abs. 
Microscopic analysis of the livers indicate that immunity is directed against the infected 
hepatocytes and eliminated by treatment with anti-IFN-y. In vitro studies have shown that 
this peptide activates only a Thl type T cell response, and that protection is better than
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that found with any univalent vaccine designed to induce protective CD8+ T cell 
responses.
1.7.5 
CD4 T Cell Inducing Vaccines in Humans
A CS protein based vaccine called RTS,S protected 6 out of 7 malaria naïve volunteers 
against subsequent malaria challenge (Stoute et al., 1997). This vaccine consists of a hybrid 
of the central NANP repeat region, most of the carboxy-terminus of CS (containing the 
main T cell epitope regions) fused to hepatitis B surface Ag in a complex adjuvent mixture 
(SBAS4). The anti-CS Ab levels induced were very high in most cases but did not correlate 
with protection in these donors. RTS,S induced high levels of IFN-y secreting CS-specific 
CD4+ T cells, and no CD8+ T cell responses were detectable (Stoute et a l, 1997, Lalvani et 
al. y 1999). The CD4+ T cell responses induced by RTS,S are thought to play a role in the 
protection seen in vaccinees. Phase I field trials are now complete (Doherty et a l, 1999), 
and Phase II field trials are currently underway in The Gambia. This is the first pre- 
erythrocytic stage vaccine to go to field trials in a malaria endemic population.
Thus, vaccine development has mainly focused on the induction of CD8+ T cell responses 
to pre-erythrocytic stage antigens, despite clear evidence for a protective role for CD4+ T 
cells. CD4 T cell induction is now regarded as a useful component in malaria vaccine 
design. Several CD4+ T cell epitope regions have been identified within CS protein, but 
they mainly fall within highly polymorphic regions of the antigen. Any new CD4+ T cell 
epitopes identified within other more conserved pre-erythrocytic antigens such as TRAP 
might therefore be useful components of a future malaria vaccine, particularly those that 
are conserved.
1.8
OTHER CYTOKINES & PRE-ERYTHROCYTIC IMMUNITY
In addition to the protective role for the Thl type cytokine IFN-y, and a putative role for 
Th2 type responses mediated by IT-4, IL-5 and IT-10, there is evidence to suggest that
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other cytokines are also protective (Del Giudice et a l, 1990, Nüssler et a l, 1991a). The 
inhibitory effects of IL-1 on intrahepatic development of human and murine parasites have 
been reported (Mellouk et a l, 1987). Tumour necrosis factor (TNF) inhibits the 
development of P. berghei in vitro in a hepatoma cell line (Schofield et a l, 1987b), but not 
P. yoe/n-infected hepatocytes (Mellouk et a l, 1991, Nüssler et a l, 1991b). In co-cultures 
of hépatocytes and nonparenchymal cells, TNF has been shown to inhibit parasites by 
inducing nonparenchymal cells to release IL-6 (Nüssler et a l, 1991a, Nüssler et a l, 1991b).
The concept of an anti-toxic vaccine is based upon the observation that individuals who are 
frequently exposed to malaria suffer few symptoms, but remain susceptible to infection 
(Playfair et a l, 1994). Many immune processes are probably at play here, including the 
acquisition of Abs to tumour necrosis factor (TNF-)-inducing parasite toxins (Bate and 
Kwiatkowski, 1994). Parasite antigens probably induce a variety of cytokines, and the 
critical matter is the fine balance between a protective response, and one that is harmful. It 
is important not to suppress the host’s natural cytokine response to infection to an extent 
that gives increased susceptibility to the parasite (Kwiatkowski, 1995).
1.9 
HLA & PRE-ERYTHROCYTIC IMMUNITY
Several studies suggest that malaria plays a role in the maintenance of MHC 
polymorphism. Thus, different MHC alleles are thought to provide varying degrees of 
protection against malaria due to restriction of T cell recognition of malaria antigens to 
certain HLA types. Hill and colleagues demonstrated that the HLA class I antigen HLA- 
B*53, and the HLA class II haplotype DRB1 * 1302-DQB1 *0501, are associated with 
reduced susceptibility to severe malaria (Hill et a l, 1991). Both of these HLA types are 
more frequent in West Africans than other racial groups, suggesting that natural selection 
by malaria contributed to this elevated frequency.
P. falciparum contains thousands of potential T cell epitopes, each with varying HLA 
restriction patterns. The fact that certain HLA types are protective suggests that many
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responses are probably of limited protective value. In an attempt to identify HLA-B53 
restricted T cell epitopes that might mediate the protective effect of this HLA allele, 60 
putative HLA-B53 binding peptides were synthesised from 4 pre-erythrocytic antigens: 
namely CS protein, TRAP, sporozoite hepatocyte binding antigen (SHEBA) and liver 
stage antigen 1 (LSA-1). Only one HLA-B53 restricted CTL epitope was identified in 
malaria immune Gambians, within the pre-erythrocytic antigen LSA-1, suggesting that this 
epitope may be of protective significance (Hill et a l, 1992b).
HLA types vary widely between the different populations of the world, and there is 
considerable HLA variation between different African ethnic groups (Hill et a l, 1992a). 
Despite this, the effect of this HLA variation on the pattern of T cell epitope recognition 
for pre-erythrocytic vaccine candidate antigens has not been investigated for different 
African populations. Clearly this is important in terms of malaria vaccines designed to be 
widely effective among different ethnic groups.
1.10
MALARIA IMMUNOSUPPRESSION
Widespread nonresponsiveness to malaria antigens has been a consistent feature in field 
studies of T cell responses in naturally exposed populations. Thus, despite a lifetime of 
exposure, T cells specific for both variant and conserved pre-erythrocytic malaria antigens 
are not found consistently in healthy aparasitaemic individuals (Good et a l, 1988d, Riley 
et a l, 1988b, Quakyi et a l, 1989, Troye-Blomberg et a l, 1989, Eposito et a l, 1992, 
Doolan et a l, 1993, Doolan et a l, 1994, Plebanski et a l, 1997a). T cell responses are also 
generally suppressed during the course of malaria infection (Ho et a l, 1986, Theander et 
a l, 1986, Riley et a l, 1988a, Chemtai and Okelo, 1989, Hviid et a l, 1991b). The precise 
mechanisms of such immunological non-responsiveness remain unclear, but a variety of 
mechanisms have been proposed.
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1.10.1
T Cell Tolerance and Anergy
T cell tolerance is classically described as the intrathymic deletion of self reactive T cell 
clones during the neonatal period (Burnet, 1959). It has been proposed that T cell tolerance 
induction might explain generalised non-responsiveness to malaria antigens. There is 
considerable homology between malaria and human Ags (McLaughlin et a l, 1987), and 
these homologous regions eg the thrombospondin like domain in CS protein (Lawler and 
Hynes, 1986) and TRAP (Robson et a l, 1988), are poorly immunogenic. Active tolerance 
induction may occur during the neonatal period, and T cells that respond to those foreign 
proteins or peptides seen at this stage when immunity is developing may be deleted. 
Indeed, T cell tolerance was induced in neonatal mice by immunising with CS protein 
specific T and B cell epitopes (Pombo et a l, 1988). Thus children may be bom with a 
degree of T cell tolerance to malaria proteins in endemic regions of the world.
There is evidence that post thymic mechanisms can lead to tolerance in peripheral T 
lymphocytes. Post thymic tolerance induction may depend on a number of factors 
including the antigen dose (Ferber et a l, 1994), and the route of exposure and frequency of 
dosing (Aichele et al, 1995). If antigen is not presented with the correct co-stimulatory 
molecules, or by professional antigen presenting cells, this may also lead to induction of 
tolerant T cells (Lamb et a l, 1983). Whether this should be described as true tolerance or 
anergy is debatable, since the mechanism is more one of functional silencing of T cells, 
rather than clonal deletion. Therefore anergy might seem a more appropriate description.
The presence of small amounts of antigen on the surface of hepatocytes can lead to T cell 
anergy to that antigen (Ferber et a l, 1994), an effect that may be because hepatocytes lack 
the necessary co-stimulatory molecules to activate T cells successfully. Similarly, 
expression of small doses of pre-erythrocytic antigenic epitopes on the surface of infected 
hepatocytes in naturally exposed donors may be one mechanism whereby malaria specific 
anergy might be induced. Repeated stimulation by normal APC can lead to T cell anergy in 
previously activated T cells (Suzuki et a l, 1988). Since malaria exposure is continuous and
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repeated throughout life, this mechanism may also lead to malaria specific peripheral 
tolerance induction. It has been shown that T cell responsiveness to malaria antigens can be 
restored in PBMC from healthy individuals in vitro by the addition of IL-2 (Mshana et a l , 
1990), and IL-2 is known to reverse T cell anergy in certain cases (Essery et a l, 1988). It is 
feasible that the IL-2 is acting on anergic cells in these donors. The contribution of 
tolerance and / or anergy to the T cell non-responsiveness to pre-erythrocytic malaria 
antigens is still not understood.
1.10.2
‘Original Antigenic Sin’
The concept of ‘original antigenic sin’ describes a process whereby epitope sharing 
between pathogens leads to one pathogen inducing responses before the other pathogen has 
been experienced. When exposure to the second pathogen occurs, a skewed repertoire of 
responses results due to prior exposure to the cross-reactive epitope from the first 
organism. It has been proposed that this mechanism may play a role in the lack of T cell 
reactivity in malaria, despite lifelong exposure (Good et a l, 1993). Malaria antigens contain 
regions homologous to other organisms, and exposure to such non-malaria organisms may 
lead to priming of T cell responses which are cross-reactive with malaria epitopes. Indeed 
many malaria naïve adults have T cells specific for malaria parasites (Zevering et a l, 1992, 
Good et a l, 1993). These cross-reactive T cells may preferentially expand following 
exposure to malaria sporozoites, and thus skew the repertoire of the T cell response. This 
may in turn divert the immune response towards these common epitope regions which 
may not be protective, and away from responses to protective T cell epitopes within the 
antigen.
1.10.3
Immunosuppressive T Cells Subsets
T cell responsiveness can be restored in PBMC from healthy individuals in vitro by the 
removal of supposedly immunosuppressive CD8+ T cells (Riley et a l, 1989, Mshana et 
a l, 1990, Theander et a l, 1993), which suggests an immunosuppressive role by activated
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T cells. Indeed, seasonal variations in peripheral T cell function have been directly 
demonstrated to be due to differences in the suppressive capacity of CD8+ T cells 
(Theander et a l, 1993), although the precise nature of these putative suppressor cells has 
yet to be established.
1.10.4 
T Cell Redistribution
Neither IL-2 nor CDS T cell removal restores T cell responsiveness in malaria patients, 
suggesting another mechanism for the immunosuppression (Ho et al., 1986, Ho et ai,
1988). In fact these patients exhibit decreased suppressor cell function (Gilbreath et al, 
1983), and several studies have demonstrated malaria-associated lymphopaenia, with 
reduced CD3+ and CD4+ T cells (Ho et a l, 1986). A decrease in cells expressing high levels 
of the endothelial adhesion factor LFA-1 (lymphocyte function associated antigen type 1) 
is also a feature of malaria (Hviid et a l, 1991a). It is thought that T cells become 
redistributed during malaria episodes, presumably to sites of endothelial activation.
1.10.5 
Antigenic Polymorphism
Current strains of P. falciparum are estimated to have arisen from a single ancestral strain 
some 25-60 thousand years ago, depending upon the nucleotide substitution rate (Rich et 
a l, 1998). This has allowed the parasite time to develop numerous strategies for avoiding 
the host’s natural defences. The immune selection pressure afforded by malaria is apparent 
when one considers that it is responsible for maintaining a variety of genetic disorders such 
as sickle cell, thalassaemia and G6PD deficiency within the gene pool, simply because the 
heterozygous state is protective against P. falciparum (Allison, 1954, Flint et a l, 1986, 
Ruwende et a l, 1995). Exactly how CD4+ and CD8+ T cells exert their selective pressure 
on the malaria parasite leading to the generation of polymorphism remains unclear.
At the pre-erythrocytic stage of infection the most highly expressed antigen, CS protein, 
has developed numerous polymorphisms in the dominant T cell epitope regions (de la
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Cruz et a l, 1988b, Good et a l, 1988c, Good et a l, 1988d, de Groot et a l, 1989). Most 
nucleotide changes lead to amino acid changes, suggesting there is a powerful immune 
selection pressure operating at these sites. The highest level of variation within CS is found 
in two immunodominant proliferation-inducing CD4 T cell epitope regions within the 
carboxy-terminus of CS, denoted Th2R (aa 326-347) and Th3R (aa 361-380) (Good et a l, 
1988d), where up to 14 different variants of Th2R occur naturally (Lockyer et a l, 1989, 
Doolan et a l, 1992, Shi et a l, 1992), nine of which co-exist in The Gambia where many of 
the studies in this thesis were based (Conway et a l, 1991, Lockyer et a l, 1989). CD8 T 
cell epitopes, denoted Tc2R (aa 327-335) and Tc3R (aa 369-375), also exist within these 
regions and exhibit a high level of polymorphism (Doolan et a l, 1991, Malik et a l, 1991, 
Shi et a l, 1992, Aidoo et a l, 1995).
Field studies demonstrate that responses to polymorphic epitope regions within CS 
protein are generally strain specific (de la Cruz et a l, 1988a, de la Cruz et a l, 1989, 
Udhayakumar et a l, 1994, Zevering et a l, 1994), although one study in Gambians shows a 
high degree of cross-recognition of 3 strains (de Groot et a l, 1989). Thus, polymorphism 
probably provides an immune escape strategy whereby certain strains are not recognised 
despite previous parasite exposure. Such antigenic diversity presents a major obstacle for 
malaria vaccine development. One strategy to overcome this is to focus on conserved 
regions of antigens, although possibly the reason such regions remain conserved is that 
they are nonprotective. The pre-erythrocytic antigens TRAP, LSA-1 and START are more 
conserved, perhaps making them more attractive vaccine candidates than CS protein 
(Fidock et a l, 1994b, Fidock et a l, 1994c, Robson et a l, 1998).
1.10.6
Altered Peptide Ligand Antagonism / Immune Interference
There is good evidence that natural selection by malaria plays a role in maintaining the 
MHC polymorphism seen in malaria endemic regions of the world (Hill et a l, 1991, Hill et 
a l, 1992b). The precise mechanism for this is not fully understood, although the process 
known as altered peptide ligand (APL) antagonism may play a role. This is the process
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whereby the simultaneous presence of a variant antagonistic epitope delivers an altered 
signal to the responding T lymphocyte leading to either decreased or absent responsiveness 
to the agonist peptide (Figure 1.4). Studies of CTL responses to HIV and hepatitis B show 
that certain naturally occurring variants of epitopes within these organisms specifically 
down-regulate the CTL response by APL antagonism (Bertoletti et a l, 1994, Klenerman et 
al., 1994). Gilbert and colleagues found that two HLA-B35 restricted CDS T cell epitopes 
in CS protein, named cp26 and cp29, can lead to impairment of CTL activity by this 
process (Gilbert et a i, 1998). These epitopes vary by just one amino acid residue at 
position 2, and are able to interfere with the activation of memory cells to one another. It 
was found that cp26 and cp29 occur together more frequently in naturally exposed children 
than would be expected by chance. The authors conclude that cohabitation of cp26 and 
cp29 could result from the strains facilitating one another’s survival through mutual 
antagonism of CTL to the other variant at the liver stage of infection.
Mathematical modelling of population dynamics of closely related variant epitopes in P. 
falciparum malaria have demonstrated that a necessary component for the persistence of 
new variants is an ability to avoid specific de novo responses (Gupta and Hill, 1995). It 
has been shown that APL antagonism for the CTL variants cp26 and cp29 of CS protein 
can operate at the level of T cell priming, and prevent the generation of peptide specific T 
cells from naïve precursors when presented on the same antigen presenting cell (APC) 
(Plebanski et a l, 1997b). This process has been termed “immune interference”, and in 
malaria exposed populations could lead to a lifelong inability to respond to a particular 
parasite strain, and thus exposed but functionally naïve hosts. Such immune interference 
has been demonstrated in vivo in a mouse model of malaria where co-immunisation with an 
agonist / antagonist combination of peptide immunogens led to a substantial decrease in the 
primed response to the agonist (Plebanski et al., 1999). This immune evasion strategy is 
more powerful than the selection of epitopes which fail to bind MHC or to cross-react, 
since it prevents the emergence of alternative target epitopes (Gilbert et a l, 1998, 
Davenport, 1995).
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Altered peptide ligands o fT  cell epitopes prevent correct T cell activation (as in A) by 3 main mechanisms: 
preventing T  cell recognition through the M HC receptor (B), altered signal through the T  cell receptor (C), 
or failure to bind to the M HC molecule (D).
Interference with T cell priming by APL antagonism generates defective effector T cells, 
capable of proliferation in response to antigen, but not of killing, or of producing 
potentially protective liver stage cytokines like IFN-y or TNFa (Plebanski et a l, 1999).
The phenomena of APL acting at the effector stage, and causing immune interference of T 
cell priming, are very important considerations in terms of malaria vaccine design. Vaccines 
containing APL may antagonise protective T cell responses to naturally occurring variants, 
rather than boost a protective response. Immune interference may prevent the priming of 
protective immune responses in malaria naïve vaccinees. The existence of altered peptide 
ligands has not been studied for the CD4 epitope regions of CS protein, or indeed for CD4 
T cell responses to any infectious pathogen. It is important to establish whether such 
mechanisms are at play for any antigen intended for use in malaria vaccines.
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CHAPTER 2
METHODS
2.1
ANTIBODY ELISA
Antibody ELISAs were performed in The Gambia by technical staff in the malaria 
laboratory. The antibody responses to the tetrapeptide (NANP) repeat of CS were 
measured using a specific ELISA with plate adsorbed R32LR antigen. A standard reference 
serum of known concentration (provided by the Walter Reed Army Institute of Research, 
Washington DC, USA) was used on every plate as a positive control (Gordon et a l, 1995). 
Microwells were coated with 50 pi of R32LR at 0.1 mg/ml in PBS 0.2% boiled casein, and 
were incubated overnight at room temperature (RT). After emptying, wells were blocked 
with 0.5% boiled casein / 1% Tween in phosphate buffered saline (PBS) (Sigma, Dorset, 
UK) for 1 hour at RT. Wells were aspirated and 50 pi of the appropriate serum dilution 
was added per well. Assays were conducted in triplicate, with blank wells and standard 
reference positive and negative sera on each plate. After 2 hours incubation at RT plates 
were washed 4X with PBS-1% Tween, and 50pl of anti-human conjugated peroxidase 
(Kirkegaard and Perry Laboratories, Gaithersburg, MD) was added to each well. Plates 
were incubated for 1 hour at RT, washed 4X with PBS-1% Tween, and 100 pi of ABTS 
substrate solution was added per well. After a further 1 hour incubation at RT, 10 pi of 
20% SDS (Sigma, Dorset, UK) was added to stop the reaction, and absorbance read at 414 
nm. Titres were expressed in comparison to the standard reference serum.
2.2
BINDING ASSAYS
HLA-DR binding assays for the 9 Th2R variants of CS were carried out by Drs Colin 
Gelder and Keith Hart. They were performed blind to all cellular results using the principal 
of competitive binding with a promiscuously binding invariant chain [li-(96-l 14)] 
biotinylated CLIP peptide (I*) as described (Davenport et a l, 1995a, Davenport et al.
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1995b). Test peptides in DMSO (Sigma, UK) were serially diluted 1:10 in pH5 buffer 
(0.02 M 2-N-morpholinoethaqne-sulphonic acid in 0.1 M NaCl and 0.02% sodium azide) 
and incubated at 37°C for 24 hr with competitor peptide I* (0.1 mg) and purified HLA 
class II protein (0.15 mg). Solutions were neutralised with Tris-HCl (pH 7.5) before 
transfer to 96 well BSA-blocked immunoplates (Nunc, UK) pre-coated with L-243 Ab 
(anti-HLA class II) (Sigma, UK). After 2 hr, plates were washed 3X with PBS 0.1% 
Tween 20 (PBS-T) (Sigma, UK) and 3X with PBS. Plates were developed with avidin- 
horseradish peroxidase (ExtrAvidin; Sigma, St Louis, MO, USA) / biotinylated anti-avidin 
mAb (Sigma, UK) and developed with o-phenylene diamine (0.4 mg / ml) in phosphate 
citrate buffer. The reaction was monitored every 5 min at 495 nm and was terminated with 
12.5% sulphuric acid. Peak pre-equilibrium values were used to calculate the concentration 
of unlabelled peptide required to inhibit 50% binding of *1 (-(Ymax*X / (IC5o + X) + 
background) using GraphPad Prism 2.0. Binding assays were repeated in triplicate at least 
twice and the mean calculated.
2.3 
CLONING BY LIMITING DILUTION
PBMC from donor D57 (HLA-DR 15,4;-DQ6, 8;-DP52,53) were resuspended at 4xl06/ml 
in RPMI/10% NHS supplemented with 2% penicillin/streptomycin and 1% L-glutamine 
(RN10) and cultured at 37°C, 5% C02 with 25pg/ml V6 peptide. On day 7, blast T cells 
were isolated by density gradient interphase on Percoll (Sigma, UK) (30%-40% dilution in 
RPMI) after 20 min centrifugation at 600xg, were pelleted, resuspended in media with 
10u/ml human purified IL-2 (Lymphocult T-HP, Biotest AG, Dreieich, Germany), and 
cultured for 7 days at 37°C, 5% C02. The blast cell line was shown to be V6 specific and 
HLA-DR 15 restricted in IFN-y ELISPOT assays utilising a panel of class II matched and 
mismatched PBMC as presenters (data not shown). The cultured isolated blast cells were 
pelleted and resuspended with autologous irradiated (2000 rads) PBMC at a ratio of 1:50 
effectors presenters in RN10 media supplemented with 10u/ml IL-2. Blast cell dilutions of 
1 cell, 10 cells and 100 cells per 20pl of media were made, and 20pl of these preparations 
were plated onto terasaki plates (Costar, UK), and incubated at 37°C for 1 week. lOpl of
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RN10 media with 10u/ml IL-2 was added to each well, and plates incubated for a further 7 
days. The cells in the terasaki plates were then scored visually under the microscope, and 
positive wells were transferred to 96 well round bottomed plates (Beckton Dickinson, 
France). These cells were then restimulated using a 3 way mixed lymphocyte reaction 
(MLR) with irradiated (2000 rads) PBMC in 10u/ml IL-2 and lpg/ml PH A (Wellcome 
Pharmaceuticals, UK), and placed in an incubator at 37°C / 5% C02. 10u/ml IL-2 was 
added every 5 days and cells were split when necessary.
Six clones were isolated from 600 initial wells (C1-C6). Clone Cl failed to survive for re­
testing, and was excluded from the study. The T cell receptor (TCR) (3-chain from clones 
C3 and C4 was sequenced by Dr. G. Gillespie in Oxford confirming for each the existence 
of a single dominant (3-chain TCR product (data not shown). T cell clones were confirmed 
to be CD4 positive by FACScan analysis (data not shown).
2.4 
CONTROL ANTIGENS
The following control antigens were used where indicated throughout the text:
Purified protein derivative from Mycobacterium bovis (PPD) (Serumstatens Institut, 
Denmark) was used as the positive control for IFN-y ex-vivo ELISPOT assays and 
lymphoproliferation assays; the mitogen phytohaemagglutinin (PHA) (Wellcome 
Pharmaceuticals, UK) was used as a positive control in IL-4 and IL-10 ELISPOT assays; 
tetanus toxoid (TT) (Evans Biomedical, UK) was used as an additional positive control for 
selected ELISPOT assays. PPD, TT and PHA were reconstituted in sterile media, and 
were added to wells to give the correct final concentration. Media alone was added to the 
negative control wells to give the background response.
2.5 
DNA EXTRACTION
All DNA extractions were performed by myself, Mr. P. Akinwunmi (in The Gambia), and 
Mr. K. Odhiambo and Mr. E. Sheu (in Kenya) using Qiagen QIAmp Blood Kits (Qiagen,
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Crawley, UK). All reactions were carried out at room temperature (unless otherwise 
stated) and all reagents / collection tubes were provided in the kits. 200pl of heparinised 
whole blood or Ficoll red blood cell pellet (see PBMC preparation) was placed in a 1.5 ml 
microfuge tube, and 25 pi of QIAGEN Protease stock solution and 200pl Buffer AL added 
to the sample. The pellet was vortexed for 15 seconds, and incubated for 10 minutes at 
70°C. 210 pi of ethanol (96-100%) was added to the sample which was then vortexed for 
15 seconds. A QIAmp spin column was placed in a 2ml collection tube. The above mixture 
was applied, the cap closed, and centrifuged at 6000xg for 1 minute. The QIAmp spin 
column was placed in a clean 2ml collection tube, and the tube containing the filtrate 
discarded. The spin column was opened, 500 pi of Buffer AW added, and spun at 6000xg 
for 1 minute. The spin column was placed in a clean 2ml collection tube, and the filtrate 
discarded. Another 500 pi of Buffer AW was added to the spin column, and spun for 3 
minutes in a microfuge at full speed. The spin column was placed in a clean 1.5ml 
microfuge tube, and the tube containing the filtrate discarded. The DNA was eluted with 
200 pi of Buffer AE preheated to 70°C, and the tube incubated at RT for 1 minute, then 
centrifuged at 6000xg for 1 minute. Eluted DNA was stored at -20°C until required for 
analysis.
2.6
DONORS
The studies in Africa were carried out at 2 centres, namely the MRC Research Unit in 
Fajara, The Gambia, and the Wellcome Trust Research Laboratories in Kilifi, Kenya. 
Different cohorts of donors were used for different studies, and these are detailed in the 
relevant chapters.
2.6.1
The Gambia, West Africa
The studies in chapters 3, 4 and 5 involved the use of PBMC from Gambian donors. Maps 
and location of donors are detailed in the text.
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2.6.2
Kilifi District, Kenya, East Africa
The studies in chapters 5 and 6 were performed using PBMC from Kenyan donors 
recruited from Kilifi District, Kenya. Maps and location of donors are given in the text.
2.6.3 
Malaria Naïve Donors
Healthy adult donors who had never been exposed to malaria were recruited from the staff 
at the John Radcliffe Hospital in Oxford, UK. All were aged 21-50 years, and a travel 
history was taken to ensure no previous risk of malaria exposure. All donors were fit and 
well at the time of blood sampling. A further 15 healthy adults were also recruited in 
Oxford for other studies regardless of previous exposure to malaria.
2.7 
ELISPOT ASSAYS 
2.7.1 
ELISPOT Coating Plates
All ELISPOT assays were carried out using 96 well MAIP S4510 0.45pm plates coated 
with a hydrophobic high protein binding Immobilon-P membrane / polyvinylidene (PVDF) 
(Millipore, Watford, UK). ELISPOT kits supplied by Mabtech (Mabtech, Nacka, 
Sweden) were used for all ELISPOT assays. The plates were coated initially with either 
monoclonal anti-human IFN-y Ab (1-D1K), anti-human IL-4 (IL4-I) or IL-10 (9-D7) 
according to the cytokine to be assayed. The coating mAb was diluted to a concentration of 
15 pg/ml in sterile PBS (Sigma, Dorset, UK), and 50pl added to each well of the 96 well 
plate. Plates were incubated for 3 hours at room temperature, or overnight at 4°C. The 
coating mAb was then flicked off, and plates washed 5X with sterile PBS (Sigma, Dorset, 
UK). The plates were then blocked by adding lOOpl RPMI-1640/10% PCS (RIO) to each 
well, and incubating for 1 hour at room temperature. This blocking media was then flicked 
off and the plate was ready for adding the cells to be assayed for cytokine production.
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2.7.2 
ELISPOT Ex-vivo PBMC / Lines / Clones
All cells were resuspended in RPMI 1640 supplemented with 5% pre-selected batch tested 
normal human serum (NHS) and 2% penicillin/streptomycin, 1% L-glutamine (RN5 
media). The cell concentrations used were 8xl06/ml for freshly isolated PBMC, lx l05/ml 
for T cell lines, and Ix loV m l for T cell clones, following preliminary titrations (not 
shown). Cells were applied at 50pl per well, and the peptide or control antigen, and APCs 
when indicated, were added to each well to make a final volume of lOOpl. Peptides and 
PPD were used at a final concentration of 25pg/ml following preliminary titrations (see 
below), unless otherwise stated. 8x104 cells were used in the PHA positive control test 
wells for the IL-4 and IL-10 ex-vivo ELISPOT assays, and PHA was used at 1 pg/ml. 
Irradiated (2000 rads) APCs (see PBMC Methods) were added to ELISPOT wells at an 
APC:responder cell ratio of 1:4 in assays using PBMC and positively selected T cells; 
100:1 for clones and 10:1 for cell lines. Incubation times were optimised following 
preliminary studies in Oxford (data not shown). Plates were incubated for 16 hours at 
37°C, 5% C02 for the IFN-y assay, and 24 hours for IL4 and IL10 assays.
2.7.3 
ELISPOT Cultured Cells
The culture medium for all cultured ELISPOT assays was a-MEM (Life Technologies, 
UK) with 10% batch tested NHS, supplemented with 2% penicillin/streptomycin and 1% 
L-glutamine (MEM 10). 1x106 cells in 1ml MEM 10 were placed in separate wells of a 48 
well flat bottomed tissue culture plate, and peptides / peptide pools were added to give a 
final concentration of 25pg/ml per peptide. Plates were placed in an incubator at 37°C, 5% 
C02, and 10u/ml IL-2 (Lymphocult T, Biotest AG, Dreieich, Germany) was added on 
days 5 and 10. On day 14 the PBMC were washed once in RPMI, and resuspended at 
lx l06/ml. They were then tested at lOOpl/well in 96 well MAIP ELISPOT plates (1x10s 
cells) in standard 16 hour IFN-y ELISPOT assays against the test peptides and negative 
control.
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2.7.4
ELISPOT Peptide Titrations
Preliminary titration assays with CS and TRAP derived peptides were performed to assess 
the optimal range for T cell epitope mapping. This was established to be within the range 
10-100pg/mL I chose a working concentration of 25pg/ml for TRAP peptides and PPD 
since at this concentration all positive ELISPOT responses will be detected, although peak 
responses generally occurred at 50-100pg/ml. Phytohaemagglutinin was used as the 
positive control for IL-4 and IL-10 assays at 1 pg/ml to ensure that the detection reagents 
were working. PPD and PHA responses were unaffected by the addition of selected CS 
protein and TRAP peptides used in the studies, over a range of concentrations from 10 to 
1 OOpg/ml, thus confirming their lack of toxicity (data not shown).
2.7.5
ELISPOT Antagonism Assays
PBMC in media in 96 well ELISPOT plates were first pre-pulsed with index peptide at a 
suboptimal concentration of 25pg/ml, and incubated at 37°C, 5% C02 for 1 hour. The 
antagonistic peptide was then added directly to the individual test wells at a concentration 
of 50-100pg/ml. The plate was left to incubate at 37°C, 5% C02 as for the standard ex- 
vivo ELISPOT assay according to the cytokine coating the plate (IFN-y, IL-4 or IL-10).
2.7.6
ELISPOT Inhibitory mAb Assays
Anti-TGFP (Genzyme, Cambridge, MA) and anti-IL-10 (Genzyme, Cambridge, MA) 
were applied to the ex-vivo ELISPOT wells at lOng/ml for both mAbs. Where reversal of 
inhibition was not observed (for anti-TGFp) the dose was increased to 100ng/ml. The 
mAbs were added to the ELISPOT wells 1 hour before the putative antagonistic peptides, 
at the same time as the index peptide.
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2.7.7 
ELISPOT Developing Plates
The ELISPOT plates were removed from the incubator after the required incubation time 
(see above) and the cells flicked off. The plates were then washed 4 times with PBS 
containing 0.05% Tween 20 (PBS-T) (Sigma) to remove adherent cells, and then twice with 
PBS alone. A second biotinylated monoclonal Ab to either IFN-y (7-B6-1-Biotin, 
Mabtech, Nacka, Sweden), IL-4 (IL4-II-Biotin, Mabtech), or IL-10 (12G8-Biotin, 
Mabtech) was diluted to 1 pg/ml with sterile PBS. 50pl of the mAb solution was applied to 
each well, and plates were incubated for a minimum of 2 hours at room temperature. The 
plates were then washed again as above (4X PBS-T, 2X PBS). The conjugation enzyme 
streptavidin alkaline phosphatase (Mabtech, Nacka, Sweden) was diluted to a 
concentration of 1 pg/ml in sterile PBS, and 50pl was applied to each ELISPOT well. Plates 
were incubated for a further 1 hour at room temperature, and washed again as above (4X 
PBS-T, 2X PBS). Cytokine secreting cells were visualised by the addition of the 
chromogenic precipitable alkaline phosphatase substrate 5-bromo 4-chloro 3-indolyl 
phospho/nitro blue tetrazolim (BCIP/NPT) (Bio Rad, Kernel Hempstead, UK). This was 
prepared by the addition of 200pl of 20X Development Buffer, 50pl of Substrate A and 
50pl of Substrate B, added in that order to 4.8 mis of sterile distilled water (Sigma, UK). 
50pl of this solution was added to each ELISPOT well, and allowed to incubate at room 
temperature until dark purple spots emerged (typically 10-20 minutes). The reaction was 
then halted by washing plates under running tap water, and plates were left to dry in air for 
a few hours.
Wells were scored with the aid of a dissection microscope at x20 magnification, for the 
number of cells producing IFN-y, according to the number of purple spots or spot forming 
units (SFUs) per well. Three observers scored every positive well in order to increase our 
confidence in this subjective scoring system. The results were expressed as SFUs / 106 
PBMC added. In certain cases results were confirmed using the AID Elispot reader 
(Autoimmun Diagnostika GmbH, Strasberg, Germany), and scored using the AID Elispot 
software version 2.0 (Autoimmun Diagnostika). A peptide specific response was scored
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positive if the antigen stimulated response was statistically above the background 
(unstimulated) response, with 95% confidence using a statistical table (see Section 2.16.1 
for details).
2.8
FLUORESCENCE ACTIVATED CELL SORTER (FACS)
2.8.1
FACS Cell Surface Marker Staining
Cells for FACScan analysis were stained with the relevant monoclonal Abs (fluorochrome 
conjugated CDS, CD4, CDS, CD 14, CD22, CDS8) derived from a number of sources 
(DAKO, Denmark / Becton Dickinson, USA / Serotec, UK) according to the protocol 
recommended for each individual antibody. Generally, cells were washed in 1% NHS in 
PBS/0.1% (w/v) sodium azide (PBS-NHSlaz), pelleted and incubated with the mAb on ice 
for 20-30 minutes. Cells were then washed 2x with PBS-NHSlaz, and resuspended in 
isoton buffer (Becton Dickinson) for analysis. When necessary cells were fixed with 200pl 
PBS/0.4% (w/v) paraformaldehyde (see below).
2.8.2
FACS Intracellular IL-10 Staining
Donor D57 CD4+ T cell line (2xl06 cells) derived from Percoll isolated blast cells (see 
Cloning Methods) was stimulated in culture with HLA-DR 15 matched irradiated (2000 
rads) PBMC (2xl06 cells) either alone, with V6 at 20pg/ml, or with V6 at 20pg/ml first and 
V5 at 40pg/ml added 1 hour later. These cells were then incubated in 1ml flat bottomed 
wells (Becton Dickinson, France) for 18 hours at 5% C02, 37°C, and 2jaM monesin 
(Biosource International, USA) was then added to the cultures which were incubated for a 
further 6 hours. Cells were first stained with the appropriate anti-cell fluorescent labelled 
surface markers and fixed according to the protocol above. The fixed cells were 
permeabilised in PBS-NHSlaz with 0.1% (w/v) saponin. Anti-IL-10 RPE-conjugated mAb 
(Biosource International, USA) was then added to the cells which were incubated on ice for
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30 minutes. Cells were then washed twice in the permeabilisation buffer and suspended in 
a required volume of isoton buffer (Becton Dickinson) for FACScan analysis.
2.8.3 
FACS Data Collection and Analysis
FACScanning and analysis was performed by myself, M. Plebanski (my supervisor), A. 
Vargas and V. Appay in Oxford. FACScanning was performed using the FACSCalibur Cell 
Sorter machine (Becton Dickinson, USA). Data was collected and analysed using 
CELLQuest software (Becton Dickinson, UK).
2.9 
HLA CLASS II PHOTOTYPING 
2.9.1 
Polymerase Chain Reaction
HLA class II phototyping was performed by myself, and Drs C. Gelder and K. Hart 
according to the published protocol (Bunce et a l, 1995). Genomic DNA for class II HLA 
typing was amplified in 96 well thermowell V plates (Costar, High Wycombe, UK) using 
the Phoenix thermocycler (Teche, Cambridge, UK). The primer mixes and amplification 
primers were provided by Drs C. Gelder and K. Hart, according to the published sequences 
and specificity’s (Bunce et a l, 1995). All amplification primers were designed to give a 
melting point of 58-62°C. PCR reaction mixtures consisted of 67mM Tris Base pH8.8, 
16.6mM ammonium sulphate, 2mM magnesium chloride, 0.01% Tween 20, 200pM of 
dNTP, l-4pM of each allele-specific primer, 0.1 pM of DRB 1 control primers, 0.1-0.01pg 
DNA, and 0.1875 units Taq Polymerase (Advanced Biotechnology, London, UK). The 
final volume of all PCR reactions was 13pl, consisting of 8pl of buffer, DNA and enzyme 
mixture and 5 pi of primer mix (containing allele and control primers in distilled water). lOpl 
of mineral oil was overlayed on this.
Trays were sealed with thermo well sealer (Costar, UK). The cycling parameters for 13 pi 
reactions in rapid-cycling PCR machines were as follows: 1 minute 96°C, 5 cycles of 25
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seconds at 96°C, 45 seconds at 70°C, 45 seconds at 72°C, 21 cycles of 25 seconds at 
96°C, 50 seconds at 65°C, 45 seconds at 72°C, 4 cycles of 25 seconds at 96°C, 60 seconds 
at 55°C, 120 seconds at 72°C.
2.9.2
Gel Electrophoresis
PCR products were electrophoresed in 2% agarose gels containing 0.5pg/ml ethidium 
bromide after the addition of lOpl of loading buffer consisting of 0.05% Orange G, 30% v/v 
glycerol, and 0.5x TBE buffer (89mM Tris base, 89mM boric acid, 2mM EDTA, pH8.0). 
Flowgen gel tanks (Flowgen, Sittingboume, UK) allowed multiple loading of reactions with 
a multichannel pipette. Gels were run for 30-50 minutes at 15V/cm in 0.5x TBE buffer, 
were visualised using UV illumination, and scored according to phototype pattern.
2.10
MAGNETIC BEAD CELL DEPLETION / SELECTION
2.10.1 
Reagents 
Monoclonal Abs
Mouse anti-human CD45RO, CD45RA and CD45RB (all from Serotec, Oxford, UK) were 
used at a concentration of 1:100 with PBMC at lx l07/ml in RPMI-1640/10% ECS (R10) 
medium (see below). Mouse anti-human CD38 (Serotec, UK) was also used at 1:100 
dilution, and added to cells at lx l0 7/ml in R10. Cells for CCR7 depletion were incubated in 
rat anti-human CCR7 mAb (rat IgG2a clone 3D 12 provided by Dr. R. Forster, Max- 
Delbrueck-Center for Molecular Medicine, Berlin, Germany) at lOOpl mAb per 5xl06 
PBMC in lOOpl PBS/3% PCS.
Dynabeads
CD4+ and CD8+ cell depletions of PBMC were performed using anti-human M-450 CD4 
(T helper) and M-450 CD8 (T cytotoxic) magnetic Dynabeads respectively (Dynal, 
Bromborough, UK). Pre-washed goat anti-mouse Dynabeads (Dynal, Oslo, Norway) were 
used to deplete cells coated with mouse anti-human mAbs (CD45RO, CD45RA, CD45RB,
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CDS8). Washed sheep anti-rat Dynabeads (Dynal, Norway) were used to deplete the rat 
anti-human CCR7 coated PBMC. CD4+ cell selections from PBMC were performed using 
CD4 Positive Isolation Kits (Dynal, UK). For the positive selection of CDS 8  ^ cells I used 
CELLection™ Pan Mouse IgG Kit (Dynal, UK).
2.10.2
Washing Dynabeads
Dynabeads were first washed by resuspending in the vial and transferring the required 
amount (approximately 5 beads per cell to be depleted) into a sterile test tube, and placing 
the tube on a Dynal Magnetic Particle Concentrator (MPC) magnet (Dynal, Oslo, 
Norway). The fluid was removed by pipette, the tube removed from the magnet, and the 
beads resuspended in 1ml of PBS/2% PCS. The tube was re-applied to the MPC magnet, 
and the washing procedure with PBS/2% PCS repeated twice. Beads were resuspended to 
the original volume in PBS/2% PCS after washing.
2.10.3
Cell Depletion Protocols 
CD4* and CDS* Cells
CD4+ and CD8+ cell depletions of PBMC were performed using anti-human CD4 and CD8 
magnetic Dynabeads (see above) (Dynal, UK) respectively as follows. PBMC for 
depletion were resuspended in PBS/2% PCS at l-5xl07 cells/ml, and cooled to 4°C. 
Dynabeads were added (5 per estimated cell to be depleted) and cells incubated at 4°C for 
30 minutes with gentle rotation. The rosetted cells were then placed on an MPC magnet for 
2-3 minutes, and the depleted supernatant transferred to a fresh tube. Cells were recounted 
following a further 2 rounds of depletion on the magnet.
CD45RO*, CD45RA*, CD45RB*, CCR7* and CD38* Cells
Depletion of PBMC expressing CD45RO, CD45RA, CD45RB, CCR7 and CD38 were 
performed using the same basic protocol. Thus, the relevant mAbs were added to the cell 
preparations at the required concentrations (see above), and incubated at 4°C for 30 
minutes. Cells were then washed 3X in media, and pre-washed Dynabeads were added to
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the mixture (5 per cell to be depleted). Cells were incubated with the Dynabeads for 20-30 
minutes with gentle rotation at 4°C, and the rosetted cells were removed by magnetic 
depletion on an MPC magnet as above. Cells were washed 3X with RIO, counted and set 
up in the relevant assays.
FACScan analysis of depleted and purified cells (see above) performed for selected donors 
confirmed that depletions and puriRations were 90-95% effective. ‘Mock depletions’ were 
also performed as additional controls for selected donors whereby either the mAb alone, or 
the beads alone, were added to PBMC in parallel assays to ensure that they were not 
responsible for any effects seen.
2.10.4
Positive Cell Selection 
CD4* Cells
CD4+ cell selections from PBMC were performed using CD4 Positive Isolation Kits 
(Dynal, UK). The Dynabeads were washed in exactly the same way as detailed above. 
PBMC for depletion were resuspended in PBS/2% PCS at l-5xl07 cells/ml, and cooled to 
4°C. Dynabeads were added (5 per estimated cell to be depleted) and cells incubated at 4°C 
for 20 minutes with gentle rotation. The rosetted cells were then collected by placing on an 
MPC magnet for 2-3 minutes, and the supernatant was discarded. The bead bound isolated 
cells were then washed 4X with PBS/2% PCS, and resuspended in RPMI 1640/1% PCS 
(R l)at IxlO8 cells/ml. One unit (lOpl) of DETACHaBEAD was then added per lOOpl of 
cell suspension. Cells were incubated for 45-60 minutes at room temperature with gentle 
mixing, then placed on an MPC magnet for 2-3 minutes. The supernatant contains the 
released positively selected cells, and these were transferred by pipette to a fresh tube. The 
beads were then washed 2X in medium and supernatant collected to obtain residual cells. 
Detached cells were washed 3X in R l, counted and resuspended for use in assays.
CD38+ Cells
For the positive selection of CD38+ cells I used CELLection™ Pan Mouse IgG Kit 
(Dynal, UK). The Dynabeads were washed according to the above procedure. Beads were
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then coated with mouse anti-human CD38 mAh (Serotec, UK) by adding Ijag mAb (Ijal of 
1 mg/ml) to every lOOjal washed beads (0.25jag mAb / 107 beads), and incubating for 30 
minutes at RT with gentle rotation. Beads were then placed on a Dynal MPC magnet for 2- 
3 minutes, and the fluid pipetted off. The tube was removed from the magnet, and 
resuspended in 1ml PBS/0.1% BSA. This washing procedure was performed 3X, and the 
mAb coated beads then resuspended in their original volume with PBS/0.1% BSA.
The PBMC were resuspended in RPMI/1% PCS at 10-40xl06/ml and cooled to 4°C. The 
precoated beads were resuspended and the desired volume (5 per cell to be depleted) were 
transferred to a sterile tube, placed on a magnet, and the buffer removed. The PBMC 
suspension was then applied and the coated beads and PBMC mixed by light whirlmixing. 
Cells were then incubated for 15 minutes at 4°C by gentle rotation on a mixer. The tube 
was then placed on a magnet for 2-3 minutes, and the supernatant pipetted and discarded. 
The tube was removed from the magnet, and resuspended in 0.5-lml RPMI/1% PCS, 
placed back on a magnet and after 2-3 minutes the supernatant removed. This washing step 
was repeated 3X. The rosetted cells were then resuspended in 200pl RPMI/1% PCS 
medium pre-warmed to 37°C, and 4pl of DNase solution (provided) added per 107-108 
Dynabeads used. The tube was then incubated for 15 minutes at RT with gentle mixing, the 
rosetted cells flushed through a pipette and placed on a Dynal magnet for 2-3 minutes. The 
released cells in the supernatant were pipetted into a fresh tube containing 200pl 
RPMI/10% PCS. The residual cells were obtained by flushing the beads 5X through a 
narrow tipped pipette, placing on a magnet, and transferring the suspension to the other 
released cells. Cells were then counted and resuspended in appropriate media for the assay.
2.11
MALARIA BLOOD FILMS
Thick and thin malaria blood films were prepared for most donors from Kenya and The 
Gambia who took part in the studies. In all cases they were performed by the local 
laboratory staff. For thin film preparation a small drop of blood was placed on a clean glass 
slide, and a second slide used to pull the drop across the slide and create a smear. 2-3 drops
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of blood were used for thick films, which were spread with the comer of a second slide to a 
thickness whereby print could be read through the film. Films were fixed in 100% 
methanol, dried and immersed for 10 minutes in a standard Giemsa stain (10% working 
solution, pH 7.2). They were then rinsed under tap water, dried and read under a light 
microscope.
2.12
PBMC PREPARATION
2.12.1
PBMC Isolation from Whole Blood
Heparinised whole blood was taken from donors after obtaining informed consent. This 
was transferred to 15ml or 50ml sterile Falcon tubes (Beckton Dickinson, France) 
according to the volume taken. Tubes were centrifuged at 600xg for 5 minutes, and an 
aliquot of plasma taken and frozen for future use. The blood was then layered onto an 
equal volume of Ficoll Lymphoprep™ (Nycomed, Oslo, Norway) in 15ml or 50ml Falcon 
tubes, and centrifuged at 800xg for 20 minutes (without brake). The peripheral blood 
mononuclear cell (PBMC) fraction was collected from the interphase by pastette pipette 
into fresh sterile Falcon tubes. An aliquot of the Ficoll neutrophil fraction was frozen for 
DNA extraction at a later date (see DNA extraction). The PBMC were washed three times 
in RPMI, and counted under a microscope using 0.05% Trypan Blue solution in PBS 
(Sigma, UK) using a disposable counting chamber (Fast-Read 10™, Immune Systems Ltd., 
Paignton, UK). The PBMC were then resuspended at the appropriate cell concentration, in 
the media required for the assay to be performed (e.g., RN10, MEM 10).
2.12.2
PBMC Red Blood Cell Lysis
In certain cases the PBMC isolated on Ficoll contained numerous red blood cells, which 
can interfere with the ELISPOT assay. In such cases a red blood cell lysis step was 
performed as follows. lOmls ACK lysis buffer (0.15M NH4C1, ImM KHC03, 0.1 mM 
Na2EDTA, Ph 7.2) was added to the PBMC pellet, and incubated at room temperature for
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5 minutes. 25mls RPMI was then added and the sample underlayed with 2mls sterile FCS. 
This was then spun at 600xg for 10 minutes, and the supernatant containing lysed red cells 
and red cell membranes discarded. The pellet was then flicked and washed twice more with 
RPMI, and the lysed PBMC were then ready for resuspending in media for the cellular 
assay.
2.12.3 
PBMC Preparation of Adherent Cells
Adherent cells, for use as APCs in certain assays, were prepared from freshly isolated 
PBMC. The PBMC were resuspended at 5xl06/ml in sterile RPMI-1640/10% FCS (RIO) 
and 4mls placed in separate wells of a 6 well flat bottomed tissue culture plate (Beckton 
Dickinson, France). They were incubated at 37°C, 5% C02 for 1x12-2 hours, and the non­
adherent cells removed gently by pipette. The petri dish was then washed gently with RIO 
medium, and further non-adherent cells removed. The adherent cells were then scraped off 
the dish using a cell scraper (Beckton Dickinson, UK), and resuspended in RIO. The 
adherent cells were then irradiated to 2000 rads, counted and resuspended at the desired 
concentration, in the appropriate media, according to the assay for which they were 
required.
2.12.4 
PBMC Freezing
Typically 5-30x106 PBMC were frozen in a single 1.5ml cryotube vial (Nalgene, UK). The 
isolated PBMC were centrifuged to form a cell pellet, and resuspended in 250pl of neat 
FCS (Sigma, UK), and left on ice for 30 minutes. Cells were then transferred into pre­
prepared 1.5ml cryotube vials containing 250pl chilled 20% DMSO in FCS. The cryotubes 
were placed in a styrofoam container and transferred immediately to a -70°C freezer. The 
styrofoam allows for a gradual drop in temperature while cells are freezing at -70°C. The 
cryotubes were transferred to liquid nitrogen tanks for long term storage after 2 days at 
-70°C. The final volume of frozen PBMC was therefore 500pl in 10% DMSO/FCS. An 
identical method was used to freeze T cell clones and lines.
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2.12.5
PBMC Thawing
The frozen PBMC were removed from liquid nitrogen tanks and thawed in a 37°C water 
bath. As soon as the frozen cells had thawed they were transferred to a sterile 15ml Falcon 
tube (Beckton Dickinson, France). RPMI/10% FCS (RIO) media, that had been pre­
warmed to 37°C, was added slowly to the thawed cells at a rate of 2mls/minute until 6mls, 
and then topped up to lOmls. The tube was centrifuged at 600xg for 5 minutes, and the 
pellet suspended in prewarmed RIO, and centrifuged again at 600xg for 5 minutes. This 
step was repeated once more, after which the cells were counted using a disposable 
counting chamber (ISL, UK) and trypan blue (Sigma, UK) (as for freshly isolated PBMC). 
Generally 70-90% of frozen cells were recovered using this technique. The same method 
was used to thaw frozen clones and lines.
2.12.6
PBMC EBV Transformation for B Cell Lines
2-4x106 PBMC were centrifuged to a pellet in 15ml Falcon tube and resuspended in 500pl 
of EBV supernatant, and incubated at 37°C for 1 hour. The Epstein-Barr virus (EBV) 
supernatant was from an EBV infected marmoset cell line B95-8, which was provided by 
Dr. P. Thornton Everton in Oxford. The cells were washed in RPMI-1640 to remove 
excess virus, and resuspended in RPMI/10% FCS (R10) media with Ipg/ml cyclosporin A 
(Sigma, UK) at a concentration of IxlO6 cells/ml. The infected cells were plated into 24 
well tissue culture plates (Beckton Dickinson, UK), incubated at 37°C, and monitored for 
transformation (usually after 7 days). Every 7 days, half the medium of the infected cells 
was changed with fresh R10 with 2pg/ml cyclosporin A.
2.12.7
PBMC T Cell Purification
T cell purification was performed using glass bead human T cell immunocolumns (Cytovax 
Biotech. Inc., Alberta, Canada) according to the manufacturer’s instructions. Columns were
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washed with 20mls sterile PBS. Column reagent was reconstituted in 1ml sterile PBS, 
applied to the column, and left for 1 hour at room temperature. The column was then 
washed again with 20mls sterile PBS. The PBMC (maximum 1.5xl08/ml) were 
resuspended in 1ml, and applied to the column. The column was flushed through with 
sterile PBS, and the purifed T cells collected and counted for use in cellular assays.
2.13 
PEPTIDE BINDING PREDICTION PROGRAMME
A computer programme was used which predicts the binding efficacy of peptides along the 
length of an antigen to particular HLA molecules (Davenport et a l, 1995a). This 
programme was derived from pool sequence data from eluted peptides purified from HLA 
class II proteins. This method can be used to predict likely T cell epitopes within a given 
protein that will bind to the HLA type in question. All known sequences for Plasmodium 
falciparum thrombospondin related adhesive protein (TRAP) were provided by Dr. K. 
Robson. These were scanned through the prediction programme to identify sequences that 
had a high likelihood of binding to 2 protective African class II alleles, namely DRB 1*1301 
which is protective in West Africa (Hill et a l, 1991), and DRB 1*01 which is protective in 
East Africa (A. Hill, personal communication). Those with high predicted binding were 
synthesised for testing in East and West African donors.
2.14 
PEPTIDE SYNTHESIS 
2.14.1 
Commercial Synthesis
Most peptides were manufactured commercially (Research Genetics, Huntsville, USA) 
according to the sequences provided. The peptide sequences used in the various studies are 
detailed in the relevant chapters. Peptide purity was checked using reverse phase High 
Pressure Liquid Chromatograhpy (HPLC), and the presence of a single dominant peak 
confirmed.
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2.14.2 
Synthesis in Oxford
Certain peptides were manufactured by myself and Mr. K. McIntyre in Oxford, using the 
automatic peptide synthesiser (Zinsser Analytic, Maidenhead, UK). 40mg of amino acids 
attached to resins (Zinsser Analytic, UK) were weighed into labelled reaction vessels, 
which were then transferred onto the reaction block of the synthesiser, and pre-wet with 
N-dimethylformamide (DMF) for about 10 minutes. Amino acids were reconstituted at a 
concentration of 0.5M in a solution of 0.45M 1 -hydroxy-benxotriazole (HOBT) in DMF, 
except phenylalanine which was in HOBT in 1-methyl-1 pyrrolidinone (NMP). The amino 
acids were aliquoted into the amino acid containers on the synthesiser, and the amino acid 
sequences were programmed into the computer. Peptide synthesis occurred from carboxy- 
to amino-terminus, with the C terminal peptide attached to the resin. The programmed 
amino acid sequence was coupled to the C terminal peptide, one amino acid at a time until 
the sequence was complete. Peptides were then washed 4X with methanol, then 10X with 
dichloromethane (DOM), and left to dry completely under vacuum. 1ml of peptide 
cleavage solution was applied, and this solution was then transferred to a further 2mls of 
cleavage solution, and left overnight to cleave. The cleaved peptides were then mixed with 
ether, vortexed and centrifuged at 4°C, and pelleted. This procedure was repeated five 
times. The pellet was air dried after the final ether wash, dissolved in 5% acetic acid, 
transferred to glass vials, frozen on dry ice, and transferred onto a freeze drier and allowed 
to freeze dry completely. Peptides were then weighed and dissolved in DMSO, and later 
diluted to working concentrations. Peptide purity was checked using reverse phase High 
Pressure Liquid Chromatograhpy (HPLC), and the presence of a single dominant peak 
confirmed.
2.15 
PROLIFERATION ASSAYS
The culture medium for all lymphoproliferation assays was a-MEM (Life Technologies, 
UK) with 10% batch tested NHS, supplemented with 2% penicillin/streptomycin and 1% 
L-glutamine (MEM 10).
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2.15.1
Proliferation Cell Preparation
PBMC were resuspended in MEM 10 at 5xl05/ml and plated in triplicate to sextuplet in 96 
well round bottomed tissue culture plates (Beckton Dickinson, France) at 200pl/well (IxlO5 
cells) in the presence of peptides at 25pg/ml. PPD (5pg/ml) was used as a positive control, 
and medium alone was used as the background response. In certain cases, such as assessing 
proliferative responses of positively selected T cells, APCs were added to the wells to allow 
antigen presentation. They were added at an APC:responder cell ratio of 1:4.
2.15.2
Proliferation Transwell Experiments
0.4pm Cell Culture Inserts HD (Becton Dickinson, France) were placed in 24 well flat 
bottomed tissue culture plates. The cells were otherwise prepared in exactly the same way 
as above, and used at a concentration of lx l06/ml in MEM 10. Peptides were utilised at a 
final concentration of 25pg/ml. Culture plates were incubated for 5 days, and then plated 
onto 96 well round bottomed tissue culture plates in triplicate to sextuplet (as above). The 
effect of the cells present in the transwells was therefore assessed.
2.15.3
Proliferation Antagonism Assays
Two types of proliferation antagonism assays were performed using PBMC (Chapter 4). 
In the ‘sequential pulsing’ assay, half the PBMC were irradiated (2000 rads) and then 
incubated for 3 hours with the index peptide (25pg/ml). They were then washed 3X with 
RPMI, and incubated for 3 hours with the putative antagonist peptide (50pg/ml). They 
were then washed again, and mixed 1:1 with untreated PBMC as the responder cells at a 
final concentration of 2xl06 cells/well. In the ‘separate pulsing’ assay, the PBMC were 
prepulsed for 3 hours separately with either index peptide or putative antagonist (both at 
50pg/ml), and added to untreated responder PBMC at a 1:1 ratio.
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2.15.4
Proliferation Harvesting and Detection
Proliferation plates were incubated at 37°C/5% C02 for between 5 and 10 days according to 
the time point being assessed. IpCi [3H]thymidine (Amersham Life Sciences, UK) was then 
added to each well of 96 well round bottomed plates which were incubated for a further 16 
hours at 37°C/5% C02. Plates were then automatically harvested onto spot-on cellulose 
1205-401 filters (Wallac, Turku, Finland), and [3H]thymidine incorporation was measured 
by liquid scintillation counting in a 1205 Betaplate 13-counter, for the Gambian studies. For 
the studies in Oxford the 96 well tissue culture plates were automatically harvested onto 
Select Unifilter™-96 GF/C plates (Packard, Pangboume, UK) using the Packard 
FilterMate™ harvester (Packard, UK). Plates were counted under 30pl/well Microscint- 
20™ LSC-cocktail (Packard, UK) using the Microplate Scintillation and Luminescence 
Counter (Packard, UK). The plates were scored using TopCount™ software.
2.15.5
Proliferation Scoring
The results were either expressed as mean counts per minute (CPM) ^standard error (SE), 
or as a stimulation index (SI) of counts per minute according to the following formula: mean 
test CPM / mean background CPM. An SI value of >2 was taken as the cut off value for a 
positive response in the study in The Gambia (Chapter 3) (Bennett and Riley, 1992).
2.16
STATISTICAL METHODS
The statistical table for scoring positive ELISPOT wells was compiled by Drs. W. Reece 
and P. Milligan in Oxford. The analysis for protection was performed by Amanda Ross, 
the statistician in Kilifi, Kenya. Drs. M. Gravenor and A. Cervino in Oxford helped with 
the analysis of other aspects of the data.
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2.16.1
Statistical Scoring Method for ELISPOT Assays
Statistical analysis for comparing background (unstimulated) to antigen stimulated wells 
were compiled into a statistical significance table (Table 2.1) by Drs. P Milligan and W. 
Reece according to a number of mathematical assumptions (Sokal and Rohlf, 1995). It 
assumes that if the control unstimulated cells have C spots, and the peptide specific cells 
have T spots, then each test well in the plate can have C + T spots. Assuming that the 
probability of each spot (C + T) appearing in two different wells is the same, the statistical 
table assesses the likelihood of T or more spots appearing in the test well. If the frequency 
of likelihood is less than 5%, then the probability of a spot appearing in the test well must 
be greater than that of a spot appearing in the control well within 95% confidence. Where 
test wells are scored positive in this thesis, they have fallen within this 95% confidence 
interval, and thus have a <5% probability that they arose by chance.
2.16.2
T Cell Assay Correlation Analysis, The Gambia (Chapter 3)
Statistical analysis comparing responses to the 3 T cell assays (ex-vivo ELISPOT, cultured 
ELISPOT and proliferation) was performed by Dr. M. Gravenor in Oxford. A simulation 
approach was used to test whether the pattern of response to each peptide was correlated 
over the three assays. For each donor he summarised the correlation between a pair of 
assays by counting the number of times a positive result was found for the corresponding 
peptides. The average value was calculated over all donors for each pair of assay 
comparisons. The distribution of this average index under the null hypothesis of no 
correlation was calculated using binomial distributions with n = 48 donors, and the 
probability of a success estimated from the average number of positive responses in each 
assay. %2 tests were used to assess associations between antibody level, categorised as low 
(< 4pg/ml), medium (4-10pg/ml) and high (> 10pg/ml), blood smears (positive or negative), 
and assay responses (responds to at least one peptide or no response). In addition, 
proliferative stimulation index values were compared directly with Ab levels (pg/ml) to 
assess for an association.
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2.16.3
Effects of Depleting Cells / Antagonism Assays (Chapters 3 & 4)
The effect of depleting cell populations expressing various activation markers from PBMC 
(Chapter 3) were assessed using student’s t-tests where enough donors were tested. The 
proliferation counts were log transformed for this analysis. Student’s t-tests were also used 
to assess the effect of adding putative antagonistic peptides to assays (Chapter 4).
2.16.4
East / West Africa & Adults / Children Comparisons (Chapters 5 & 6)
The comparisons of responses between East and West Africans and adults and children 
was performed by myself, with the help of Dr. A. Cervino in Oxford. Proportions of 
donors responding in different groups were compared used standard chi squared analysis, 
having first established that the background levels were comparable. Where the numbers in 
each group for comparison were very small, Fisher’s p-value value for 2-tailed analysis 
was used. The precursor frequency values (SFU / 106 PBMC) were compared using t-tests 
to look for evidence of a significant difference between groups.
2.16.5
Analysis for Protection (Chapter 6)
Statistical analysis for protection was performed by Amanda Ross, the statistician in 
Kilifi, since the data is stored on a data base in Kilifi and is confidential at present. 
Analysis was performed using the STATA version 6 (STATA Corporation, TX, USA) 
computer programme. The endpoints for the analysis were chosen before the analysis 
began for the following 3 parameters:
Number of donors with parasitaemia over 2 months (any parasitaemia and >104/pl)
Number of donors with parasitaemia over 6 months (any parasitaemia and >104/pl)
A delay in time to first parasitaemia (any parasitaemia and >104/pl)
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Fisher’s exact tests were used to compare the proportions of donors with at least one 
episode of parasitaemia who had specific TRAP epitope T cell responses with those who 
did not have the response (Results 6.3.4 and 6.3.5). The mean total SFU values were 
compared for those who subsequently did and did not have an episode using two sample t- 
tests (see Results 6.3.6). Kaplan-Meier estimates of the proportion of donors remaining 
episode free were plotted against time following the cross-sectional analysis of TRAP 
ELISPOT responses. Log-rank tests were used to compare survival experience for those 
donors with particular TRAP T cell epitope responses to those without (Results 6.3.4 and
6.3.5). Maentel-Haenzel tests for homogeneity were used to assess whether there was 
evidence of a significantly different effect of having a TRAP response in different age 
groups (Results 6.3.5).
The relationship between total SFU and time to first parasitaemia appeared to be non 
linear, thus total SFU values were divided into 4 categories (< 0, 0-49, 50-99, > 100) to 
look for Kaplan-Meier survival, rather than assessed as a continuous variable (Results
6.3.6). Cox’s proportional hazards were used for analysis of total SFU and time to first 
episode of parasitaemia. The estimated effect of each total SFU category was presented as 
an estimated hazard ratio for an individual in each category compared to the baseline group 
(those with total SFU <0). It was assumed for this analysis that the effect of total SFU 
remained constant with time. A hazard ratio <1 meant that the hazard was less than the 
baseline category, and >1 meant greater than the baseline group. Differences in time to first 
episode between the categories were investigated using a likelihood ratio test, both 
univariately and after adjusting for age.
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Section o f statistical table used to score ELISPOT plates for positive responses. The number o f spots (SFU) 
in the test wells (along the top) are compared to the number in the background wells (down the side) and a 
test response is only considered positive i f  it falls in the 95% probability and above (shaded boxes).
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CHAPTER 3
DIFFERENT T CELL EFFECTOR FUNCTIONS TO CS 
PROTEIN EPITOPES IN ADULT GAMBIANS: THE ROLE 
OF DISTINCT MEMORY T CELL SUBSETS
3.1 
INTRODUCTION
The circumsporozoite protein is the most widely studied of all the pre-erythrocytic 
antigens, and natural immunity to CS protein has been comprehensively assessed in field 
studies in malaria endemic regions of the world (reviewed in Chapter 1). There is extensive 
data supporting a protective role in animals, but more limited evidence for humans. Most 
human field studies of CD4 T cell mediated immunity have focused on lymphoproliferative 
responses to peptides and antigens (Good et a l, 1988d, Hoffman et a l, 1989b, de Groot et 
a l, 1989, Zevering et a l, 1990), yet none have convincingly shown an association between 
proliferative responses to CS protein and protection against disease. Responses in such 
studies are generally low grade, and widespread nonresponsiveness has been a consistent 
observation.
Few studies have measured for IFN-y release by T cells, even though IFN-y may be the 
cytokine by which T cells mediate their protective effect (reviewed in Chapter 1). In those 
studies which have assessed IFN-y release in response to CS protein, it has been done by 
ELISA, and no association between lymphoproliferation and IFN-y release is seen (Riley et 
a l, 1990). This lack of association between proliferation and IFN-y release is also a feature 
of responses to the blood stage antigen MSP-1 (Riley et a l, 1992, Riley et a l, 1993), and 
is seen in other infectious diseases such as Mycobacterium leprae (Mutis et a l, 1993). This 
raises the questions of what role such proliferative responses play in protective immunity, 
and whether the IFN-y responses are a separate entity. Indeed, recent studies have 
demonstrated that memory T cells may selectively perform different effector functions 
such as lymphokine secretion (Mosmann and Coffman, 1989, Street and Mossman, 1991,
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Hollsberg et a l, 1995, Sallusto et a l, 1999), or cytotoxicity (Hollsberg et a l, 1995), and 
may also differ in their susceptibility to apoptotic signals (Varadhachary et a i, 1997, 
Zhang et a i, 1997), and in rapidity of response (Swain, 1991). Moreover, a recent study in 
Gabonese children showed a protective association between cultured (day 6) IFN-y 
responses to liver stage antigen 1 (LSA-1) peptides and recurrence of infection, whilst 
proliferative responses to the same peptides were not protective (Luty et al., 1999).
The enzyme linked immunospot (ELISPOT) assay has been refined to allow the 
identification of T cells which can secrete IFN-y within 6 hours of antigen stimulation 
(Lalvani et a l, 1997). The rapidity of this response makes it a prime candidate for a 
protective role during the short time period (average 5-10 days) during which the parasites 
are found inside liver cells. Indeed, rapid IFN-y ELISPOT responses to CS protein have 
been correlated with protection in the mouse model of malaria (Plebanski et a l, 1998). 
Additional information can be gained from the highly sensitive ELISPOT since it 
determines the precise number of IFN-y producing cells circulating in peripheral blood. The 
ELISPOT assay is also less time consuming (overnight versus 5 days) than the 
proliferation assay, and does not require the use of radioactivity which is not always 
available in the tropics. It is a robust, simple and sensitive technique, and can be used to 
screen for multiple epitope responses at one time, and is thus a convenient assay to 
employ in large scale field studies of malaria and other infectious diseases.
3.2
STUDY DESIGN
3.2.1
Rationale
This study was designed to address whether such rapid T cell effector function, as 
measured by IFN-y ELISPOT assay, focuses on the same T cell epitopes as those 
identified by proliferative assays. I performed three T cell assays simultaneously in malaria 
exposed Gambian adults to assess immunity to a series of 15mer CS protein derived 
epitopes. Thus, lymphoproliferation, rapid IFN-y ELISPOT using freshly isolated PBMC
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{ex-vivo ELISPOT), and IFN-y ELISPOT assays after re-stimulation and expansion in 
vitro (cultured ELISPOT) were performed in response to the 8 CS protein epitopes 
selected for the study (Figure 3.1). It is not known if anti-CS Ab levels correlate with IFN- 
y T cell responses, and there are conflicting reports as to whether Ab responses correlate 
with proliferation in natural immunity to CS protein (Good et a l, 1988d, Hoffman et a l, 
1989b, de Groot et a l, 1989, Riley et a l, 1990). Thus, serum Ab levels to recombinant CS 
protein were assessed in parallel for each donor by ELISA, to look for a correlation 
between the 3 T cell assays. Malaria blood films were also performed on all donors to see 
if there was any relationship between blood film positivity and T cell responses to CS.
3.2.2
Study Site and Volunteers
Peripheral blood mononuclear cells (PBMCs) were collected from 50 healthy adult male 
volunteers (donors D1-D50) from Dampha Kunda, Upper River Division, The Gambia 
between February and March 1997 (Figure 3.2). This represents the middle of the dry 
season when malaria transmission rates are low. The malaria season begins 5 months later 
after the rains commence, with high malaria transmission rates occurring between August 
and November. Forty eight donor samples were used for the main comparative study of 3 
T cell assays (donors D1-D48), and the remaining 2 donors (D49 and D50) were tested in 
limited assays only (see below).
Twenty malaria naïve adult donors were recruited from the laboratory in Oxford for the 
assessment of responses of naïve donors to peptides from CS protein. A detailed travel 
history was taken from each of these donors to confirm that they had never been exposed 
to malaria. A further 15 healthy adult donors were recruited from the staff at the John 
Radcliffe Hospital regardless of previous malaria exposure to test the effects of CD38 / 
CCR7 depletion to common recall antigens.
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Figure 3.2
D a m p h a
Healthy adult donors were recruited from  3 sites in The Gambia: Bakau, B refet and Dampha 
Kunda. The 3 Gambian studies (Chapters 3, 4, and 5) used donors from  different study sites, 
and the details are given in the relevant sections o f  the text.
3.2.3 
Peptides
Thirty seven 15mer peptides (overlapping by 5 residues) extending from the NANP repeat 
region to the carboxy terminus of CS protein (aa 273-412) from strains NF54 and 7G8 
were synthesised commercially. All peptides were tested in IFN-y ELISPOT in five 
randomly selected Gambian adults (Table 3.1). Eight peptides spanning residues 328-397 
(C1-C8) were selected for the study (Figure 3.1), consisting of a combination of NF54 
(peptides C1-C4, C7-C8) and 7G8 strain (C4-C8) derived sequences. These two strains 
vary by 6 nucleotide substitutions across residues 328 -397, all of which lead to amino acid 
changes (Caspers et al., 1989). Peptides C4, C l and C8 are identical for NF54 and 7G8. 
The relative frequencies of NF54 and 7G8 variants in the Basse region of The Gambia in 
November 1997 were as follows: 7G8 Th2R epitope 0.12, NF54 Th2R epitope 0.07, 7G8 
Th3R epitope 0.05, NF54 Th3R epitope 0.26 (A. Alloueche, personal communication). 
Peptides corresponding to the known Th2R (aa 326-347, called peptide V6) and Th3R (aa 
361-380) epitope regions of CS protein clone NF54 were similarly synthesized 
commercially (Figure 3.1). All peptides were reconstituted in RPMI-1640 (Gibco, 
Glasgow, UK), and RPMI was used as the negative control in all assays. Four peptide 
pools, consisting of two non-overlapping peptides per pool, were prepared in which to 
culture cells for a later IFN-y ELISPOT assay: pool A contained peptides C 1 and C4; pool 
B peptides C2 and C6; pool C peptides C3 and Cl; and pool D peptides C5 and C8 (see 
Figure 3.1 for location of peptides). Peptide pools were added to the cells for culture to 
give a concentration of 25pg/ml per peptide. Purified protein derivative (PPD) (Statens 
Seruminstitut, Copenhagen, Denmark) was used as a generally positive control.
3.2.4
Statistical Methods
Statistical analysis for this study was done by Dr M Gravenor. A simulation approach 
was used to test whether the patterns of responses to each peptide were correlated over 
the ex-vivo ELISPOT, cultured ELISPOT and proliferative assays. For each donor he 
summarised the correlation between a pair of assays by counting the number of times the
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Table 3.1
Peptide | 1 s 
aa
7
2 7
8
28
9
29
1 0 
33
1 1
34
1 2
35
1 3 
36
1 4
37
1 9 
38
20
39 
21
40
PPD
273
278
283
288
293
298
303
308
313
318
323
328
333
338
1 5 343 Both
1 6 348 Both
1 7 453 Both
1 8 358 Both
363
368
373
22 378 Both
23 383 Both
24 388 Both
25 393 Both
26 398 Both
NA
NF54 
or 7G8
Both
Both
Both
Both
Both
Both
7G8
NF54
7G8
NF54
7GB
NF54
7G8
NF54
Donor 
T1 T 2 T 3 T 4 T5
7G8
NF54
7GB
NF54
7GB
NF54
NA
IFN-Y ELISPOT pilot study testing 37 ISmer CS peptides from strains NF54 and 7G8 o f  circumsporozoite
protein in S Gambian donors. The peptides marked with an asterisk (CI-C8) were selected fo r the main 
study.
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same result was found for the corresponding peptides. This is a maximum of 8 when the 
individual shows the same response to each peptide in each assay. The average value was 
calculated over all donors for each pair of assay comparisons. The distribution of this 
average index under the null hypothesis of no correlation was calculated using binomial 
distributions with n = 48, and the probability of a success estimated from the average 
number of positive responses in each assay.
Standard chi square tests were used to assess associations between antibody level, 
categorised as low (<4pg/ml), medium (4-10pg/ml) and high (>10pg/ml), blood smears 
(positive or negative), and assay responses (responds to at least one peptide or no 
response). In addition, proliferative stimulation index values were compared directly with 
Ab levels (pg/ml) to assess for an association. The effects of depleting cells expressing 
various surface markers were assessed using paired students’ t-tests. The proliferation 
counts were log transformed for this comparison.
3.3 
RESULTS 
3.3.1
Lack of Correlation Between Responses to CS Protein Determined by 
Simultaneous Assessment of Three Different T Cell Effector Functions
48 donors were tested for responses to a panel of 8 overlapping peptides Cl to C8 
spanning residues 328-397 of the carboxy-terminus of CS protein (Figure 3.1) in ex-vivo 
ELISPOT, cultured ELISPOT, and lymphoproliferative assays. PPD was used as a 
positive control antigen being frequently positive in this population. Eighty four percent 
(32/38) of the 38 donors for whom there were sufficient cells to perform all 3 assays 
responded to one or more CS peptide, and all but two donors gave a positive response to 
PPD in ex-vivo ELISPOT or proliferation (Table 3.2). Twenty malaria naïve adult donors 
recruited in Oxford were tested for ex-vivo IFN-y ELISPOT responses to peptides Cl to 
C8, and no positive responses were found, whilst all naïve donors responded to PPD (not 
shown).
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Table 3.2
A b
D 1 4 .3
D 2 1.4
D 3 4 .3
D 4 5 4 .0
0 5 1 .6
D 6 1.6
0 7 241
0 8 1 1 .3
0 9 2.1
D I O 2 .8
D l l 1.1
0 1 2 1 6 .9
0 1 3 1.8
0 1 4 0 .5
0 1 5 1 6 .9
D I G 4.1
0 1 7 2.1
0 1 8 1 0 .4
0 1 9 1 7 .4
0 2 0 1 .2
0 2 1 0 .6
0 2 2 2 .2
0 2 3 5 .6
0 2 4 1 2 .8
0 2 5 7 .9
D 2 6 2.1
0 2 7 4 .6
0 2 8 2 .7
0 2 9 2 .6
D 3 0 4 .8
0 3 1 0 .9
0 3 2 1 6 .8
0 3 3 6 .7
0 3 4 5 .3
0 3 5 3.1
0 3 6 1.0
0 3 7 4 .0
0 3 8 7 .7
0 3 9 2 .4
0 4 0 14.1
0 4 1 8 .3
0 4 2 2 .0
0 4 3 1 7 .4
0 4 4 1 0 .9
0 4 5 1 4 .4
0 4 6 0 .5
0 4 7 0 .8
0 4 8 10.1
E x -v iv o  E L IS P O T
C1 C 2  C 3  C 4  0 5  0 6  0 7  0 8
C u ltu re d  E L I S P O T
B =B 8 5
H
ND
N D
I'D
N D
N D
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND ND ND ND ND ND ND
ND I N D I ND
P r o l i f e r a t i o n
0 1  0 2  0 3  0 4  0 5  0 6  0 7  0 8
ND ND ND ND ND ND ND ND
—
—
TTIy=u
ND ND ND ND ND ND ND ND
1— , —
ZZÜ
ND ND ND ND ND ND ND ND
4+4
ND ND ND ND ND ND ND ND
ND ND ND ND ND ND ND ND
#
ND ND ND ND ND ND ND ND
44- mm
ELIS P ro l
ND
ND
ND
ND
ND
ND
> 10  - 49  S FU  /million 
> 50  - 99 S FU  /million 
> 100  S FU  /million
>10  - 49  S F U  /million 
>50  - 99 S F U  /million 
> 100  SFU /million
SI >2 - <3  
SI >3 - <10  
SI >10
Summary o f  ex-vivo ELISPOT, cultured ELISPOT, proliferative responses, and anti-CS antibody levels 
(anti-R32LR) for 48 Gambian donors (D1 to D48). Filled in squares represent a positive response, and are 
shaded according to the magnitude o f the response (see key). Antibody levels are expressed in pg/ml; ND  =  
not determined, *  =  malaria blood film  positive.
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Five malaria naïve donors were tested in cultured ELISPOT, and four donors in 
lymphoproliferative assays, and again no positive responses were observed to the 8 CS 
peptides (not shown).
More than half of the donors who gave a positive response did so to more than one 
peptide. The maximum number of peptides to which an individual responded was 7 in the 
ex-vivo ELISPOT assay (donor D46), 4 in the cultured ELISPOT assay (donor D32), and 
5 by lymphoproliferation (donor D45) (Table 3.2). For each T cell effector function those 
donors that gave multiple responses were different (Table 3.2). It was possible that a 
response to two overlapping peptides in a particular donor represented a single response 
to a shared T cell site, for example D42 responded in the ex-vivo ELISPOT to the 
overlapping peptides C l (aa 378-392) and C8 (aa 383-397). However, responses were also 
observed to each peptide individually over the 3 assays, for example D31 and D32 
responded to C l but not C8; D30 and D40 responded to C8 but not C7, suggesting that 
each peptide must also represent a T cell epitope in its own right.
I found that 40% of donors (19/48) responded to one or more peptide in the ex-vivo 
ELISPOT assay, 55% (22/40) in the cultured ELISPOT assay, and 40% (17/42) by 
proliferation. Eleven (23%) of the donors tested in ex-vivo ELISPOT responded to 1 
peptide only, and 8 donors (17%) responded to more than 1 peptide. Eight (20%) of the 
donors tested by cultured ELISPOT responded to one peptide only, and 14 (35%) to more 
than 1 peptide. Nine donors (21%) proliferated to one peptide and 8 (19%) donors gave 
multiple responses by lymphoproliferation. Thus cultured ELISPOT gave double the 
number of multiple epitope responders (35%) compared to the other 2 assays (17% & 
19%). The cultured ELISPOT responses were of a much higher magnitude (mean 224 
±30.6 SE) than the ex-vivo responses (mean 39 ±5.3 SE) (Table 3.3), probably reflecting 
their 2 week expansion period in vitro and differences in the population measured (see 
later). The lymphoproliferative responses were generally low (mean SI 4.6 ±0.7 SE).
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Low grade T cell responses are characteristic of malaria induced natural immunity both to 
pre-erythrocytic stage (Good et a l, 1988d, Riley et a l, 1990) and blood stage antigens 
(Riley et a l, 1992, Lee et a l, 2000), a phenomenon which is discussed in detail in the 
introduction (Chapter 1).
A positive response to each peptide in the ex-vivo ELISPOT was not significantly 
correlated with the corresponding peptide response in proliferation (p = 0.57). This result 
is in agreement with the lack of correlation between proliferative responses and IFN-y 
release seen in response to the 2 blood stage malaria antigens Pfl 5 5/ring-infected 
erythrocyte surface antigen (RESA) (Troye-Blomberg et a l, 1990) and merozoite surface 
protein 1 (/yMSPl) (Riley et a l, 1993) in naturally exposed Gambian adults. I also failed 
to find a correlation between the ex-vivo and cultured ELISPOT responses (p = 0.65). One 
might predict that proliferation and cultured ELISPOT would detect the same T cells, since 
both assays measure cells re-stimulated in culture. However, in this study the pattern of 
peptide responses was not significantly correlated over the two assays (p = 0.12). Thus, 
for no individual peptide did a positive response for one of the three T cell effector 
functions correlate significantly with a positive response to another.
The PBMC were stimulated differently for each of the 3 T cell assays, which may 
contribute to their lack of correlation, for example by preferentially promoting the 
activation of a different T cell subset. Thus, the cultured ELISPOT cells were cultured for 
14 days in MEM-10 medium in a 48 well tissue culture plate and IL-2 was added on 2 
occasions. The proliferating cells were also cultured in MEM-10, but only for 5 days, and 
no IL-2 was used. The ELISPOT assays using the ex-vivo cells and cultured cells were 
performed in exactly the same way except that less cultured cells (1 x 105) were added per 
well in the assay since after culture the reactive cells would have otherwise been too 
numerous to score visually.
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3.3.2
Different Immunodominant Epitopes are the Target of Diverse T Cell Effector 
Functions
Lymphoproliferative assays in naturally exposed donors have identified 3 
immunodominant T cell epitope domains located outside the repetitive region of CS, called 
the Th2R (aa 326-347), Th3R (aa 361-380) (Good et a l, 1988d, Shi et a l, 1992), and 
CS.T3 (aa 378-398) regions (Sinigaglia et a l, 1988a). All of these domains are covered by 
the peptides assayed in this study (Figure 3.1). Up to 25% of naturally exposed adults 
respond to the Th2R region and 43% to the Th3R region of CS protein (Good et al, 
1988d). Sinigaglia and colleagues found that 56% of naturally exposed adults from the 
Ivory Coast respond to region CS.T3, and a surprisingly high proportion (one third) of 
malaria naïves also had a proliferative response to CS.T3 in this study (Sinigaglia et al, 
1988a). However, Good and colleagues found no proliferative responses to the equivalent 
peptide 27 (aa 380-399) in 35 Gambian adult volunteers (Good et a l, 1988d). Similarly, 
Hoffman and colleagues found no proliferative responses to CS protein residues 381-400, 
and only 1 responder to residues 376-395, in a study of 28 Kenyan adults (Hoffman et al, 
1989b).
The most frequent positive response in ex-vivo ELISPOT in this study was to CS peptide 
C6 (aa 368-382) (19% donors) which overlaps the Th3R region (aa 361-380); whereas in 
cultured ELISPOT it was to peptide C2 (aa 333-347) (27% donors) which is contained 
within the Th2R region (aa 326-347). In assays of T cell proliferation, peptide C6 (Th2R) 
(19% of donors) was recognised most frequently, with C2 (Th2R) next in frequency (17% 
of donors). Peptide C8 (aa 383-397) was the second most commonly recognised epitope in 
ex-vivo ELISPOT (15% of donors) in our study. This peptide corresponds to the CS.T3 
(aa 378-398) region which is recognised in association with at least 7 different class II HLA 
DR types (Sinigaglia et a l, 1988b), although the minimal epitope corresponding to C8 is 
recognised by only 3 of these 7 DR types. Thus, each assay gives a different hierarchy of 
epitope responses, although individual epitopes are recognised at frequencies similar to 
previous studies.
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CD4 and CDS depletion studies confirmed that IFN-y ELISPOT responses to epitopes 
C l, C2, C3 and C6 were CD4 mediated (Figures 3.3 A-D). It is probable that the other 4 
epitopes are also CD4 epitopes in nature. Similar depletion studies for cultured ELISPOT 
responses to 15mer epitopes spanning the entire carboxy-terminus of CS protein using 
PBMC from RTS,S vaccinated Europeans confirmed that the responses were CD4 
mediated in 37/40 cases tested (W. Reece, personal communication).
3.3.3 
Correlates with Antibody Responses to CS Protein in Naturally Exposed Adults
Several studies of natural immunity to CS protein find no correlation between proliferation 
and anti-CS Ab levels (Riley et a l, 1990, Good et a l, 1988d, de Groot et a l, 1989). 
However, in a separate study Hoffman and colleagues do observe a correlation (Hoffman et 
a l, 1989b). To explore this issue further, I tested for a correlation with anti-CS Ab levels 
and proliferation to the carboxy-terminus of CS. Since I also assessed for new T cell 
effector functions {ex-vivo and cultured IFN-y secretion), it was important to determine 
whether a correlation with Ab levels might now be found. Anti-CS antibody levels were 
tested for the 48 donors above, and ranged from 0.5 to 241pg/ml (mean 11.5 ±4.9 SE, Table 
3.2). Forty six percent of donors had low anti-CS Ab levels of <4pg/ml which are generally 
considered to be background levels, 25% had moderate levels between 4 and 10pg/ml, and 
29% had high levels of >10pg/ml.
A comparison of Ab levels with positive responses in the 3 assays demonstrated that there 
was no correlation between Ab levels and ex-vivo or cultured ELISPOT (%2 test, p = 0.3 
and 0.4 respectively), but a borderline correlation was found for those who gave positive 
proliferative responses (p = 0.05). Thirty two percent of positive responders in the ex- 
vivo ELISPOT, 36% in cultured ELISPOT, and 47% of those whose T cells proliferated to 
the CS peptides had high Ab levels (>10pg/ml), with no significant correlation between 
high antibody production and a positive assay response in ex-vivo ELISPOT (%2 test p = 
0.8) or cultured ELISPOT (p = 0.6).
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CD4 and CD8 depletion studies showed that IFN-y ELISPOT responses o f  undepleted PBMC (Total, black 
bars) to 4 peptides (Cl, C2, C3 and C6) were lost in the CD4 depleted wells (stippled bars), but 
maintained in the CDS depleted wells (chequered bars).
The correlation between Ab production and positive lymphoproliferation no longer 
reached significance (p = 0.06) when only those donors with high Ab levels were 
considered. Thus, although proliferation correlated rather weakly with Ab levels, no 
correlation with ex-vivo or cultured IFN-y ELISPOT was found.
IFN-y has been shown to be protective in animal models of malaria infection (Schofield et 
a l, 1987c, Maheshwari et a l, 1986), with evidence for a protective role in humans (Stoute 
et a l, 1997, Mellouk et a l, 1987). It was therefore considered to be an important cytokine 
to assess in our study of natural T cell immunity and correlates of antibody production. 
However, it was feasible that other cytokine responses, such as the Th2 type cytokine IL- 
4, might correlate with antibody levels. Indeed, Troye-Blomberg and colleagues find that
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there is a correlation between IL-4 production and serum Ab levels to peptides derived 
from the blood stage antigen Pfl55 / RESA in malaria (Troye-Blomberg et a l, 1990). Anti- 
CS Ab levels were thus assessed in parallel by IL-4 and IFN-y ELISPOT to the 
immunodominant epitopes Th2R (aa 326-347) and Th3R (aa 361-380) of E/NF54 strain of 
CS protein (see Figure 3.1) for 19 of the 48 donors recruited to this study. An additional 
two donors were also tested for IL-4 and IFN-y responses to these 2 epitopes (D49 and 
D50) (Table 3.4). Two donors had a positive IL-4 ELISPOT response to the Th2R 
epitope, one of whom gave a positive IFN-y response (Table 3.4). The three donors who 
produced IL-4 in response to the Th3R region also produced IFN-y to the same epitope. 
The frequency of IFN-y responders (29%) was greater than the IL-4 response rate (19%). 
No correlation was apparent between Ab levels and IL-4 ELISPOT responses in these 
donors, although the number of IL-4 responders was small (n = 4).
3.3.4
Parasitaemia Does Not Correlate with Immunological Parameters
All donors had thick and thin malaria blood films performed at the time of blood collection, 
and fourteen donors (29%) were found to be parasitaemic with asexual forms of P. 
falciparum. Four of the blood film positive donors had background anti-CS Ab levels 
(<4pg/ml), six had moderate levels (4-10pg/ml), and four donors had high antibody levels 
(>10pg/ml), with no correlation between smear positivity and Ab level (%2 test, p = 0.5). 
Similarly, there was no association between blood smear positivity and any of the three T 
cell assays employed in this study (ex-vivo ELISPOT p = 0.8, cultured ELISPOT p = 0.9, 
proliferation p = 0.7).
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3.3.5 
Effect of CD45RO, CD45RA and CD45RB Depletion of PBMC on the 3 T Cell
Assays
The lack of correlation between epitope responses measured by these 3 T cell assays 
suggested that different memory T cell subtypes were involved. Differentiating memory T 
cells has however proved to be an elusive goal. Until recently, human isoforms of CD45 (a 
phosphatase involved in cell signalling) have provided the only means of identifying 
memory T cells. Thus, memory / effector T cells have been characterised as expressing a 
CD45RAlowROhlgh phenotype (Mackay, 1993), and naïve T cells express the converse 
CD45RAhlghR 0 low phenotype. Indeed, memory T cells capable of proliferation or rapid 
IFN-y secretion have been shown to be CD45RO+ (Plebanski et a l, 1992, Lalvani et al, 
1997). I found that depletion of PBMC expressing CD45RA and CD45RO had the 
predicted effect on ex-vivo ELISPOT and proliferative responses to PPD. Thus, CD45RA 
depletion did not lead to a significant effect in ELISPOT (n = 6, p = 0.49) or proliferation 
assays (n = 5, p = 0.11) (Figure 3.4A and B, representative results for 3 donors). CD45RO 
depletion should cause a loss of memory T cells, and indeed depletion led to a significant 
decline in IFN-y ELISPOT responses (n = 7, p = 0.004), although the decline observed in 
the proliferation assays was not significant (n = 4, p = 0.08), probably because only 4 
donors were tested (Figure 3.4A and B, results for 3 donors).
Horgan and colleagues demonstrated that CD45RB expression may define different subsets 
of CD45RO+ memory cells in humans which have differential abilities to proliferate and 
induce cytokines (Horgan et a l, 1994). Indeed, in rats CD45RB expression has been shown 
to identify a T cell subset within the CD45RO+ group specifically capable of IFN-y 
secretion (Swain, 1991). I was therefore interested to see whether the CD45RB+ cells were 
responsible for rapid IFN-y release detected by ELISPOT. As predicted, depleting 
CD45RB cells led to a significant decrease in the IFN-y ELISPOT PPD response (n = 8, p 
= 0.017) (Figure 3.4B). The effect on lymphoproliferative responses was highly variable in 
the 7 donors tested (p = 0.67).
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Effect o f depleting cells expressing the surface markers CD45RO (white bars), CD45RA (hatched bars) and 
CD45RB (stippled bars) on the undepleted PBMC (Total, black bars) response to PPD by ex-vivo ELISPOT 
(A) and lymphoproliferation (B). Representative results for 3 donors.
3.3.6
CCR7 Cells are Required to Generate Cultured IFN-y ELISPOT Responses, But 
Not ex-vivo IFN-y ELISPOT or Proliferative Responses
Sallusto and colleagues used a mAb to demonstrate that human memory CD45RO+ T cells 
can be divided into two functionally distinct subsets characterised by the presence or 
absence of expression of the chemokine receptor CCR7 (Sallusto et a l, 1999). The CCR7" 
group mediates rapid effector function, and is capable of rapid cytokine production 
including IFN-y. I hypothesised that this T cell subgroup, denoted TEM (effector memory), 
is a likely candidate mediator of ex-vivo ELISPOT responses. A second T cell group, 
denoted TCM (central memory), is CCR7+ and requires further in-vivo stimulation and 
culture prior to the production of cytokines such as IFN-y. I predicted that CCR7+ cells 
might be required to generate cultured ELISPOT responses.
To test this hypothesis I obtained an aliquot of the CCR7 mAb used in the studies by 
Sallusto and colleagues. Frozen PBMC from donor D41 from The Gambian study were
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defrosted and depleted for cells expressing CCR7 (see Methods). The cells were then 
tested in an overnight IFN-y ELISPOT assay against 4 pools of the CS peptides Cl to C8. 
The undepleted PBMC responded to peptides C1-C6 in the original study, and the CCR7 
depleted PBMC gave comparable ELISPOT responses to the equivalent peptide pools 
(Figure 3.5A). This confirmed that the ex-vivo ELISPOT required CCR7" cells, but not 
CCR7+ cells to generate a response. Donor KT, who is known to respond to the CS 
derived Th2R malaria epitope V6, was depleted of PBMC expressing CCR7, and ex-vivo 
ELISPOT, cultured ELISPOT and proliferation assays were set up in parallel with 
undepleted and depleted cells. The ex-vivo ELISPOT response was comparable for 
undepleted and CCR7" PBMC (Figure 3.5B), whereas the cultured ELISPOT response 
which was positive for the undepleted PBMC, was significantly reduced following CCR7 
depletion prior to culture (Figure 3.5C). The lymphoproliferative response was present in 
both undepleted and depleted cells with comparable stimulation indices of 2.4 and 3.4 
respectively (Figure 3.3D).
This confirms the hypothesis that CCR7" cells mediate ex-vivo ELISPOT responses, and 
that cultured ELISPOT responses cannot be generated in the absence of CCR7+ cells. 
Studies for 2 more donors to an HLA-A2 restricted influenza epitope and PPD showed the 
same trend with ex-vivo and proliferative responses present in the CCR7 depleted wells, 
but failure to generate cultured ELISPOT responses following CCR7+ cell depletion 
(Figures 3.6 A-F). These different T cell subsets may therefore mediate different effector 
functions for MHC class I as well as class II restricted epitope responses.
I thus have preliminary evidence in 4 donors supporting my hypothesis that the ex-vivo 
ELISPOT measures CCR7 circulating effector T cells (TEM cells) in response to antigen, 
whilst the cultured ELISPOT detects a CCR7+ central memory population (TCm cells). The 
original study by Sallusto and colleagues showed that the CCR7+ and CCR7" cells are 
capable of proliferation, and thus would not be expected to be decreased by CCR7 
depletion if the same number of cells are used in the undepleted and depleted assays.
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Standard error bars are shown.
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3.3.7
Proliferation and Rapid IFN-y Responses to PPD are Differentially Regulated by 
CD38+ Cells
CCR7 depletion can thus distinguish those cells mediating cultured ELISPOT responses, 
from ex-vivo ELISPOT and lymphoproliferative responses. However, the lack of 
correlation between IFN-y production and proliferation still needed to be explained. In 
preliminary assays, PBMC depleted of those cells expressing the T cell activation markers 
CD27, NKA (EB6) and NKB (CD 158b), failed to show consistent differences in reactivity 
in either proliferative or IFN-y assays compared to undepleted PBMC (not shown). 
Expression of CD38 has been used as a marker of activation in human T cells (Funaro et 
a l, 1990), and CDS8 ligation can induce early IFN-y production in the absence of 
proliferation (Ausiello et a l, 1995). I thus hypothesised that depletion of cells expressing 
CDS 8 might differentiate ex-vivo IFN-y ELISPOT and lymphoproliferative responses.
In order to explore the role of CD38+ cells in the 3 different assays in more detail I 
analysed responses to the common recall antigen PPD. Surprisingly, I observed a reciprocal 
effect of CD38 depletion on ex-vivo IFN-y ELISPOT compared to lymphoproliferation. In 
ex-vivo ELISPOT, depletion of CD38 cells led to a significant drop in PPD response in 5 
out of 8 donors tested (Figure 3.7A) with no change in two donors, and an increase in one. 
The day 5 lymphoproliferative response to PPD was concomitantly increased in 7 out of 8 
of these donors following CD38 depletion (Figure 3.7B). Cultured ELISPOT responses 
performed to PPD on two of these donors showed a drop in response on CD38 depletion 
in one donor, and no change in the other (not shown).
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The effect of CD38 depletion was greatest when the initial PBMC proliferative response 
was low, and as the starting PBMC proliferative capacity increased, the effect of CD38 
depletion became less pronounced. A plot of the log (3-counts to PPD for the undepleted 
PBMC on the x-axis, against the log fold increase in count following CD38 depletion for 14 
donors, gave a straight line (R2 = 0.93, p = 2xl0"7) (Figure 3.8). This strongly suggested 
that the starting count was highly correlated to the subsequent increase in count following 
depletion.
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in proliferation following CD38 depletion (Log fo ld  increase CPM). A logarithmic plot for 14 donors gave 
a straight line, R2 = 0.93, p  = 2x10'7. This suggested that the magnitude o f  the initial PBMC CPM was 
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greatest effect, but i f  the starting values were high initially then depletion o f  CD38 cells had little or no
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Thus, where a donor gave poor proliferative responses to PPD (CPM <500), CD38 
depletion led to marked enhancement of responses, suggesting that CD38+ cells were 
actively suppressing the response. As the starting PBMC proliferative response increased 
(CPM 1x 104-3 x 104), the effect of CD38 depletion diminished. At the highest starting 
proliferative responses (CPM 7xl04), there was no effect following CD38 depletion. Thus, 
CD38+ cells seem to actively suppress the PBMC proliferative response in certain donors, 
but not in others.
It was possible that the enhanced proliferative responses seen for CD38* PBMC was a 
result of differential time peaks for depleted compared to undepleted PBMC. To exclude 
this possibility I performed proliferative assays to PPD on undepleted and CD38" PBMC 
on days 5, 6 and 7 for five donors (Figs 3.9A and B, representative results for 2 donors). 
For all donors the effect of enhanced proliferative responses following CD38 depletion was 
maintained over the 3 days, and the peak proliferative response occurred on day 5 for 
undepleted and CD38 depleted PBMC.
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Proliferative time course experiments indicated that the CD38 depleted PBMC (hatched bars) had higher 
proliferative counts compared to undepleted PBMC (black bars) over a 3 day period. Standard error bars 
are shown.
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CDS 8 is expressed on macrophage / monocytes in addition to activated T cells (Funaro et 
a l, 1990), and hence the effect of depletion of CD38+ cells might have been due to loss of 
suppressive antigen presenting cells (APCs). I thus purified T cells for donor HM, and 
assessed the effect of CDS8 depletion of T cells on PPD proliferative responses. Adherent 
cells were irradiated and used as APCs in the T cell assays. I confirmed that the effect of 
CDS8 depletion can occur for purified T cells (Figure 3.1 OB), as well as PBMC (Figure 
3.10A), although this does not exclude an additional role for CDS8  ^ APCs. Ex-vivo 
ELISPOT and cultured ELISPOT responses using purified T cells and irradiated APCs at 
the same time led to an unchanged ex-vivo response (Figure 3.10C), and a diminished 
cultured ELISPOT response (Figures 3.10D). This result (unchanged ex-vivo and decreased 
cultured ELISPOT on CDS 8 depletion) was confirmed in T cell studies for 2 more donors 
(not shown).
3.3.8
CD38 Depletion Enhances PBMC Proliferation to a CS Protein CD4 T Cell Epitope 
in a Malaria Exposed Donor
I was curious to see if the same phenomenon could be demonstrated for a malaria response, 
since it has long been postulated that malaria immunosuppression may be caused by an 
actively suppressive T cell subset. I depleted donor KT PBMC of CDS 8 cells, and tested 
responses to the immunodominant Th2R CD4 malaria epitope V6 (see Figure 3.1 for 
location of epitope within CS). Day 5 lymphoproliferative responses were significantly 
enhanced on CDS8 depletion (Figure 3.11A, n = 2 experiments); ex-vivo ELISPOT 
responses were not significantly different (Figure 3.1 IB, n = 2 experiments); and cultured 
ELISPOT responses were markedly decreased (Figure 3.11C, n = 2 experiments).
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Figure 3.11
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3.3.9
CD38+ T Cells Do Not Proliferate and Actively Inhibit Lymphoproliferative 
Responses
Having established that removal of CD38+ cells from PBMC or T cells led to an enhanced 
proliferative response to PPD and the Th2R malaria epitope, I wanted to investigate the 
mechanism of this effect. In order to do this I recruited a number of healthy adult donors 
from the laboratory in Oxford who responded to a variety of common antigens including 
PPD, tetanus toxoid (TT), and a crude gluten digest (GUI), which is thought to contain a 
number of CD4 epitopes (R. Anderson, personal communication). CD38 depletion of 
PBMC was found to enhance proliferative responses to TT, a CD4 T cell response, in 2 
out of 3 donors tested (Figure 3.12C), and GUI in 2 of 3 donors tested (Figure 3.12B). 
PH A responses were unaffected by CD38 depletion in these 3 donors (Figure 3.12D, 
suggesting that the effect is antigen specific.
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CD38 depletion (hatched bars) o f  PBMC (black bars) was found  to effect lymphoproliferative responses to 
PPD (A), a gluten derived peptide digest called GUI (B), and tetanus toxoid or TT (C). There was no 
significant effect on the response to the mitogen PHA (D), suggesting that the response was antigen 
specific. Representative results fo r  one donor. Standard error bars are shown.
I investigated whether adding back CD38+ cells actively inhibits proliferation. PBMC were 
thus depleted of CD38+ cells, and the effect of adding these back to the CD38" cell fraction 
was investigated. The GUI response for donor RA was actively inhibited by adding back 
CD38+ PBMC (67% inhibition), and the CD38+ cells alone did not proliferate (Figure 
3.13A). The CD38+ cells were added at a ratio of 1:2 38+:38" cells, with a constant number 
of CD38" cells in all wells in which they were tested. In the same donor CD38 depletion 
had no effect on the initial vigorous proliferative response to TT, and adding back the 
CD38+ cells also had no effect (Figure 3.13B).
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Figure 3.13
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Adding CD38+ cells back to the CDS8' cells led to a 67% inhibition o f  the proliferative response to GUI fo r  
donor RA (A). Neither the irradiated adherent cells, nor the CD38+ cells were able to proliferate. There 
was no effect o f  CD38 depletion on the vigorous TT proliferative response (B), and adding back CD38+ 
cells had no effect in this case. This is consistent with the earlier observations fo r  PPD that a high 
starting CPM was generally not under the influence o f  CD38+ suppressor cells, and also shows antigen 
specificity fo r  the effect. Standard error bars are shown.
This further supports our hypothesis that CD38+ cells tend not to be suppressive when 
the initial proliferative response is high, and also shows antigen specificity. Inhibitory 
CD38+ cells might exert their inhibitory effect either by a direct effect on the proliferating 
cells, or via the production of inhibitory cytokines such as IL-10 and TGF-|3. In order to 
investigate whether direct cell-cell contact was required, or whether a soluble mediator was 
involved, I performed experiments with transwells. Thus, I added back CD38+ cells either 
directly into the well containing CD38" cells, or into transwells which allow the passage of 
soluble inhibitory factors but no direct cell contact. I found for PPD and TT responses that 
there was no inhibition when 38+ cells were placed in a transwell (38* out + 38+ trans), but 
that direct addition of CD38+ cells (38" out + 38+ out) led to inhibition of the response 
(Figures 3.14A and B). Direct addition led to a 47% inhibition of the PPD response, and a 
51% inhibition of the TT response. The corresponding change in counts on adding CD38+
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cells across a transwell were 0% for PPD and 14% for TT. Interestingly, addition of 
undepleted PBMC also caused an inhibitory effect of 36% for the PPD response, but had 
no effect on the TT response. It is possible that the CD38+ fraction of the undepleted 
PBMC was inhibitory in the former case.
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The inhibitory effect o f  the CD38+ cells required cell-cell contact. A significant inhibitory effect was seen
when CD38+ cells were added directly to CD38' cells (38' out and 38+ out), but not when added to a
+ < 
transwell (38' out and 38 trans). This was demonstrated fo r  PPD (A) and TT (B) specific responses.
Standard error bars are shown. Ratio o f  CD38+:CD38' was 1:2
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The above experiments were performed using PBMC, but since the responses to PPD, TT 
and GUI are predominantly thought to be CD4 in nature, I went on to perform experiments 
using purified CD4+ T cells. Experiments were performed for 3 donors. Inhibition by 
CD4+38+ T cells was demonstrated in all 3 cases. Donor KF CD4+38" cells proliferated 
vigorously to PPD, and this was inhibited by 25% when CD4+38+ cells were added to the 
well at a 1:1 ratio (Figure 3.15A). It is important to note that the wells containing the 
inhibitory cells had twice the number of cells per well compared to the CD4 38" wells, 
since a constant number of CD38" cells was used for all experiments. CD38+ cells at a ratio 
of 1:8 were able to cause 53% inhibition of a CD4 CD38' T cell PPD response for donor 
BU (Figure 3.15B), which is the lowest ratio at which I have observed inhibition. Similar 
results were obtained for a GUI response in 1 donor with 31% suppression at a ratio of 1:4 
38+:38" CD4+ T cells. CD4+38+ cells did not proliferate in the two previous experiments.
I have therefore demonstrated that CD38+ PBMC suppressed proliferation by 47%-67% 
in 2 donors, and CD4+38+ T cells suppressed proliferation by 25%-53% in 3 donors. The 
lowest ratio at which I observed suppression of proliferation was 1:8 CD38 :CD38" cells. 
FACScan analysis for the above donors showed that 2-12% of CD4 T cells and 4-10% of 
CD8 T cells express CD38 on their surface, with marked variation between donors. Thus I 
have demonstrated inhibition of proliferation in-vitro at ratios of CD38+:38" CD4 T cells 
that exist in-vivo, further supporting an in-vivo immunosuppressive role for the CD38+ 
population.
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Figure 3.15
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The enhanced proliferation follow ing CD38 depletion (4+38), and subsequent inhibition by adding back 
CD38+ cells (4+38' + 4+38+), was demonstrated using purified CD4+ T cells from  2 donors KF (A) and BU  
(B). Standard error bars are shown.
3.4 
DISCUSSION
By assaying three T cell effector functions simultaneously in malaria exposed Gambians, I 
obtained an increased number of CS protein responsive donors than found in previous 
studies employing proliferation assays alone. Thus the number of individuals with T cells 
capable of responding to a particular antigen can be greatly underestimated unless multiple 
parameters of T cell activation are measured. Importantly, I show that epitope regions may 
be entirely missed if only proliferative assays are performed. The pattern of reactivity for 
each donor varied according to the effector function assessed, exposing different 
immunodominant regions in the carboxy-terminus of CS, and providing a broader picture of 
T cell reactivity for each donor.
All adults living in this region of The Gambia are repeatedly exposed to malaria throughout 
their life, and have developed a state of partial immunity by adulthood. Despite this, 46% 
of donors had low anti-CS Ab levels of <4pg/ml. I found that proliferative responses were 
weakly but significantly correlated with anti-CS Ab levels, a result consistent with the
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findings of Hoffman and colleagues (Hoffman et a l, 1989b), although other studies report 
no such correlation (Riley et a l, 1990, Good et a l, 1988d, de Groot et a l, 1989). This 
correlation was no longer significant if only those donors with high Ab levels (>10pg/ml) 
were considered, and thus our result regarding correlation is tentative. The ex-vivo and 
cultured IFN-y ELISPOT responses did not correlate with Ab levels, nor was a correlation 
between Abs and IL-4 ELISPOT responses to CS protein seen in Gambian adults. The 
latter differs from the findings of Troye-Blomberg and colleagues who reported a 
correlation between IL-4 production and elevated serum Ab levels to peptides from the 
blood stage Ag P/155 / RESA in a study of 8 adult Gambian donors (Troye-Blomberg et 
a l, 1990).
Thirty five percent (17/48) of naturally exposed donors in this study gave a T cell 
response with a concurrent low Ab response (<4pg/ml) suggesting that T cell functions 
other than help in Ab production play a role in natural immunity to malaria. A further ten 
percent (5/48) of the donors in this study had low Ab levels and no peptide response in 
any of the 3 assays. Such T cell nonresponsiveness is characteristic of natural immunity to 
malaria antigens, both in parasitaemic and aparasitaemic individuals (Good et a l, 1988d, 
Riley et a l, 1988b, Troye-Blomberg et a l, 1989, Hviid et a l, 1990), the possible causes for 
which are reviewed in Chapter 1.
There was no correlation between positive responses in any of the three T cell assays, 
suggesting that each assay detects a distinct functional T cell subset. Depletion studies 
confirmed that IFN-y ex-vivo ELISPOT and proliferative responses were mediated by 
CD45RA'RO+ cells (Mackay, 1993). CD45RB expression has been shown to define a T 
cell subset within the CD45RO+ memory T cell subset that is capable of IFN-y secretion 
(Swain, 1991), and indeed depletion of CD45RB cells led to a significant decline in IFN-y 
ELISPOT responses to PPD, but had a variable effect on lymphoproliferation.
Recently, human memory CD45RO+ T cells have been divided into two functionally 
distinct subsets according to the presence or absence of expression of the chemokine
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receptor CCR7 (Sallusto et a l, 1999). Depletion of cells expressing the chemokine receptor 
CCR7 showed that cultured ELISPOT responses require the presence of CCR7+ cells, 
whereas ex-vivo ELISPOT and lymphoproliferative responses do not. I thus have 
preliminary evidence in 4 donors supporting our hypothesis that the ex-vivo ELISPOT 
detects CCR7" circulating effector T cells (TEM cells) in response to antigen, whilst the 
cultured ELISPOT detects a CCR7+ central memory population (TCm cells). CCR7 
controls homing to secondary lymphoid organs, and its ligand is expressed on endothelial 
cells. CCR7+ cells home to lymph nodes, whereas CCR7* cells express receptors for 
migration to inflamed tissues.
Depletion of cells expressing the T cell activation marker CD38, led to increased 
lymphoproliferative responses to PPD, with either decreased or unchanged IFN-y 
ELISPOT responses. This effect on lymphoproliferation was dependant on the original 
proliferative response in the undepleted PBMC. Thus, only those donors with low to 
moderate counts to PPD prior to depletion, had enhanced counts following depletion. This 
phenomenon was highly correlated for 14 donors, and those with the lowest starting 
counts had the greatest relative increase following depletion. The enhancement of 
responses following CD38 depletion was shown to be mediated by a direct suppressive 
effect of CD38+ PBMC in 2 donors, and more specifically CD4+38+ T cells in 3 donors. A 
CD4 T cell malaria epitope proliferative response was also enhanced by CD38 depletion, 
confirming the relevance of this mechanism of T cell immunosuppression to malaria. M y 
findings are in keeping with previously published data in the murine model showing that a 
population of CD4+38* T cells mounts a vigorous proliferative response, but that the 
presence of a CD38+ population significantly inhibits anti-CD3 induced proliferation 
(Read et a l, 1998).
CD38 is a type II transmembrane glycoprotein with catalytic activity, but largely 
unknown function, expressed by different immunocompetent cells including activated T 
cells (Funaro et a l, 1990, Lund et a l, 1998). Like CCR7, its natural ligand is an endothelial 
receptor, in this case CD31, and CD38 is thought to play a role in endothelial adhesion of
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activated T cells. Human CD38 expression is increased in a variety of pathological 
conditions such as myeloma and lymphoma. An association between high levels of CD38 
expression on CD8+ T cells and poor prognosis in HIV infection is also well established 
(Giorgi et a l, 1993, Liu et a l, 1997), although the basis of this association is unknown. The 
immunoregulatory effect that I describe could play a role, since high CD38 expression may 
lead to a decreased proliferative capacity in response to the virus. CD38 expression has not 
been investigated in malaria, but a putative role in the poor lymphoproliferative responses 
that characterise natural immunity in malaria exposed donors is attractive. Understanding 
the differential immunoregulatory role of human CD38+ T cells may be important in the 
development of vaccines for malaria, and indeed other infectious diseases where 
proliferative and IFN-y responses play a protective role such as tuberculosis (Torres et a l, 
1994, S inha et a l, 1997) and leishmaniasis (Haberer et a l, 1998).
In summary, I have provided evidence that the currently accepted classification of memory 
T cells is incomplete. It is likely that they can be further subdivided, each group with a 
unique role in defence against disease. I have confirmed that CCR7+ cells are necessary to 
generate a cultured ELISPOT response, but are not required for ex-vivo ELISPOT 
responses or lymphoproliferation. I have also demonstrated that regulatory CD4+38+ T 
cells suppress lymphoproliferative responses to several CD4 antigens. Further assessment 
for T cells expressing various chemokine receptors (eg. CXCR3, CXCR4 and CCR5) 
(Sallusto e ta l,  1998), or cell surface markers (CD27, CD 148) (Baars et a l, 1995, Tangye 
et a l, 1998) may well lead to further subcategorisation of memory T cells. The precise role 
of these T cell subsets in protection against malaria, and indeed other infectious diseases, 
remains to be determined, with the exciting prospect that understanding these important 
issues will facilitate development of a new generation of immunoregulatory vaccines.
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CHAPTER 4
ALTERED PEPTIDE LIGAND ANTAGONISM FOR A 
VARIANT CD4 T CELL EPITOPE OF CS PROTEIN
4.1
INTRODUCTION
I demonstrated in chapter 3 that the number of donors responding to CS protein derived 
peptides can be greatly enhanced by employing 3 T cell assays simultaneously (ex-vivo 
IFN-y ELISPOT, cultured IFN-y ELISPOT and lymphoproliferation). The 15mer epitopes 
used for this study were derived from of two allelic variants of CS (clone NF54 and 7G8). 
However, the carboxy-terminus of CS, which contains most of the T cell epitope regions, 
is highly polymorphic. Individuals living in malaria endemic regions may expect to see 
multiple CS variants throughout a lifetime of parasite exposure, with over 10 polymorphic 
variants of particular epitopes present in a region at any one time.
The highest level of variation is found in two immunodominant proliferation inducing CD4 
T cell epitope regions within the carboxy-terminus of CS, denoted Th2R (aa 326-347) and 
Th3R (aa 361-380) (see Figure 3.1). CD8 T cell epitopes also exist within these regions, 
and are named Tc2R (aa 327-335) and Tc3R (aa 369-375) respectively. Exclusively 
nonsynonymous nucleotide changes occur in these epitope regions suggesting that they are 
under significant immune selection pressure, and that polymorphism is maintained as an 
immune escape strategy employed by the parasite. However, it has not been determined 
how CD4 T cells exert such selective pressure on the malaria parasite.
Adult Gambians receive an average of five bites from malaria infected mosquitoes every 
year, and by adulthood will have received in the order of 100 infectious bites (Greenwood 
e ta l,  1987, Gupta era/., 1994). Despite this continual antigenic exposure, many Gambian 
donors fail to respond to CS protein in proliferation assays (Good et al., 1988d, Good et 
a l, 1988b), even to the universally binding variant of the Th2R epitope (Calvo-Calle et a l,
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1997). Epitope polymorphism is not responsible for this low reactivity since 
lymphoproliferative responses to polymorphic variants of the Th2R and Th3R CD4 
epitope regions are generally non-crossreactive (de la Cruz et a l, 1988a, de la Cruz et a l, 
1989, Udhayakumar et a l, 1994, Zevering et a l, 1994). Again this is curious given that 
adults will have been exposed to each of the variants during their lifetime, and might be 
expected to respond to all variants. A generalised immunosuppression is unlikely to 
explain these phenomena since responses to other recall antigens such as PPD are found at 
the expected frequencies (Ho et a l, 1986). I hypothesised that perhaps more subtle 
immune evasion strategies are at play here.
Gilbert, Plebanski and colleagues found that an HLA-B35 restricted CD8 variant T cell 
epitope (Tc3R derived) can lead to impairment of the CTL activity to a second variant of 
the same epitope region by a process known as altered peptide ligand antagonism (APL) 
(Gilbert et a l, 1998). Thus, the variant denoted cp26 switches off CTL responses to cp29, 
and in fact cp29 can in turn antagonise cp26. The same authors demonstrate that cp26 and 
cp29 can mutually interfere with the induction of primary CTL responses in vitro. They 
further demonstrate that APL leads to a skewed parasite distribution of the 2 strains in 
naturally exposed Gambians (Gilbert et a l, 1998), thus suggesting the in vivo relevance of 
this phenomenon. Antagonism has not however been studied for any CD4 CS T cell 
epitope regions, nor indeed for a CD4 T cell response to any infectious pathogen.
4.2
STUDY DESIGN
4.2.1
Rationale
I first aimed to assess whether polymorphism in the immunodominant Th2R CD4 T cell 
epitope region generates variants with little cross-reactivity. I performed IFN-y ELISPOT 
assays using PBMC from adult Gambians to 9 naturally occurring Th2R variants present 
in The Gambia (Table 4.1). Given our evidence in the previous chapters that this assay 
detects effector memory T cells (TEM) in response to recent exposure (e.g. up to 2
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months), it might be particularly useful for assessing true cross-reactivity, as opposed to 
cross-recognition of multiple variants, since each donor is unlikely to have been exposed to 
multiple strains in the preceding few months. I then addressed whether APL within the 
Th2R CD4 T cell epitope region might play a role in the maintenance of natural 
polymorphism within this region.
4.2.2
Study Site and Volunteers
Healthy adult informed consent volunteers were recruited from the villages of Brefet, 
Dampha Kunda and Bakau in The Gambia (Figure 3.2). Malaria exposed adults working at 
the John Radcliffe Hospital, Oxford were also recruited. A further 20 healthy adults who 
had never been exposed to malaria were recruited from the John Radcliffe Hospital in 
Oxford, and used as naïve controls.
4.3
RESULTS
4.3.1
IFN-y ELISPOT Responses to Variants of the Th2R CD4 Epitope Region Are Found 
in Less Than Half of Naturally Exposed Adult Gambians and Show Limited Cross- 
Reactivity
The Th2R CD4 T cell epitope region of CS has at least 9 naturally occurring variants in 
The Gambia, and the Th3R CD4 epitope region has a minimum of 8 (de la Cruz et al, 
1987, Good e ta l,  1988d, Lockyer et a l, 1989). Variant V6 of the Th2R region (see Table
4.1) exhibits a broad spectrum of HLA-DR binding (Calvo-Calle et a l, 1997). The amino 
acid variants arise at positions 329, 332, 333, 336, 337, 339 and 342, 5 of which are 
dimorphic, and 2 are trimorphic (Table 4.1). I first studied the binding potential of all 9 
variants of this region to three common African alleles (HLA-DRB1 * 1302, HLA- 
DRB1*0101, and HLA-DRB 1*1501) using an in vitro binding assay (Davenport et a l, 
1995b) (see Methods). All variants bound to HLA-DRB1*1501, and 8/9 to HLA- 
DRB 1*1302 and HLA-DRB 1*0101 (IC50<100pg/ml) (Table 4.1).
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T able 4.1
VARIANT SEQUENCE D R 1302 DR1 DR15
V1 P S D Q H I E K Y L K T I Q N S L S T E W S + + + + + +
V2 P S D Q H I E K Y L K  T I K N S L S T E W S + + + + +
V3 P S D Q H I E K Y L Q K I Q N S L S T E W S + + + + + + +
V4 P S D Q H I E K Y L Q K I K N S L S T E W S + + + + +
V5 P S D Q H I E K Y L Q K I R N S L S T E W S + + + + + + +
V6 P S D K H I K E Y L N K I Q N S L S T E W S + + + + + + +
V7 P S D K H I E Q Y L N T I Q N S L S T E W S + + + + + +
V8 P S D  K H I E Q Y L K K I Q N S L S T E W S - - + + +
V9 P S D K H I E Q Y L K K I K N S I  S T E W S + + + + + + +
pCLIP + + + + ND
PTT + + ND + +
Binding o f  natural variant peptides o f  the Th2R CD4 T cell epitope region o f  CS protein. Polymorphic 
positions are marked in bold. Peptides were scored as high (+ + +), medium (++) and low (+), or 
undetectable (-) binding capacity (IC50 <1, 1-25, 25-100, > 1 OOpg/ml respectively) to each HLA-DR allele 
tested. The universally binding epitopes from  TT (pTT) and CLIP (pCLIP) were used as positive controls. 
ND  = not determined.
Early IFN-y release from freshly isolated PBMC, to the 9 Gambian variants of the Th2R 
region, was assessed by ELISPOT (Table 4.2A). Of 56 healthy adult Gambians tested, 
only 20 (36%) responded to any Th2R peptide despite the fact that all donors had a 
lifetime of malaria exposure (Table 4.2). In only 9 donors (16%) were more than one 
variant peptide recognised, suggesting remarkable specificity when an IFN-y ELISPOT 
response occurred. Indeed, all amino acid changes in these variant epitopes could lead to 
lack of cross-recognition in these individuals. Many infections in The Gambia are known to 
be co-infections of two or more strains of CS (Gilbert et a l, 1998), and I postulated that 
non-responders for IFN-y, a characteristic Thl type cytokine, might have generated a Th2 
type cytokine response characterised by IL-4 production instead (Mosmann and Coffman,
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1989). I thus measured stimulation of early IL-4 production in parallel with IFN-y in 22 of 
the donors. Only 3 of the 22 donors gave an IL-4 response, and all of them produced IFN-y 
to the same variant (Table 4.2 A). None of the 20 malaria naïve donors tested reacted to any 
of the variants in identical early lymphokine release assays.
V I  V 2  V 3  V 4  V 5  V 6  V 7  V 8  V 9
Table 4.2
Donors 1 - 1 6 *
Donors 1 7 - 3 6  
Donor 37 
Donor 38 
Donor 39 
Donor 40*
Donor 41*
Donor 42*
Donor 43*
Donor 44*
Donor 45 
Donor 46*
Donor 47 
Donor 48 
Donor 49 
Donor 50 
Donor 51 
Donor 52 
Donor 53 
Donor 54 
Donor 55 
Donor 56
* tested for IFN-y & IL-4
Limited cross-reactivity was observed by IF N -y ex-vivo ELISPOT testing with 9 naturally occurring 
fofymofpAfc varÛMü of /Ae CD4 Tee// regfon of CS jororem. 22 qf/Ae WzvWwak (morW
with an asterisk) were tested in parallel fo r  IL-4 reactivity by overnight ELISPOT. The hatched squares 
indicate where both IFN-y and IL-4 responses were detected to the same variant epitope in the same donor. 
16 o f  the donors gave neither IF N -y  nor IL-4 responses (D l-16 at top o f  table), and no donors produced 
IL-4 alone. 20 malaria naïve donors were tested fo r  reactivity to the same variants but fa iled  to react to 
any o f  them, but gave the expected frequencies to control antigens PPD and TT and to the mitogen PHA 
(data not shown).
IFN-y and IL-4
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Cross-reactivity was further investigated by restimulating in vitro with a single Th2R 
variant peptide, and testing for cross-reactivity against all variants after 14 days of 
expansion in culture (Table 4.3). PBMC from malaria-exposed Gambians (Donors 20, 41, 
42, and 43) and malaria-exposed Europeans (Donors 57 and 58) were cultured separately 
with single variants, and then each cell line was tested for reactivity against all the other 
variants by IFN-y ELISPOT. All responses detectable after culture were either 
monospecific to the culture variant, or recognised only 2 of the 9 variants (Table 4.3). Thus 
cross-reactive responses cannot be generated even after a 14 day period of in vitro culture.
Table 4.3
V I  V 2  V 3  V 4  V 5  V 6  V 7  V 8  V 9
D58 cultured with V 1 
D20 cultured with V  2  
D20 cultured with V  3  
D41 cultured with V  6  
D42 cultured with V  6  
D43 cultured with V  6  
D57 cultured with V  6 1 (Culture Variant Non-culture Variant
PBMC were cultured with the stated variant indicated in bold and tested 14 days later fo r  cross-reactivity 
to all the 9 variants by overnight IFN-y ELISPOT assay. Two naturally malaria-exposed European donors 
who reacted specifically to variants VI (D58) and V6 (D57) in overnight IFN-y ELISPOT assays, were also 
tested to evaluate the specificity o f  VI or V6 stimulated short term T cell lines. A ll donors gave significant 
responses to the peptides in which they were cultured (black squares), and only rarely was a response 
detected to a non-culture variant (chequered squares). Donors D41, D42 and D43 gave significant 
responses to V6 by ex-vivo IF N -y ELISPOT assay, whereas donor D20 responses to V2 and V3 were 
undetectable prior to in vitro expansion.
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4.3.2
Altered Peptide Ligand Antagonism to Th2R CD4 Epitope Variants of CS Protein
Four of the 56 adult Gambians (7%) responded to the “universally binding” variant V6 of 
CS protein (Tables 4.1 and 4.2) (Calvo-Calle et a l, 1997). PBMC from three of these 
Gambians, and one other naturally exposed individual who responded to variant V6, were 
tested in early IFN-y secretion assays to assess the effect of the presence of each one of 
the other 8 variants on the V6 response (Figure 4.1). These variants were added after 
binding with a suboptimal dose of V6 had occurred in a standard antagonism assay (De 
Magistris et al, 1992) (see Methods). Responses to V6 could be partially inhibited by co­
culture with certain of the naturally occurring Th2R variants in all 4 donors studied (Figure
4.1). Surprisingly, the same variants could be inhibitory in different individuals (V2, V5, 
V7 and V9 in 2/4, 3/4, 4/4, and 2/4 respectively showed >50% inhibition).
Figure 4.1
E x - v i v o  IFN-y ELISPOT
D41 D42 D43 D57
Donor
■ V6 Alone
B + V1
□ + V2
B + V3
0  + V4
Q + V5
□ + V7
0  + 00
>
B + V9
Donors D41, D42, D43 and D57 respond to the V6 CD4 T cell epitope by IF N -y  secretion. The impact o f  
the presence o f  the other variants on the V6 response was assessed in an antagonism assay. Index peptide 
was prepulsed onto PBMC at 25pg/ml, and the other variants were added 1 hour later at 50pg/ml. The 
assay was then run as a standard ex-vivo IF N -y ELISPOT assay. For donor D43 the antagonism assay 
was repeated another 2 times with similar results, and another 12 times fo r  donor D57. Inhibition o f  
donor D57 V6 responses was observed from  5 pg/ml o fV 5  or V7 (n = 2 experiments) (data not shown).
109
This putative antagonistic altered peptide ligand effect was investigated in detail for donor 
D57. The response for D57 was specific for V6 (Table 4.3). Over a 12 month period when 
IFN-y antagonism assays were performed using D57 PBMC, V5 and V7 were usually 
inhibitory (V5 in 11 / 12 experiments, and V7 in 11 / 13 experiments) despite some 
variation in the absolute level of inhibition (mean inhibition for V5 39% ± 7 SE, p < 
0.0005; V7 39% ± 9 SE, p < 0.0009). The universally binding HLA-DR peptide from 
tetanus toxoid (pTT) did not inhibit V6 responses when used in antagonism assays (n = 3), 
and PPD responses were not inhibited by V5, V6 or V7 (n = 2) (not shown). Figures 4.2A 
and 4.2B show a representative assay for donor D57 in which PBMC proliferative 
responses induced by V6 were strongly inhibited by V5 and V7 (n = 6 assays). Significant 
inhibition by V5 but not V7 could be found even if the variant epitope was presented on a 
different antigen presenting cell (APC) from V6 (Figure 4.2A). This rraws-inhibition by V5 
suggested the possibility of a soluble suppressive mediator.
4.3.3
Selective Induction of IL-10 by Th2R CD4 T Cell Epitope Variants
Both TGF-p and IL-10 have been shown to have suppressive effects on proliferation and 
cytokine production (Moore et a l, 1993, Groux et a l, 1997), and thus were potential 
candidate mediators for the suppressive effect of V5. Indeed, inhibition of V6 induced early 
IFN-y responses by V5 could be completely reversed by neutralising anti-IL-10 but not 
anti-TGF(3 monoclonal Abs (n = 3 assays). (Figure 4.3A). This was not the case for V7 
induced inhibition, which could not be reversed by either anti-IL-10 or anti-TGFp (Figure 
4.3B). Early IL-10 production by donor D57 PBMC was assessed in ELISPOT assay in 
response to all 9 variant peptides (at 50pg/ml) either alone or in the presence of variant V6 
(at 25 pg/ml) (Figure 4.4). Variants V5 and V7 induced IL-10 both alone, and in the 
presence of V6, whereas V9 induced IL-10 only in the presence of V6. Titration of 
responses ranging from 5-100 pg/ml showed maximal IL-10 induction by V5 and V7 at 25- 
50 pg/ml (not shown). V5 and V7 alone failed to stimulate significant IFN-y or IL-4 
production at any concentration tested (5-100 pg/ml, n = 6 assays) (not shown).
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Donor D57 PBMC proliferated in response to peptide V6 (closed squares), but fa iled  to respond to 
variants V5 (A, closed triangles) and V7 (B, closed circles) in parallel assays. Antagonism o f  the V6 
specific proliferative response was induced in 2 ways. Irradiated PBMC were either sequentially prepulsed 
(open squares) with V6 fo llow ed by the putative antagonist, or separately prepulsed with V6 and 
antagonist and mixed at a 1:1 ratio (open circles). These were then washed, mixed at a 1:1 ratio with 
PBMC, and set up in standard proliferation assays. Tritiated thymidine incorporation was monitored from  
days 5-10. A representative experiment o f  6 is shown. Results are shown as mean triplicate CPM  ±SE
111
Figure 4.3
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ELISPOTs were set up fo r  antagonism assays o f  VS on V6 (A) and V7 on V6 (B). Neutralising mAbs to 
TGF(3 (lOng/ml) and IL-10 (W ng/ml), or both were added at the same time as the index peptide. Anti-IL- 
10 reversed the inhibitory effect o fV 6  (A) but not V7 (B), and anti-TG F f had no effect even when increased 
to a dose o f  lOOng/ml (n = 2 assays, data not shown). A representative experiment o f  3 is shown.
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Early IL-10 production was tested by ELISPO Tfor donor D57 to all the Th2R variants alone (open bars) 
or in V6 antagonism assays (black bars). Variants were used at SOpg/ml, and significant IL-10 production 
over control is indicated with an asterisk (p < 0.05). Titration o f  responses (5-100pg/ml) showed maximal 
IL-10 induction by V5, V6 and V7 at 25-50pg/ml, either alone or in antagonism assays (n = 2, data not 
shown).
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The effect of the V5 variant on lymphokine production by V6-specific T cells was further 
studied utilising lines and clones generated from donor D57. Assessment of intracellular IL- 
10 content of a V6 specific line (antagonisable by V5) from D57 showed doubling in 
number of IL-10 producing CD3+ T cells by V6/V5 co-stimulation compared to 
background or V6 alone (Figures 4.5A and B). ELISPOT assays conducted in parallel at the 
time of this analysis showed 100% inhibition of the V6 IFN-y response by V5 (not 
shown). The IL-10 positive cell number was unchanged for monocyte/macrophages 
(CD 14  ^cells), or activated B cells (CD22+ cells) (Figures 4.5A and B). Stimulation of V6- 
specific clones with V6 induced either IFN-y alone (clones C2, C5 and C6) or IFN-y and 
IL-10 (clones C3 and C4) secretion (Figure 4.6A and B). Stimulation of these clones with 
V6 in the presence of V5 led to a downregulation of IFN-y production (Figure 4.6A) and a 
concomitant increase in IL-10 for all clones (Figure 4.6B). Thus, IL-10 production in CD4 
T cell clones may be increased by co-stimulation with an altered peptide ligand. Oligoclonal 
responses (when clones were mixed) reflected the dominant change in IFN-y / IL-10 ratio 
toward IL-10 production when stimulated by V6 in the presence of V5, but no 
upregulation of IL-10 in the presence of V7 (Figures 4.6C and D). No IL-4 could be 
detected under any experimental condition in parallel ELISPOT assays (not shown).
I found that clones C3 and C4 use a different TCR (not shown), and that their reactivity 
pattern to V5, V6 and V7 was different. Thus, clone C4 failed to produce IL-10 to VS and 
V7, but still showed significant IL-10 induction by V6-V5 or V6-V7 co-stimulation (Figure 
4.7A). By contrast, clone C3 responded to each of V6, VS and V7 alone by IL-10 
secretion. As expected, both clones responded by IFN-y secretion to V6, but not to VS or 
V7 alone (not shown). Fresh PBMC responses behaved more similarly in reactivity to 
clone C3, with IL-10 usually produced to both VS and V7, although not to V6 (Figure 
4.7B).
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A Vô-specific CD4 T cell line from  donor D57 was stimulated with HLA-DR 15-matched PBMC alone 
(white bars), or with V6 (20pg/ml) (black bars), or V6 then V5 (40pg/ml) (hatched bars). The phenotype o f  
IL-10 positive cells was analysed by FACScan (CD3 fo r  T cells, CD 14 fo r  monocytes/macrophages, CD22 
fo r  activated B cells). The data is presented as IL-10 positive cells per million (A) and percent CD3, CD 14 
and CD22 positive cells (B). The protocol resulted in 100% inhibition o f  the V6 IF N -y  response by V5 in 
an ELISPOT assay conducted in parallel with the same samples (data not shown).
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Vô-specific T cell clones generated from  donor D57 were tested in ELISPOT antagonism assays. IFN- 
Y (A), IL-4 (data not shown) and IL-10 (B) production were assessed in parallel. Clones C2, C3, C4, C5 
and C6 were utilised at 500 cells/well with either irradiated HLA-matched PBMC or an autologous Bel 
line (at 50,000/well) as presenters. Oligoclonal responses were assessed by mixing all clones (C and D). 
Results shown are from  single experiments performed in duplicate and are representative o f  four separate 
experiments fo r  clones C3 and C4, two fo r  C5 and C6, and one fo r  C2. No significant IL-4 production 
was detected in any o f  the experiments.
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Donor D57 clones C3 and C4 were further tested fo r  their ability to respond by IL-10 production to V5 or 
V7 alone, compared to V5 and V7 in the presence o f  V6. Clone C3 showed weak IL-10 reactivity over 
background to V6 or V7 alone or V6+V7 (p<0.05) and strong reactivity to V5 alone or V6+V5 (p<0.001). 
By contrast, clone C4 fa iled  to respond significantly to VS, V6, or V7, but responded well to V6+V5 and  
V6+V7 (p < 0.05). Both clones responded to V6 but not VS or V7 by ex-vivo IF N -y  ELISPOT (data not 
shown). The results shown are from  a single experiment performed in triplicate. Freshly isolated PBMC  
from  donor D 57 were set up in parallel agonism and antagonism IF N -y  and IL-10 ELISPOT assays (B). 
One o f  2 representative assays is shown.
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4.4
DISCUSSION
The family of nine naturally occurring Th2R CD4 T cell epitope variants tested here 
showed a remarkable lack of cross-reactivity in IFN-y assays. This is in keeping with the 
findings of others, and suggested that T cell responses may not be detected unless all 
variants are tested. It also means that CD4 T cell responses of donors living in malaria 
endemic regions should not be susceptible to heterologous boosting, thus limiting their 
persistence in vivo. This lack of cross-reactivity presents major problems for the design of 
vaccines based on circumsporozoite protein, since the incorporation of polymorphic 
epitope regions is unlikely to provide heterologous protection if the vaccine also induces 
non-crossreactive responses.
It was difficult to understand how such a large family of variants, where each one 
“altruistically” minimises cross-reactivity, may have been selected (Davenport, 1995). The 
existence of specific aa variation at predicted non-MHC binding residues in the 
immunodominant Th2R epitope region of CS suggested that it may be under an unusual 
form of selective pressure. Natural variation in cytotoxic epitope regions of hepatitis B 
virus and HIV have been shown to behave as altered peptide ligands, providing an immune 
escape strategy for these viruses (Bertoletti et a l, 1994, Klenerman et a l, 1994). Malaria 
has also been shown to utilise APL as an immune evasion strategy via 2 allelic CTL 
epitopes of the Tc3R region of CS (Gilbert et a l, 1998). The study showed that parasites 
bearing two epitope variants of an HLA-B35 restricted CS epitope may gain a mutual 
advantage by reciprocal APL antagonism of CTL lytic activity.
I thus investigated whether CD4 T cell variant epitopes within the Th2R region of CS 
might antagonise one another, and indeed found that selected variants downregulate IFN-y 
and proliferative responses by preferential induction of IL-10. Clones capable of high IL- 
10 secretion, with low or absent secretion of other lymphokines such as IL-2, IL-4, IL-5, 
or IFN-y, have been denoted Trl (Groux et a l, 1997). Here, I show that the ratio of IFN-y 
to IL-10 can be changed during both rapid polyclonal responses and when using long term
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Vclones. Therefore, Tri may be an inducible phenotype. I induced IL-10 production by an 
altered peptide ligand, but other stimuli may also lead to a similar rapid conversion. Indeed, 
changes in lymphokine production could be a useful part of a natural response, switching 
from early effector cells producing upregulatory cytokines, to a downregulatory 
phenotype at a later stage.
Interleukin 10 is a pleiotropic lymphokine that can down-regulate MHC class II molecules 
on APCs, inhibit nitric oxide production, prevent T cell priming and proliferation, and 
suppress IFN-y, TNFa, GM-CSF and LT production by T cells (Moore et a l, 1993, Le 
Moine et a l, 1999, Akdis and Blaser, 1999, Groux and Powrie, 1999). Thus, IL-10 
inducing APL bearing strains may generally benefit the parasite population. The finding 
that V5 inhibited V6 responses even when presented on separate APCs, lends support to 
this putative /r<ms-effect of IL-10 secretion. The mechanism I observed for V5 might be 
better described as a suppressive dominant form of “partial agonism”, rather than 
antagonism per se, although the term antagonism has been used to describe a variety of 
related phenomena (Jameson and Bevan, 1995).
The same APL negatively affected both rapid IFN-y secretion and proliferation in parallel 
assays in donor 57. This may make this immune evasion mechanism singularly powerful, 
given our evidence suggesting that these two effector functions may be mediated by 
different memory T cell subsets (Chapter 3). V7 also induced IL-10 from PBMC, but IL- 
10 neutralisation did not reverse V7 induced inhibition, suggesting that additional 
suppressive mechanisms might be operating. Two nonexclusive hypotheses may account 
for the strong inhibitory effect of APL in polyclonal IFN-y and proliferative responses. 
The first hypothesis is that separate T cell populations react to V6 (by IFN-y production) 
or V5 (by IL-10 production). When both are induced in the same culture, the IL-10 induced 
by V5 may non-specifically downregulate V6 IFN-y responses. However, IFN-y ELISPOT 
PPD responses were not inhibited by V5 co-stimulation in parallel assays in our donors in 
whom V6 inhibition was seen. Thus, IL-10 production alone does not explain the inhibition 
of V6 responses. An alternative mechanism is that T cells bearing the same TCR,
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recognising both V5 and V6, may be susceptible to differential lymphokine regulation by 
APL antagonism. In support of this hypothesis, differential IFN-y and IL-10 production to 
V6 alone, compared to V6 co-presented with V5, could be demonstrated at the clonal level. 
Once the IFN-y / IL-10 ratio decreases for a single clone, the IL-10 produced may play a 
positive feedback role in promoting an IL-10 biased response.
Naturally occurring Th2R specific CD4 T cell responses may therefore change 
qualitatively in response to co-stimulation by APL-bearing parasites. IFN-y secreting T 
cells capable of changing toward IL-10 secretion may not be restricted to the Th2R epitope 
region in malaria, and may even be a common occurrence. Indeed, a study of malaria 
infected children and adults in Gabon observed that approximately half of the IL-10 
producing CD4 and CDS T cells co-express IFN-y (Winkler et a l, 1998, Winkler et al, 
1999). The authors suggest that this might reflect an indirect feedback mechanism for 
inhibition of IFN-y expression. I further propose that such cells may represent transitory 
populations capable of changing from IFN-y to IL-10 secretion, and may thus provide a 
fertile ground for parasite driven immune modulation. Preliminary studies of rapid IL-10 
secretion in adult Gambian donors suggested that the majority (10 / 12) have high 
background levels of IL-10 secretion, although how this phenomenon relates to malaria 
exposure remains to be determined. Similar cell populations capable of simultaneous IFN-y 
and IL-10 production have been described in other diseases such as Lyme disease, and 
murine viral bronchiolitis (Hussell et a l, 1996). Indeed, rapid IFN-y / IL-10 modulation is 
likely to play a pivotal role in both infectious and autoimmune disease progression 
(Mahanty and Nutman, 1995, O'Garra et a l, 1997, Trinchieri, 1997, Cobbold and 
Waldmann, 1998, Hill, 1998, Mason and Powrie, 1998).
High levels of IL-10 present in the liver may hinder T cell priming by hépatocytes (Le 
Moine et a l, 1999). Thus IL-10 induction by agonist / antagonist Th2R epitopes is likely 
to prevent the priming of IFN-y producing cells (Moore et a l, 1993, Groux et a l, 1997) 
and extend the benefit to the parasite population by generating a population of susceptible 
hosts (Plebanski et a l, 1999). This may provide one more mechanism whereby lifelong
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malaria exposed individuals exhibit unusually low levels of T cell reactivity to P. 
falciparum (Doolan et a l, 1993, Doolan et a l, 1994, Plebanski et a l, 1997a). The 
mechanism I describe in this chapter results in rapid suppression of potentially protective 
responses. It may also explain, through inefficient priming in an IL-10 rich milieu, how 
both low levels of reactivity are generated and maintained, and how a family of allelic 
immunodominant epitopes are selected and maintained.
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CHAPTER 5
T CELL RESPONSES TO THROMBOSPONDIN RELATED 
ADHESIVE PROTEIN (TRAP): COMPARISONS BETWEEN 
EAST AND WEST AFRICANS
5.1 
INTRODUCTION
In the previous chapter I provided several reasons why CS protein may not be the ideal 
vaccine candidate antigen for induction of protective CD4 T cell responses. It is highly 
polymorphic in its immunodominant CD4 T cell epitope regions, and cross-strain 
recognition of polymorphic variants of one such region was infrequently seen in adult 
Gambians. Moreover, naturally occurring allelic variants of the immunodominant CD4 T 
cell epitope region, denoted Th2R, acted as altered peptide ligands and switched off 
protective IFN-y T cell responses in favour of production of the immunosuppressive Th2 
type T cell cytokine IL-10. There is therefore increasing interest in identifying alternative 
antigens for use in pre-erythrocytic vaccines. Thrombospondin related adhesive protein 
(TRAP) may be such a candidate antigen.
jyTRAP, also known as sporozoite surface protein 2 (SSP2) (Rogers et al., 1992), is 
discussed in detail in chapter 1. It is less polymorphic than CS protein (Robson et a l, 
1990, Robson et a l , 1998), although most nucleotide changes result in amino acid changes 
(Robson et a l, 1990). TRAP is required for motility of sporozoites, is released onto the 
sporozoite surface upon contact with target cells, and is involved in invasion of and entry 
into hepatocytes. There is evidence in animals and humans that TRAP is a protective 
antigen. Protective CTL have been demonstrated in murine models of malaria (Khusmith et 
a l, 1991, Khusmith et a l, 1994, Schneider et a l, 1998,), and several HLA restricted CTL 
TRAP epitopes have been identified in irradiated sporozoite immunized human volunteers 
(Wizel et a l, 1995b, Wizel et a l, 1995a, Doolan et a l, 1997), and naturally exposed adult 
donors (Aidoo et a l, 1995, Plebanski et a l, 1997a). Potentially protective antibodies to
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TRAP have been demonstrated in the murine model (Müller et a l, 1993), and naturally 
exposed humans (Scarselli et a l, 1993). Despite increasing evidence for a protective role for 
CD4+ T cells at the pre-erythrocytic stage of infection, no CD4 T cell epitopes in P/TRAP 
have been identified.
5.2
STUDY DESIGN
5.2.1
Rationale
This study aimed to map CD4 T cell epitopes within P/TRAP by screening for IFN-y 
ELISPOT responses to TRAP derived peptides, using PBMC from naturally exposed 
Africans. It was also of interest to assess the degree of induction of Th2 type T cell 
cy to k in es  IL-4 and IL-10 in selected donors, since it is not known if TRAP induces such 
responses. The degree of cross-recognition of naturally occurring variants of selected 
TRAP T cell epitopes was assessed by IFN-y ELISPOT, to see if multiple variants could 
be recognised by the same donor. Given that CS variant epitope regions were susceptible 
to APL (Chapter 4), the differential induction of IFN-y or IL-10 by variants of the same T 
cell epitope region within TRAP was assessed for in selected donors, as was IL-4 
induction by variant peptides in the same donors.
5.2.2
Donors and Study Area 
The Gambia
Peripheral blood mononuclear cells (PBMC) from 42 healthy adult male volunteers from 
Dampha Kunda, Upper River Division, The Gambia (Figure 3.2) were collected and frozen 
between March and April 1997. To compare reactivity in freshly isolated PBMC, a further 
8 healthy adult male and female donors from the village of Brefet, Western Division, The 
Gambia (Figure 3.2) were tested at the time of our study in December 1997. Thus a total of 
50 Gambian donors were recruited to the study. High malaria transmission in The Gambia
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occurs between August and November, commencing shortly after the rainy season begins, 
and thus all samples were taken during the dry season.
Kenya
Sixty five adult Kenyans were recruited between mid June and mid July 1998, which is at 
the beginning of the high transmission season (June to August) (Mbogo et a l, 1995). They 
were either healthy adult male blood transfusion donors (n = 42, D1-D42), or malaria 
exposed African employees based at Kilifi district hospital, coastal Kenya (n = 23; 15 male 
/ 8 female) (Figure 5.1). A further 25 male blood transfusion donors (K1-K25) were 
recruited in September 1999 for the TRAP variant T cell epitope analysis. This represents 
a period of low malaria transmission in Kilifi. The donors were recruited from the whole of 
Kilifi district, both North and South of the creek. Malaria transmission intensity varies for 
different regions of Kilifi, but is generally regarded as low intensity in Northern Kilifi, and 
high intensity in Southern Kilifi (Gupta et a l, 1999).
Malaria naïve donors
Fifteen malaria naïve adult employees at the John Radcliffe Hospital in Oxford were 
recruited and tested in the UK under identical conditions to The Gambian and Kenyan 
samples.
5.2.3
Peptides
A panel of fifty 20mer peptides (tpl-tp50; aa 1-510), overlapping by ten amino acids, 
derived from /yTRAP clone NF54 were synthesized commercially (Research Genetics) 
(Figure 5.2, Table 5.1 for aa sequences). Three /yfR A P 20mers covering the carboxy- 
terminus region (tp51, tp52 and tp53; aa 526-545, 541-560 and 555-574) were synthesized 
using a standard Fmoc/t-butyl solid-phase Zinsser Analytical synthesizer (Zinsser 
Analytic) (Table 5.1). Eleven TRAP pools were made by combining the above TRAP 
peptides (Table 5.2), and were used in selected donors to narrow down the positive 
response before testing to individual peptides.
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T able 5.1
PEPTIDE AA SEQUENCE CO N/VAR
tpl 1 -2 0 M N H L G N V K Y L V I V F L I F F D L Conserved
tp2 1 1 -3 0 V I V F L I F F D L F L V N G R D V Q N Conserved
tp3 2 1 - 4 0 F L V N G R D V Q N N I V D E I K Y R E Variant
tp4 3 1 - 5 0 N I V D E I K Y R E E V C N D E V D L Y Variant
tp5 4 1 - 6 0 E V C N D E V D L Y L L M D C S G S I R Variant
tp6 5 1 - 7 0 L L M D C S G S I R R H N W V N H A V P Variant
tp? 6 1 - 8 0 R H N W V N H A V P L A M K L I Q Q L N Variant
tp8 7 1 - 9 0 L A M K L I Q Q L N L N D N A I H L Y A Variant
tp9 8 1 - 1 0 0 L N D N A I H L Y A S V F S N N A R E I Variant
tpIO 9 1 - 1 1 0 S V F S N N A R E I I R L H S D A S K N Variant
tp l 1 1 0 1 - 1 2 0 I R L H S D A S K N K E K A L I I I K S Variant
tp1 2 1 1 1 -1 3 0 K E K A L I I I K S L L S T N L P Y G K Variant
tpl 3 1 2 1 - 1 4 0 L L S T N L P Y G K T N L T D A L L Q V Variant
tpl 4 1 3 1 - 1 5 0 T N L T D A L L Q V R K H L N D R I N R Variant
tpl 5 141 -1 60 R K H L N D R I N R E N A N Q L V V I L Conserved
tpl 6 1 5 1 - 1 7 0 E N A N Q L V V I L T D G I P D S I Q D Conserved
tpl 7 1 6 1 - 1 8 0 T D G I P D S I Q D S L K E S R K L S D Variant
tpl 8 1 7 1 - 1 9 0 S L K E S R K L S D R G V K I A V F G I Variant
tpl 9 1 8 1 - 2 0 0 R G V K I A V F G I G Q G I N V A F N R Variant
tp20 1 9 1 - 2 1 0 G Q G I N V A F N R F L V G C H P S D G Conserved
tp21 2 0 1 - 2 2 0 F L V G C H P S D G ,  K C N L Y A D S A W Conserved
tp22 21 1 -2 3 0 K C N L Y A D S A W E N V K N V I G P F Conserved
tp23 2 2 1 - 2 4 0 E N V K N V I G P F M K A V C V E V E K Conserved
tp24 2 3 1 - 2 5 0 M K A V C V E V E K T A S C G V W D E W Conserved
tp25 2 4 1 - 2 6 0 T A S C G V W D E W S P C S V T C G K G Conserved
tp26 2 5 1 - 2 7 0 S P C S V T C G K G T R S R K R E I L H Conserved
tp27 2 6 1 - 2 8 0 T R S R K R E I L H E G C T S E L Q E Q Variant
tp28 2 7 1 - 2 9 0 E G C T S E L Q E Q C E E E R C L P K R Variant
tp29 2 8 1 - 3 0 0 C E E E R C L P K R E P L D V P D E P E Variant
tp30 2 9 1 - 3 1 0 E P L D V P D E P E D D Q P R P R G D N Variant
tp31 3 0 1 - 3 2 0 D D Q P R P R G D N F A V E K P N E N I Variant
tp32 31 1 -3 3 0 F A V E K P N E N I I D N N P Q E P S P Variant
tp33 3 2 1 - 3 4 0 I D N N P Q E P S P N P E E G K G E N P Variant
tp34 3 3 1 - 3 5 0 N P E E G K G E N P N G F D L D E N P E Variant
tp35 3 4 1 - 3 6 0 N G F D L D E N P E N P P N P P N P P N Variant
tp36 3 5 1 - 3 7 0 N P P N P P N P P N P P N P P N P P N P Variant
tp37 3 6 1 - 3 8 0 P P N P P N P P N P D I P E Q E P N I P Variant
tp38 3 7 1 - 3 9 0 D I P E Q E P N I P E D S E K E V P S D Variant
tp39 3 8 1 - 4 0 0 E D S E K E V P S D V P K N P E D D R E Conserved
tp40 3 9 1 - 4 1 0 V P K N P E D D R E E N F D I P K K P E Variant
tp41 4 0 1 - 4 2 0 E N F D I P K K P E N K H D N Q N N L P Variant
tp42 41 1 -4 3 0 N K H D N Q N N L P N D K S D R Y I P Y Variant
tp43 4 2 1 - 4 4 0 N D K S D R Y I P Y S P L S P K V L D N Variant
tp44 4 3 1 - 4 5 0 S P L S P K V L D N E R K Q S D P Q S Q Variant
tp45 4 4 1 - 4 6 0 E R K Q S D P Q S Q D N N G N R H V P N Conserved
tp46 4 5 1 - 4 7 0 D N N G N R H V P N S E D R E T R P H G Variant
tp47 4 6 1 - 4 8 0 S E D R E T R P H G R N N E N R S Y N R Variant
tp48 4 7 1 - 4 9 0 R N N E N R S Y N R K H N N T P K H P E Variant
tp49 4 8 1 - 5 0 0 K H N N T P K H P E R E E H E K P D N N Variant
tp50 4 9 1 - 5 1 0 R E E H E K P D N N K K K A G S D N K Y Variant
tp51 5 2 6 - 5 4 5 A G L A Y K F V V P G A A T P Y A G E P Variant
tp52 5 4 0 - 5 5 9 Y A G E P A P F D E T L G E E D K D L D Variant
tp53 5 5 5 - 5 7 4 E D K D L D E P E Q F R L P E E N E W N Conserved
Overlapping TRAP 20mer peptides. Variant residues indicated in bold type.
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T able 5.2
Pool Name Peptides
P1 tp l, tp11, tp21, tp31, tp41
P2 tp2, tp12, tp22,
CMCOCL
CMxfQ.
P3 tp3, tp13,
COCXJ
C
l
COCOCL tp43
P4 tp4, p14, tp24,
"M
"
COCL tp44
p5 tp5, tp15, tp25, tp35, tp45
P6 tp6, tp16, tp26,
CDCOCL
CDxfCL
P7 tp7, tp l 7, tp27, tp37, tp47
P8 tp8, tp18,
COCMQ
. tp38, tp48
P9 tp9, tp19, tp29, tp39, tp49
p1 0 tp10 , tp20
oCOCL , tp40
oIDCL
P11 tp51 , tp52 , tp53
TRAP peptide pools used fo r  screening fo r  responses.
The variant TRAP peptides, derived from 10 naturally occurring strains of P/TRAP (Table 
5.3), were synthesised commercially (Research Genetics). PPD (Statens Seruminstitut) 
was utilised as a positive control for the IFN-y ELISPOT, and RPMI alone as the negative 
control.
TRAP derived peptides predicted to have a high likelihood of binding to certain HLA class 
II haplotypes by a computer algorithm programme (Davenport et a l, 1995a) were also 
selected for this study (see Methods). I screened for binding to two different HLA types: 
HLA-DRB1 * 1302 which is common in The Gambia (approximately 17% of healthy 
adults) and is associated with protection against malaria in West Africa (Hill et a l, 1991); 
and HLA-DRB 1*01 which is relatively uncommon in The Gambia (approximately 4%), is 
not associated with protection in Gambians, but is protective in East Africans (A.V.S. Hill, 
personal communication).
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T able 5.3
PEPTIDE SEQUENCE STRAIN
tp2 VIVFLIFFDLFLVNGRDVQN CONSERVED
tp4 NIVDEIKY REEVCNDEVDLY NF54/FCR3/K1/DD2/HB3/7901/7G8/3D7/ITO4
tp4x NIVDEIKY SEEVCNDQVDLY T996
tp5 EVCNDEVDLYLLMDCSGSIR NF54/FCR3/K1/DD2/HB3/7901/7G8/3D7/ITO4
tp5x EVCNDQVD LYLLMDCSGSIR T996
tp6 LLMDCSGSIRRHNWVN HAVP 7G8/T996/ITO4/FCR3/K1/7901 /3D 7/IT 04
tp6x LLMDCSGSIRRHNWV KHAVP DD2/HB3
tpl 4 TNLTDALLQVRKHLNDRINR N F54/H B3/T996/3D7
tpl 4x TNLSDALLQVRKHLNDRINR IT04/FCR3/K1/DD2/7G8
tpl 4y TNLTDALLEVRKHLNDRINR 7901
tp23 ENVKNVIGPFMKAVCVEVEK CONSERVED
tp30 EPLDVP D EPEDDQPRPRGDN NF54/T996/3D 7
tp30x EPLDVP H EPEDDQPRPRGDN IT04/K1/FCR3
tp30y EPLDVP Q EPEDDQPRPRGDN 7 9 0 1 /7G 8/D D2/HB3
tp31 DDQPRPRGDN F AVEKP NENI NF54
tp31 x DDQPRPRGDNS SVQKPEENI T996/7G 8
tp31 y DDQPRPRGDN F AVEKP KEN I ITO4/3D7/FCR3/7901
tp31 z DDQPRPRGDN FAVEKPEENI K1/DD2/HB3
tp37 PPNPPNPPNPDIPEQEPNIP IT04/3D7/HB3/DD2/FCR3
tp37x PPNPPNPPNPDIPEQKPNIP T996/NF54
tp37y PPNPPNPPNPDIPERKPNIP 7901
tp37z PPNPPNPPNPDIPQQEPNIP 7G8/K1
tp38 DIP EQEPNIPEDSEKEVPSD IT04/3D7/HB3/DD2/FCR3
tp38x DIP EQKPNIPEDSEKEVPSD T996/NF54
tp38y DIPERKPNIPEDSEKEVPSD 7901
tp38z DIP QQEPNIPEDSEKEVPSD 7G8/K1
tp40 VPKNPEDDREENFDIP KKPE CONSERVED
tp43 NDKSDRYIPYSPLSPKVLDN NF54
tp43v NDKSDRSIPYSPLPPKVLDN IT04/K1/FCR3
tp43w NDKSDRY IPYSPLPPN VLDN 7GB
tp43x NDKSDRN IPYSPLPPKVLDN T996
tp43y NDKSDRY IPYSPLAPKVLDN 3D7
tp43z NDKSDRY IPYSPLPPKVLDN 7901/HB3/DD2
tp47 SEDRETR PHGRNNENRSYNR CONSERVED
tp51 AGLAYKFVVPGAATPYAGEP CONSERVED
Pool 4-6a: tp4 + tp5 + tp6 N F54/7G 8/3 D7/FCR3/K1/79 0 1 /I T 04
Pool 4-6b: tp4x + tp5x + tp6 T996
Pool 4-6c: tp4 + tp5 + tp6x DD2/HB3
Variant peptides selected fo r  the study in Kenyan adults. NB tp40, 47 and 51 are conserved across the 10 
strains, but not worldwide. Variant residues are in bold type.
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I scanned all known TRAP sequences worldwide using the prediction programme 
(Davenport et a l, 1995a), and 9 peptides (tvl-tv8) which had a high predicted binding 
affinity to either of the two haplotypes were selected, including two polymorphic regions 
(tv4 and tv5) (Table 5.4A). These were synthesized using a standard Fmoc/t-butyl solid- 
phase Zinsser Analytical synthesizer. These were made into 3 pools for preliminary 
screening studies in certain donors (Table 5.4B).
Table 5.4
A.
PEPTIDE AA SEQUENCE
DRB1 *1 302 
BINDING
DRB1 *01 
BINDING ORIGIN
t v 1 13-32 VFLIFFDLFLVNGRDVQNNI 1.16 1.27 Conserved
tv2 34-53 DEIKY SEEVCNDQVDLYLLM 1.05 1,27 Thailand
tv3 44-58 NDQVD LYLLMDCSGS 0.94 1.21 Thailand
tv4a 89-108 VAN IFSNNAKEIIRLHSDAS 1.26 1.04 Indochina/Braz/Honduras
tv4b 89-108 YASVFSNNAKEIIRLHSDAS 1.27 1.04 Africa
tv4c 89-108 YVNVFSNNAKEIIRLHSDAS 1.06 1.16 W.Africa/Thailand
tv5a 124-38 TNLPYGRTNLTDALL 0.92 1.16 Africa/Thai/Honduras
tv5b 124-38 TNLPYGRTNLSDALL 0.92 1.14 Thai/Indochina/Brazil
tv6 164-78 IPDSIQDSLKESRKL 1.23 1.12 Thai/I ndoc/Afr/Hond/Braz
tv? 251-65 SPCSVTCGKGTRSRK 1.29 1.18 Conserved
tv8 431-50 SPLPPKVLDNERKQSDPQSQ 1.28 1.17 Thai/lndoch/Ugand/Hond
B.
POOL NAME PEPTIDES
vl tv1, tv4a, tv5a, tv8
v2 tv2, tv4b, tv5b, tv7
v3 tv3, tv4c, tv6
TRAP tv peptides selected according to high predicted binding to 2 common HLA haplotypes, DRB1 *01 
and DRB1*1302. Predicted binding values are given fo r  each peptide (>1.2 is considered to be a high 
predictive value).
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5.2.4
Statistical Methods
Proportions of donors responding in different studies were compared used standard chi 
squared analysis, having first established that the background levels were comparable. 
Where the numbers in each group for comparison were very small, Fisher’s value for 2- 
tailed analysis was calculated for the %2 p-value. The precursor frequency values (SFU / 
106 PBMC) were compared using t-tests to assess for differences between groups.
5.3
RESULTS
5.3.1
IFN-y Secreting T Cells From Semi-immune Gambian Adults Recognise Multiple 
Epitopes Along the Length of PJTRAP
Forty one of 50 individuals recruited to the Gambian study were tested using frozen 
peripheral blood mononuclear cells (PBMC) for early IFN-y ELISPOT responses to the 50 
overlapping 20mers (tpl-tp50) spanning amino acid residues 1-510 of f/TRAP (Table
5.1). They were screened first for responses to 10 pools of 5 peptides per pool (Table
5.2), and where a positive response was seen to a pool (Figure 5.3A) they were screened to 
the individual peptides within that pool (Figures 5.3B and C). A positive response was 
assigned if the peptide test well response was regarded as significantly above background 
(P<0.05) according to the statistical table discussed in methods. Thirty two percent 
(13/41) of individuals screened had T cell responses to a defined tp TRAP peptide (Table 
5.5A). Over half of those who gave a positive IFN-y ELISPOT responded to one peptide 
only, and the maximum number of tp epitopes to which an individual responded was five 
(donor G73). The positive responses ranged from 13 to 89 spot forming units (SFU, see 
Methods) per 106 PBMC with an arithmetic mean of 28.2 ±1.2 SE (Table 5.5A). The 
responses were repeated at least twice for each donor (pools and individual peptides), and 
were consistent on re-testing up to 4 times per donor.
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Figure 5.3
A.
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Mapping fo r  IFN-y ELISPOT responses to TRAP peptides involved firs t screening fo r  positive responses to 
pools o f  TRAP peptides (A). Where a positive response to pools was observed, the constituent peptides 
within that pool were tested (B and C). Donor G97 thus responded to peptide tp27 (contained in pool 7) 
and tp38 (contained in pool 8). * represents a significant positive response above background (p < 0.05).
I therefore detected between 13 and 89 circulating T cells per million in peripheral blood 
capable of producing IFN-y in response to individual PfTRAP epitopes. The fact that the 
numbers were low suggested that only low levels of circulating T cells recognise TRAP 
antigen in immune individuals. The levels were comparable to the precursor frequency 
levels reported for CD8 T cells to TRAP using chromium release assays in naturally 
exposed donors of 16 to 86 per million PBMC (Plebanski et a i, 1997a). Low level T cell 
reactivity is a well recognised feature of natural immunity to malaria, and is discussed in
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the introduction (Chapter 1). Eleven of the 41 donors above, and a further 6 donors not 
screened above, were tested for reactivity to 3 peptides covering the 48 terminal amino 
acids of the carboxy-terminus of TRAP (tp51-tp53, aa 526-574) (Table 5.1). None of 
these seventeen individuals gave a positive response, however six of them gave positive 
responses to other TRAP peptides in this study. Seventy percent of donors gave a 
positive PPD response (64 ±9 SE SFU / 106 PBMC).
I thus identified 21 novel T cell epitopes denoted tp within iy iR A P which lead to IFN-y 
production in Gambian adults, by screening 47 of the 50 individuals recruited to this study 
(Tables 5.5). Seventeen of these epitopes (81%) fall in polymorphic regions of TRAP, 
which is not surprising since TRAP has numerous point mutations along its length 
(Robson et al., 1990, Robson et al., 1998). Many of the variant epitopes identified contain 
polymorphisms which are exclusive to malaria endemic regions of the world other than 
Africa, such as Southeast Asia and Central America. Taking this into account, the number 
of conserved West African tp epitopes identified in this study was nine (Table 5.5). The 
four that are conserved worldwide (tp22, tp23, tp24, tp25) span aa residues 211-260, and 
are clustered in a highly conserved region towards the end of the ‘A-like domain’ (aa 48- 
241) and incorporating most of the Region II sulphatide binding domain (aa 246-267) 
(Figure 5.2). The remaining five which are conserved in West Africa (tp6, tpl4, tp39, tp40, 
tp41) are distributed along the length of TRAP.
5.3.2 
Double the Reactivity to TRAP in East Africans Compared to West Africans
A similar study to The Gambian one described above was performed using PBMC from 
healthy adult Kenyans from Kilifi district, coastal Kenya (Figure 5.1). It was not known if 
differences in reactivity would exist between the two African populations. This is clearly 
an important consideration in terms of vaccines designed to be effective in different malaria 
endemic regions of the world. Thus, 65 healthy adult Kenyans were recruited, and their 
PBMC were tested for reactivity to the same panel of overlapping 20mer TRAP peptides 
(tpl-tp53) used in The Gambia (Table 5.1).
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Table 5.5
A. IFN- y ELISPOT R esponses in Adult Gambians
EPITOPE FREQ DONORS SFU/106 P-VALUE WORLDWIDE WEST AFRICA
tp4 2% G 58 15 0.05 Variant Variant
tp5 2% G110 20 0.05 Variant Variant
tp6 2% G99 25 0.05 Variant Conserved
tp10 2% G73 13 0.05 Variant Variant
tp11 5% G73/131 40/17 0.005/0.05 Variant Variant
tp13 2% G73 23 0.05 Variant Variant
tp14 5% G73/85 20/13 0.05/0.05 Variant Conserved
tp22 2% G55 20 0.05 Conserved Conserved
tp23 2% G110 20 0.05 Conserved Conserved
tp24 2% G58 30 0.05 Conserved Conserved
tp25 2% G132 21 0.05 Conserved Conserved
tp27 2% G97 36 0.05 Variant Variant
tp33 2% G102 22 0.05 Variant Variant
tp38 2% G101 23 0.01 Variant Variant
tp39 2% G132 24 0.05 Variant Conserved
tp40 2% G 95 21 0.05 Variant Conserved
tp41 2% G95 48 0.001 Variant Conserved
tp43 2% G73 33 0.005 Variant Variant
tp47 2% G60 53 0.005 Variant Variant
tp48 2% G46 46 0.001 Variant Variant
tp50 7% G85/60/102 32/60/30 0.05/0.001/0.05 Variant Variant
B. IFN- y ELISPOT Responses in Adult Gambians
EPITOPE FREQ DONORS SFU/106 P-VALUE WORLDWIDE WEST AFRICA
tv1 6% G73 25 0.05 Conserved Conserved
tv4a 12% G73/96 48/20 0.001/0.05 Variant Variant
tv5a 12% G85/35 13/23 0.05/0.01 Variant Variant
C. IL-4 ELISPOT Responses in Adult Gambians
EPITOPE FREQ DONORS SFU/106 P-VALUE WORLDWIDE WEST AFRICA
tv2 7% G35 28 0.05 Variant Variant
tv4b 7% G35 33 0.01 Variant Variant
tp ll 17% G110 13 0.05 Variant Variant
Summary o f  all positive ELISPOT responses in the study o f  50 adult Gambians. The magnitude o f  each 
positive response is given (SFU/106 PBMC), and the p-value fo r  the SFU  (spot form ing units) value above 
the background response.
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IFN-y responses were assessed using a standard overnight ELISPOT assay as before. The 
first 22 donors were tested using the same pools of peptides tested in The Gambia (Table
5.2), and thereafter donors were tested immediately to the individual tp peptides without 
first screening for responses to pooled peptides.
Fifty five percent (12/22) of the Kenyan donors screened for responses to the pooled 
peptides responded to one or more pools (data not shown). This is almost double the 
reactivity rate of 32% seen in the Gambian study. This high level of reactivity was 
confirmed for the remaining 43 Kenyan adults who were screened to individual peptides. 
Sixty three percent of these (27/43) gave a positive response to at least one of the TRAP 
peptides tpl-tp50 (Table 5.6). Therefore, there was a significantly higher response rate to 
TRAP in Kenyans compared to Gambians (%2 = 8.13, p = 0.004) (Table 5.7A). The 
increased TRAP reactivity observed in Kenyan compared to Gambian adults was no longer 
significant if only the TRAP pool responders were compared (%2 = 3.12, p = 0.08), which 
is probably a reflection of the smaller sample size for the Kenyans. Reactivity to 9 Th2R 
and 8 Th3R CD4 T cell epitope variants of CS were assessed in parallel to TRAP 
responses in 64 Kenyan donors. I found an overall response rate of 32.8% (21/64) to these 
17 epitopes in the Kenyan adults, compared to 46.8% (22/47) reactivity in a similar study 
using PBMC from Gambian adults from Dampha Kunda and Brefet (not shown). Thus, 
there was no significant difference in the T cell reactivity to CS protein between adults 
from the 2 countries (%2 = 2.24, p = 0.13) (Table 5.7A). The number of donors capable of 
giving a positive TRAP peptide T cell IFN-y response was thus greater in the Kenyans 
compared to Gambians. The magnitude of positive T cell responses (specific responder 
cells / 106 PBMC) were comparable between the Kenyan donors (arithmetic mean 33.6 
SFU ±2.1 SE / 106 PBMC), and Gambian donors (28.2 ±1.2 SE / 106 PBMC) (p = 0.25) 
(Table 5.7B). Eighty six percent (56/65) of the Kenyan donors gave a positive PPD 
response, which is significantly higher than the 70% (33/47) of Gambians who responded 
(%2 = 4.25, p = 0.04) (Table 5.7A). The PPD precursor frequencies (SFU/106 PBMC) were 
also significantly higher in Kenyans compared to the Gambians (p = 0.03) (Table 5.7B).
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T able 5.6
IFN- y ELISPOT R esponses in Adult Kenyans
EPITOPE DONORS FREQ SFU/106 PBMC P-VALUES
*P1 D11 2% 30
tp2 D 1 1 /2 3 /3 4 ,OK 9% 3 3 ,4 3 ,2 3 ,9 5
tp3 D16.0K
tp4 D1 2/3 4/3 7/3 9, OK
tp5 D 1 9 /2 3 / 2 4 / 3 0
tp6 D 1 6 / 2 1 / 2 7 / 3 4 / 3 6
tp7 D11/23,OK
tp8 0 2 3 /2 7
tp9 035
tp12 0 1 1 /2 6
tp13 023
tp14 D1 1 /1 4 /1 6 /1 7
tpl 5 D 11/13
tp16 0 1 1 /1 3
tp17 011
tpl 8 D 28/40
tp1 9 D13 /42 ,OK
tp20 D40.OK
tp21 DM
tp22 0 2 3 /2 7
tp23 D1 1 /1 4 /1 9
tp24 D14
tp25 0 1 1 /2 7
tp26 0 1 1 /2 7
tp27 MN,D13,OK
tp28 D13 /34 ,OK
tp29 D37.0K
tp30 0 2 1 / 2 7 / 3 4
tp31 0 2 3 /3 4 /3 9 ,OK
tp32 OK
tp34 D40
tp35 D11
tp36 0 1 1 /1 6
tp37 D23/34/40.OK
tp38 D 11/23/34 , OK 
tp39 0 2 1 /3 4
tp40 D14 /3 4 /4 0 ,OK
tp42 MN.D11
tp43 BM.TK
tp44 CK
tp45
tp47
tp48
tp49
tp50
tp51
tp52
tp53
5% 18 ,108
12% 2 3 ,2 0 ,1 8 ,8 0 ,4 3
9% 2 8 ,1 5 ,5 5 ,4 3
12% 2 0 ,1 8 ,1 8 ,2 5 ,1 8
7% 2 3 ,1 8 ,5 5
5% 3 5 ,1 5
2 % 20
5% 2 3 ,4 0
2 % 18
9% 3 0 ,1 8 ,3 5 ,2 0
5% 2 5 ,2 8
5% 2 5 ,2 3
2 % 22
5% 4 8 ,2 3
7% 3 0 ,3 0 ,9 0
5% 2 0 ,4 8
2% 18
5% 2 3 ,2 8
7% 2 8 ,3 0 ,2 8
2% 23
5% 2 8 ,1 8
5% 3 5 ,1 8
7% 1 5 ,2 0 ,5 5
7% 2 0 ,2 5 ,6 8
5% 2 8 ,4 5
7% 2 0 ,2 0 ,3 0
9% 1 8 ,2 3 ,3 0 ,6 3
2% 148
2% 18
2% 23
5% 2 8 ,2 0
9% 2 0 ,3 3 ,2 3 ,6 3
9% 2 5 ,2 3 ,2 0 ,6 0
5% 18 ,20
9% 1 8 ,3 0 ,1 8 ,7 5
5% 15 ,23
5% 2 5 ,2 3
2% 83
2% 40
9% 5 5 ,2 0 ,6 0 ,4 3
5% 18 ,80
5% 2 0 ,8 5
2% 30
0.05
0 .0 5 ,0 .01 ,0 .05 ,0 .01
0.05 ,0 .01
0 .0 5 ,0 .0 5 ,0 .0 5 ,0 .0 1 ,0 .0 5
0 .05 ,0 .05 ,0 .05 ,0 .01  
0 .0 5 ,0 .0 5 ,0 .0 5 ,0 .0 1 ,0 .0 5  
0 .0 5 ,0 .0 5 ,0 .0 5  
0 .01 ,0 .0 5  
0.05  
0 .0 5 ,0 .0 5  
0.05
0 .0 5 ,0 .0 5 ,0 .0 1 ,0 .0 5
0.01
0 .0 5 ,0 .0 5
0 .05
0 .01 ,0 .0 5
0 . 0 1 , 0 . 0 1 , 0.01
0 .0 5 ,0 .0 5
0 .05
0 .05 ,0 .01
0 .0 5 ,0 .0 5 ,0 .0 5
0.05
0 .05 ,0 .05
0 .0 5 ,0 .0 5
0 .0 5 ,0 .0 5 ,0 .0 5
0 .05 ,0 .01 ,0 .01
0 .0 1 ,0 .0 5
0 .05 ,0 .05 ,0 .01
0 .0 5 ,0 .05 ,0 .05 ,0 .01
0.001
0.05
0.05
0 .05 ,0 .0 5
0 .05 ,0 .01 ,0 .05 ,0 .01
0 .0 5 ,0 .0 5 ,0 .0 5 ,0 .0 5
0 .05 ,0 .05
0 .0 5 ,0 .01 ,0 .05 ,0 .01
0 .05 ,0 .05
0 .0 5 ,0 .0 5
0.01
0.01
0 .0 5 ,0 .0 5 ,0 .0 0 1 ,0 .0 5
0 .05,0 .01
0.05,0 .01
0 .05
,0 .05 ,0 .052 8 ,2 8 ,2 3 ,2 8 ,3 0 ,2 0  0 .0 1 ,0 .0 5 ,0 .0 5 ,0 .0 5  
2 3 ,2 5 ,2 0  0 .0 5 ,0 .0 1 ,0 .0 5
2 0 ,8 8  0 .05,0 .01
PN
0 2 4 /2 5 .JN.OK 
D34.0K 
D25.0K 
011
D1 2/1 4/1 5/1 9 / 2 5 / 4 0  14% 
TK.0 1 2 /3 4  7%
D12.0K 5 %
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T able 5.7
A. Number of Responders
Kenya The Gambia p-value
PPD 56 / 65 
8 6%
33 / 47 
70%
0 . 0 4 *
TRAP 
(50 peptides)
27 / 43 
63%
13 / 41 
32%
0 . 0 0 4 *
CS
(18 peptides)
21 / 64 
33%
22 / 47 
47%
0 .1 3
B. Magnitude of Response
Kenya The Gambia p-value
PPD 122 +/-7 64 +/-9 0 . 0 3 *
TRAP Peptides 34 +/-4 37 +/-Ô 0 .2 5
CS Peptides 42 +/-4 ND ND
A significantly higher proportion o f  adult Kenyan donors responded to TRAP derived peptides, compared 
to adult Gambians. The PPD response rate was also higher, but was o f  borderline significance. The 
magnitude o f  the response (specific responder cells / 106 PBMC) was higher in Kenyans fo r  PPD responses 
(backgrounds were comparable), but the TRAP peptide specific values were comparable between the 2 
groups.
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5.3.3
Peptides Tested According to High Predicted Binding to HLA-DRB1*01 or 
DRB1*1302
Seventeen of the 50 donors recruited to The Gambian study were tested for IFN-y 
production against nine of the eleven tv peptides (tv4c and tv5b were not tested in this 
study) (Table 5.4A). These peptides were selected according to a high predicted binding to 
either HLA DRB 1*1302, a common African haplotype (17% Gambians, 14% Kenyans) 
which is thought to be protective in West Africa (Hill et a l, 1991), or HLA DRB 1*01 
which is infrequent in The Gambian population (4% Gambians, 10% Kenyans), and 
associated with protection in East Africa (A.V.S. Hill, personal communication). Four 
Gambian adult donors (18%) gave a positive response to a tv peptide, suggesting that this 
method of trying to identify new epitopes according to HLA binding motifs is no more 
fruitful than conventional methods using overlapping peptides. Of the 3 IFN-y stimulating 
epitopes identified in this way (Table 5.5B) one is conserved (tvl), and the remaining two 
(tv4a and tv5a) fall within polymorphic regions of TRAP. Two (tvl and tv5a) are high 
predicted binders to HLA DRB 1*01, which is not associated with protection in The 
Gambia, and one (tv4a) to the common allele HLA DRB 1*1302, which is protective. 
Interestingly tv4a has not been isolated in Africa, unlike the other 2 variants tv4b and 4c 
which are African strains (Table 5.4A).
Forty three Kenyan adults were tested for responses to all 11 tv peptides, and eleven 
(26%) of them gave a positive response to at least one (Table 5.8). This is slightly higher 
than the number of Gambian responders, although 2 more peptides were used in this 
study. A comparison of the response rate in Kenyans (23.3%, 10/43) to the same 9 tv 
peptides tested in The Gambians (22.2%, 4/18) showed almost identical reactivity rates to 
peptides selected in this manner (%2 = 0.01, p = 0.93). The commonest T cell response in 
Kenyans was to peptide tv? (5/43, 12% of donors), followed by peptide tv8 (9% of 
donors). Neither of these are predicted high binders to the protective HLA DRB 1*01 allele 
in East Africa. Epitope tv7 is conserved, thus it is a potentially useful vaccine candidate, 
and tv8 has been identified as a strain present in East Africa (Table 5.4A).
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Table 5.8
EPITOPE DONORS FREQ SF U /106 PBMC P-VALUES
t v 1 D 1 1/21 5% 2 3 ,2 3 0 .0 5 ,0 .0 5
tv 2 D 1 2 / 2 3 / 3 9 7% 3 3 , 2 0 , 3 0 0 .0 1 ,0 .0 5 ,0 .0 5
t v 3 D 1 2 /3 4 5% 1 8 ,2 0 0 .0 5 ,0 .0 5
tv 4 a D12 2% 2 3 0 .0 5
tv4b 0%
tv 4 c D16.0K 5% 2 3 ,4 5 0 .0 5 ,0 .0 5
tv 5 a D11 2% 2 3 0 .0 5
tv5b D11 2% 2 3 0 .0 5
tv 6 D 1 2 /1 9 5% 1 8 ,3 8 0 .0 5 ,0 .0 5
tv 7 D1 1 / 1 3 / 2 3 ,OK 9% 1 7 , 2 5 ,1 8 ,8 0 0 .0 5 ,0 .0 5 ,0 .0 5 ,0 .0 1
tv 8 D 1 1/1 9 / 2 1 / 3 4 , OK 12% 2 3 , 3 3 , 2 0 , 3 3 , 8 3  0 .0 5 ,0 .0 5 ,0 .0 5 ,0 .0 1 ,0 .0 1
IF N -y ELISPOT responses in Kenyan adults to the 11 tv TRAP peptides selected according to high 
predicted binding to 2 common HLA haplotypes, DRB 1*01 and DRB1*1302 (see Table 5.4).
There seems to be no relationship between epitope recognition for TRAP and predicted 
HLA binding to a locally protective class II haplotype. Four of the tv peptides have not 
been isolated from infected Africans to date (tv2, tv3, tv4a, tv5b) and are regarded as 
exclusive to other malaria endemic regions of the world (Table 5.4A). Nevertheless, all were 
recognised by Kenyan adults suggesting that either these donors have generated cross­
reactive responses to variants that are present locally, or they are present but have not 
been isolated. The TRAP variant strains present in infected West Africans are well 
established (Robson et al., 1998), and preliminary data for Kenya suggests that the African 
strains common in West Africa predominate (K. Robson, personal communication). Thus 
these responses are probably truly cross-reactive.
5.3.4
The Majority of 20mer TRAP Epitopes Elicit CD4+ T Cell Responses
CD4 and CDS T cell depletion studies were performed to establish the phenotype of the 
responding T cells where possible (see Methods). Depletion studies of Gambian PBMC 
samples confirmed that IFN-y ELISPOT responses to tpl l ,  tp27, and tp38 were CD4 T
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cell mediated (Figures 5.4A, Table 5.9). Depletion of Kenyan adult PBMC confirmed that 
responses to a further 13 of the PfTRA? tp epitopes and one tv epitope elicited CD4+ T 
cell IFN-y ELISPOT responses (Figures 5.4B and C, representative examples of 13 
experiments, Table 5.9). The PPD responses behaved as predicted and disappeared 
following CD4 T cell depletion, but were unaffected by CDS T cell depletion (Figures 5.4 
B, C and D). Interestingly, two of the tp TRAP peptides (tp5 and tp6) elicited either CD4 
or CDS responses, even in the same donor in one case (D30) (Figure 5.4D). Since both tp5 
(aa 41-60) and tp6 (aa 51-70) contain the CDS 9mer epitope tr29 (aa 51-59), then 
presumably these donors were able to process this epitope from the 20mer during an 
overnight ELISPOT assay. Dual CD4/CD8 T cell epitope regions have similarly been 
described for CS protein (Doolan et al., 1991).
Four of the 5 CTL epitopes used in our studies (tr26, tr29, tr42, tr43) are contained in tp 
20mer peptides (see Table 5.10), and in certain cases I found reactivity to either the CD4 
epitope or the CDS epitope contained within it, but not to both. For example the TRAP 
peptide tpl l  (aa 101-120) contains two known overlapping CDS T cell epitopes tr42 (aa 
107-115) and tr43 (aa 109-117). In the Gambian study donor G73 responded to tpl 1, but 
failed to respond to tr42 or tr43 (Figure 5.4E). Conversely, donor G99 responded to the 
9mer CTL epitope tr43 (aa 109-117), a response likely to be CDS mediated, but failed to 
respond to tr42 or tpl l  (Figure 5.4F). Donor G99 also responded to tp6 (aa 51-70), but 
not to the constituent CTL epitope tr29 (aa 51-59) (Figure 5.4F). These findings were 
confirmed in the Kenyan study where more than 10 donors responded to a TRAP 20mer 
tp epitope without responding to the CTL epitope contained within it (not shown). 
Therefore, a positive response to the 20mer peptide need not be due to presentation of the 
known CTL epitope contained within that 20mer peptide, although these CTL epitopes 
can be processed.
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CD4 and CD8 depletion studies in Gambians (G73, G97 and G99) and Kenyans (D13, D27 and D30) 
demonstrated that most tp 20mer TRAP epitope responses were CD4 T cell epitopes in nature (A, B and 
C). Two peptides, tp5 and tp6, were fo u n d  to elicit both CD4 and CD8 responses, even in the same donor 
in one case (D). A TRAP 20mer was recognised without a concomitant response to the CTL epitope 
contained within it (E and F) and vice versa (F).
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T able 5.9
DONORS
EPITOPE CD4 or CD8 KENYAN GAMBIAN
tp4-6 pool CD4 K7
tp4-6 pool CD4 & CD8 K23
tp5 CD4 & CD8 D30
tp6 CD4 & CD8 D16
tp9 CD4 D10
tp l  1 CD4 G131
tp l  4 CD4 D16
tp l  5 CD4 D13
tp l  9 CD4 D13
tp22 CD4 D27
tp23 CD4 D 1 1 ,K13
tv7 CD4 D11
tp26 CD4 D11
tp27 CD4 G97
tp31 CD4 K6
tp32 CD4 D4
tp37-38 pool CD4 K13
tp38 CD4 G97
tp43 CD4 K10
tp47 CD4 JN
tp50 CD4 D11
t p 5 1 CD4 D8
Summary o f  results o f  all CD4 and CDS depletion studies. Most o f  the 20mer peptides tested were CD4 T 
cell epitopes.
Table 5.10
PEPTIDE AA CONTAINED IN SEQUENCE HLA
t r 2 6 3-1 1 tp l HLGNVKYLV A2
tr 2 9 5 1 - 5 9 tp5, tp6 LLMDCSGSI A2
tr 3 9 5 1 5 - 2 3 No GIAGGLALL A2
tr 4 2 1 0 7 - 1 5 tp11 ASKNKEKAL B8
t r 4 3 1 0 9 - 1 7 tp11 KNKEKALII B8
Summary o f  the 5 CTL epitopes tested in selected donors, including the HLA restriction. Four o f  them are 
contained within the tp 20mer peptides used in the study.
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5.3.5
T Cell Repertoire Differences Between East and West Africans
Interestingly, the repertoire of T cell responses in Kenyans compared to Gambians was 
quite different. The commonest TRAP T cell epitope response in Kenyans was to peptide 
tp51 (aa 501-520) to which 14% of Kenyan adults responded (Table 5.6), yet none of the 
17 Gambians tested gave a positive response (Table 5.5A). Conversely, tp50 (aa 511-530) 
was the commonest peptide recognised by Gambian donors (7%), but was only positive 
for one of the 65 Kenyan donors tested (2%). Figure 5.5 highlights these differences in T 
cell repertoire between the 2 populations. One striking feature of this figure is that of the 
very few TRAP peptides which the Kenyans failed to respond to (5 in total), responses 
were seen to all but one of them in Gambian adults. This is in the presence of a 
considerably lower reactivity rate in the Gambian population, and strongly suggests that 
repertoire differences do exist between the 2 populations.
The data for the tv peptides, which were selected according to high predicted HLA binding 
capacity, further supports our hypothesis that the T cell repertoire of responses differ 
between the 2 populations. The two most commonly recognised peptides in the Gambian 
study were tv4a and tv5a, which were positive in 12% of donors tested, whereas only 2% 
(1/43) of Kenyan adults recognised the same peptides in a comparable study. Conversely, 
no Gambian donors recognise tv7 or tv8 which were so commonly positive among Kenyan 
adults (12% and 9% respectively).
There are many reasons why such reactivity differences might exist between the 2 
populations. These include differences in HLA type between East and West Africans, 
differences in parasite strains present in these 2 regions, and differing levels of parasite 
exposure. I have established that most of these TRAP 20mers elicit CD4 T cell responses 
(Section 5.3.4) and thus the class II HLA types of 29 Kenyan responders, and 14 of the 
Gambian responders, were established by phototyping (see Methods). This demonstrated 
that the HLA types were indeed quite different between the 2 populations (Table 5.11).
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Figure 5.5
Gam Freq Ken Freq Gam Freq Ken Freq
Figure to illustrate the differences in repertoire o f
Kenyans) and West (47 adult Gambians) Africans. Where >1 positive response was observed in the study 
the bar is filled  in. The Gambians responded to less peptide
the Gambian donors responded to 4 o f  the 5 peptides
tp33, tp41 and tp46) strongly suggesting repertoire differences.
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T able 5.11
A. Kenyan Adults
DONOR DRB1 DRB1 DRB5 DRB3 DRB4 DQB1 DQB1 tp PEPTIDE RESPONSES
BM 7 1 3 5 2 5 3 2 5 t p 4 3 / t v 7
DM 1 1 ? 5 2 4 t p21
JN 1 8 5 2 4 t p 4 7
MN 1 1 1 3 5 2 5 7 t p 2 7 , 4 2
CK 1 7 5 2 5 2 t p 2 - 4 , 7 , 1 9 , 2 0 , 2 7 - 9 , 3 1 - 2 , 3 7 - 8 , 4 0 , 4 4 , 4 7 - 9 , 5 3 / ^ 4 0 , 7 , 8
PN 1 3 5 2 6 7 t p 4 5
TK 1 2 51 5 6 t p 4 3 , 5 2
D l l 1 0 1 1 5 2 5 t p l , 2 , 7 , 1  2 , 1 4 - 1  7 , 2 3 , 2 5 - 6 , 3 5 - 6 , 3 8 , 4 2 , 5 0 / t v 1 , 5 a , 5 b , 7 , 8
D12 7 1 3 5 2 5 3 7 t p 4 , 5 1 , 5 2 , 5 3 / t v 2 , 3 , 4 a , 6
D 1 3 1 1 1 5 2 5 7 t p 1 5 , 1 6 , 1 9 , 2 7 , 2 8 / t v  7
D 1 4 1 7 5 2 2 5 t p l  4 , 2 3 , 2 4 , 4 0 , 5 1
D 15 1 1 1 2 5 2 5 7 t p51
D 16 1 1 1 5 51 5 2 5 6 t p 3 , 6 , 1 4 , 3 6 / t v 4 c
D 1 7 1 1 ? 51 5 2 t p l  4
D 19 1 1 5 2 5 7 t p 5 , 2 3 , 5 1 / t v 6 , 8
D21 1 1 3 5 2 5 3 2 5 t p 6 , 3 0 , 3 9 / t v 1  ,8
0 2 3 7 1 3 5 2 5 3 2 7 t p 2 , 5 , 7 , 8 , 1 3 , 2 2 , 3 1 , 3 7 , 3 8 / t v 2 , 7
D 2 4 1 1 1 7 5 2 5 t p ô , 4 7
D 2 5 1 1 1 2 5 2 5 t p 4 7 , 4 9 , 5 1
D 2 7 1 8 5 2 5 t p 6 , 8 , 2 2 , 2 5 , 2 6 , 3 0
D28 1 1 5 2 6 t p l  2 , 1 8
0 3 0 1 1 1 3 5 2 5 6 t p 5
0 3 4 7 1 2 5 2 5 3 2 5 t p 2 , 4 , 6 , 2 8 , 3 0 , 3 1 , 3 7 - 4 0 , 4 8 , 5 2 / t v 3
D35 1 3 1 7 5 2 2 6 t p9
D3 6 1 0 1 1 5 2 5 t pô
0 3 7 1 3 1 7 5 2 7 5 3 2 t p 4 , 2 9
D39 1 8 5 2 4 5 t p 4 , 3 1 / t v 2
D4 0 1 3 5 2 5 t p l 8 , 2 0 , 3 4 , 3 7 , 4 0 , 5 1
D4 2 1 3 5 2 6 t p l  9
B. Gambian Adults
Donor DRB1 DRB1 DRB5 DRB3 DRB4 DQB1 DQB1 tp Peptide Responses
G3 5 hD ND ND ND ND ND ND t v 5 a
G4 6 ND ND ND ND ND ND ND t p 4 8
G5 5 1 1 1 3 0 4 5 2 7 t p 2 2
G5 8 1 3 0 2  1 3 0 4 / 1 2 5 2 6 7 t p 4 , 2 4
G6 0 1 6 1 3 0 1 51 5 2 5 6 t p 4 7 , 5 0
G7 3 1 0 1 3 0 2 5 2 5 6 t p 1 0 , 1 1 , 1 3 , 1 4 , 4 3 , t v 1 , t v 4 a
G8 5 1 8 1 3 0 4 5 2 4 t p 1 4 , 5 0 , t v 5 a
G9 5 8 1 3 0 3 5 2 7 t p 4 0 , 4 1
G9 6 1 1 1 3 0 4 5 2 7 t v 4 a
G9 7 9 1 1 5 2 5 3 7 2 t p 2 7
G9 9 9 1 3 0 2 5 2 5 3 6 2 t pô
G101 1 5 1 1 51 5 2 6 7 t p 3 8
G 102 8 9 5 3 7 2 t p 3 3 , 5 0
G 1 1 0 1 3 0 2 1 3 2 1 5 2 6 7 t p 5 , 2 3
G131 1 8 1 3 0 4 5 2 4 7 t p11
G 132 4 1 0 5 3 5 8 t p 2 5 , 3 9
Kenyan and Gambian peptide responders were HLA class II  typed. No specific HLA type could be assigned 
to a particular epitope response from  this data.
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It was not possible from this data to assign a particular HLA class II type to particular 
TRAP T cell epitope responses since no common class II types emerged for individual 
epitopes. This in itself is very interesting since it may mean that the TRAP epitopes are 
recognised through multiple HLA types, rather than just one. This would certainly be 
advantageous in terms of vaccine design.
Parasite strains have been extensively typed in West Africa (Robson et al., 1988, Robson 
et a l, 1990, Robson, 1993, Robson et al., 1996, Robson et a l, 1998), and preliminary data 
for certain Kenyan donors that were blood film positive in this study suggested that similar 
strains were present in Kenya in comparable frequencies, although some new mutations do 
exist (K. Robson, personal communication). Differences in rates of parasite exposure, and 
differences in strains are discussed in conclusions.
5.3.6
Malaria Naïve Individuals Do Not Respond to TRAP 20mer Peptides
To confirm that the responses were TRAP specific, fifteen malaria naïve donors were 
tested in Oxford for IFN-y ELISPOT responses to the 10 pools of non-overlapping 20mer 
TRAP peptides tpl-tp50 (aa 1-510) (Table 5.3) using freshly isolated PBMC. The 
conditions used were identical to those used in The Gambia and Kenya, and assays were 
performed with the same peptides and batch tested serum and media. Seventy three 
percent (11/15) of the malaria naïve donors gave a positive response to PPD, and none of 
the 15 naïve donors gave a positive response to the TRAP pools containing peptides tpl-  
tp50 (not shown). The lack of responses observed in naïve adults is highly significant 
when compared to Gambian adults (%2 = 6.19, p = 0.01) and Kenyan adults (%2 = 17.56, p 
= 0.00003). Naïve donors were not assessed for responses to the tv peptides.
5.3.7 
Reactivity to Polymorphic Variants of TRAP T Cell Epitopes in Kenyans
One of the reasons for the interest in TRAP as a malaria vaccine candidate is that it is less 
polymorphic than CS, although up to 5 naturally occurring variants have been identified for
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some regions of the molecule. Throughout this chapter I have assessed for T cell responses 
to peptides derived from a single clone of P/TRAP, called NF54. It was not known how 
much reactivity would be found to multiple variants of single polymorphic T cell epitope 
regions of TRAP. In order to assess this I selected nine of the most immunogenic 
polymorphic TRAP tp epitopes from the Kenyan study, and synthesised the 
polymorphic variants from 10 naturally occurring strains (Table 5.3). These strains have 
been isolated and cloned from parasites from all over the world including East (7901) and 
West Africa (3D7, 7G8, IT04, NF54), Latin America (HB3), and South East Asia (DD2, 
K l, T996) (Robson et al., 1998).
Twenty five Kenyan adults were tested by IFN-y ELISPOT to these variant peptides from 
PfTRAP. Twenty seven peptide conditions were tested per donor, and 72% (18/25) of 
donors responded to one or more condition (Table 5.12). Forty percent (10/25) of the 
donors responded to the NF54 strain variant, thus assessing for responses to the 10 variant 
strains almost doubled the response rate to a single strain. Forty four percent (11/25) of 
the donors tested showed a degree of cross-recognition of different variant epitopes within 
variant T cell epitope regions. The majority of cross-recognition occurred to 2 variant T 
cell epitopes only, although 4 donors responded to 3 or 4 variants of a particular T cell 
epitope. Three of these latter multiple strain responses were to epitope tp31, although 5 of 
the 9 donors who gave a tp31 region response did so to one variant only. The tp31 epitope 
region contains the proposed cell recognition sequence, ROD, which is likely to be of 
functional significance.
Thirty nine percent (16/41) of positive responses to any particular epitope region 
exhibited a degree of cross-recognition, although there was only one instance in which a 
donor responded to all the variants of a particular epitope (donor K3 to all 4 tp31 variants) 
(Table 5.12). Studies of cross-recognition of the highly variable Th2R and Th3R CD4 T 
cell epitope variants of CS by IFN-y ELISPOT in Kenyan adults showed that 56.3% 
(9/16) of the Th2R responders and 40% (6/15) of the Th3R responders showed a degree of 
cross-recognition (Table 5.13).
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T able 5.13
T h 3 R
W1 W2 W3 W4 W5 W6 W7 W8
BM
DJ
DK
FC
GM
KOI
NB
D4
D5
D8
D11
D12
D14
DIS
D16
D21
D23
D25
D29
D34
040
BK.CP.DM
FM,JM,JN
K02.MF
MN.NM.OK
PN.RP.SD
BM.TK
D1-3, 6-7
D9-10
D13, 17
D19-20
D22, 24
D26-28
D30-33
D35-39
D41-43
65 Kenyan adult donors were tested by IFN-y ELISPOT assay fo r  responses to the 9 Th2R epitope variants 
and 8 ThSR epitope variants o f  CS protein. Positive responses are indicated with filled  in squares. Limited  
cross-recognition o f  variants was seen.
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Comparing the degree of cross-recognition to the TRAP epitope variant regions, with that 
seen to the immunodominant Th2R and ThSR CS epitope regions, suggested that there is 
no difference in cross-recognition of responses between these 2 important antigens (%2 = 
0.63, p = 0.43). This comparison is not entirely valid since CS is considerably more 
polymorphic than TRAP, and the study assessed responses to 2 polymorphic epitope 
regions of CS, and 7 variant epitope regions of TRAP. However, both studies addressed 
reactivity to a similar number of naturally occurring strains (9 for CS protein, 10 for 
TRAP), and the results suggest similar levels of cross-recognition.
5.3.8 
Th2 Type T Cell Responses in Gambian and Kenyan Adults
Preliminary studies screening for Th2 type responses in selected Gambian donors showed 
minimal Th2 induction. Thus, adult Gambians were screened for IL4 (n = 6) and IL10 (n = 
8) responses to the 10 pools of PJTRAŸ 20mer peptides (clone NF54) spanning residues 
1-510 (Table 5.2). Where a positive response was seen, the individual peptides within the 
pools were tested. PHA was used as the positive control in all assays. Only one of the six 
individuals tested for IL4 production gave a positive response (Table 5.5C), and none of 
the eight tested gave an IL10 response. Additionally, selected Gambian adults were 
screened for responses to the 3 peptides, tp51-53, spanning the carboxy-terminus of 
TRAP, and to the 9 tv peptides. No donors responded to tp5l-53 by IL4 (n = 13) or IL10 
(n = 2) production. One of the fifteen donors tested for IL4 production responded to two 
tv peptides (tv2 and tv4b) (Table 5.5C). Neither of the two individuals screened for IL10 
responses were positive to the tv peptides, or indeed any other TRAP peptides.
A more comprehensive study of Th2 type T cell reactivity to TRAP was performed using 
PBMC from Kenyan blood transfusion donors (1998 cohort). Twenty three donors were 
assessed in total, 22 by IFN-y, 21 by IL-4, and 8 by IL-10 ELISPOT assays (Table 5.14). 
Fifty nine percent (13/22) of donors responded to at least one pool by IFN-y production, 
and 33% (7/21) produced IL-4 (Table 5.14). The higher level of IFN-y reactivity compared 
to IL-4 reactivity failed to reach significance (%2 = 2.87, p = 0.09).
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T able 5.14
DONOR IFN-y IL-4 IL -10
TK p2,p11 v 1 p!1
GM v 1 nil n i I
KOI p5,p6 pi 1 ,v1 ,v2,v3 p! >p5
MM ND P8 pi  ,p5,v3
DJ p2,p3,v3 n i I ni l
JN P7 p i . p i  1 ,v1 p5
D43 nil ND p! ,p6,v1
D22 nil ND n i I
DIO p9 nil ND
MF n i I n i I ND
BM p3,v2 n i I ND
D34 p i -2 .p4 .pô -11,v1 ,v3 nil ND
DM P1 p9 ND
D9 n i I n i I ND
D17 p4 nil ND
D19 p3.pô.pi  1 ,v1 ,v3 nil ND
D21 pô.p9.pIO.vI nil ND
D32 n i I n i I ND
D37 p4,p9 p2,p7 ND
NB p4 n i I ND
RP nil P7 ND
D31 nil nil ND
D20 nil n i I ND
13 / 23 (57%) 7 / 21(33%) 5 / 8 (63%)
Selected Kenyan adult donors were screened in parallel IFN-y, IL-4 and IL-10 ELISPOT assays fo r  
responses to pools o f  TRAP peptides. ND  = not determined.
Where IFN-y and IL-4 responses were detected in the same donor, they were to different 
peptide pools. For example, donor D37 had an IFN-y response to pools 4 and 9, and an IL- 
4 response to pools 2 and 7 (Table 5.14). Sixty three percent (5/8) of the donors tested for 
gave an IL-10 response (Table 5.14). Two of the 5 responders produced IFN-y and IL-10 
to the same peptide pools (donors TK, KOI), although I do not know to which individual 
peptides. I thus detected similar levels of IFN-y and IL-10 reactivity (%2 = 1.39, p = 0.24), 
but higher IL-10 reactivity (63%) compared to IL-4 reactivity (33%), although the
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difference was not significant (%2 = 2.03, p = 0.22), probably because of the small sample 
size.
The West African study of Th2 T cell reactivity was less comprehensive but certain 
differences between East and West Africans were apparent. The same number of donors 
were tested in Kenya and The Gambia (n = 8) for IL-10 production to the 10 TRAP pools, 
and while none of The Gambian donors responded to the TRAP pools, half the Kenyan 
donors (4/8) gave an IL-10 response (%2 = 5.33, p = 0.02), although the significant 
difference was lost on adjusting for small numbers (2-tailed Fisher’s value p = 0.08). 
Seventeen percent (1/6) of the Gambian donors gave an IL-4 response to TRAP pools, and 
29% (6/21) of Kenyans to the same pools, analysis of which suggested no significant 
difference in IL-4 reactivity rates between the 2 countries (%2 = 0.34, p = 1.0).
5.3.9 
Thl / Th2 T Cell Responses to Variant TRAP T Cell Epitopes
I speculated that individual variant TRAP peptides may selectively induce either IFN-y or 
a Th2 (IL-4 or IL-10) type T cell responses, as observed by ELISPOT for CS protein 
epitope specific T cell responses (Chapter 4). Eleven of the 25 donors assayed for IFN-y T 
cell responses to the variant TRAP peptides (Table 5.3) were therefore tested for IL-10 
and IL-4 ELISPOT T cell responses in parallel to IFN-y. A further 4 donors were tested 
for IFN-y and IL-4 only. Fifty five percent (6/11) of donors tested for IL-10 ELISPOT 
reactivity, and 47% (7/15) of donors tested for IL-4 ELISPOT reactivity, gave positive T 
cell responses to one or more TRAP conditions (Table 5.15). There was no significant 
difference in the proportion of donors who produced IL-4 or IL-10 to this panel of TRAP 
T cell variant epitopes (%2 = 0.16, p = 0.69). The total number of IL-4 responses (n = 20) 
observed in this variant analysis was greater than the number of IL-10 responses (n = 12). 
This is in contrast to the greater IL-10 reactivity (63%), compared to IL-4 reactivity 
(33%), observed to peptides derived from one strain of TRAP (NF54) only (Section 
5.3.8), although the difference did not reach significance (p = 0.22).
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T able 5.15
A. IFN-y & IL-4 B. Tested for IFN-y, IL-4 & IL-10
K3 K4 K5 K6
tp2
K1 K7 K8 K9 K10 K12 K13 K14 K20 K21 K22
$$$ I I I N i l
tp4-6
______
t p 4 - 6 c | (  r
tp30
tp30x
tp30y
tp31 z
üËiErpQ iTnt p 3 7 x  T c M j  M M
tp37y  _ j e _
tP37z
tp40
tp47
8
ZmI^ O Z H I
J £ 3 Ï x _ M _ _ M  
tp3iyM  _ m  
j £ 3 i 7 _ B _ _ J _
g l F N - y
tnuiL 1 0
Ü I F N - y + IL-4 
H ' F N - Y  + IL-10 
M l  IL-4 + IL-10
n n  _
ND ND ND ND
tp38
tp38x
tp38y — I I I !
tp38z
tp43 I
tp43v ■
tp43w ■
tp43x
tp43y
tp43z
tp51
Kenyan adult blood transfusion donors were tested fo r  responses to the TRAP variant peptides (Table 5.3) 
by IF N -y and IL-4 (n = 4 donors) or IFN-y, IL-4 and IL-10 (n = 11 donors) ex-vivo ELISPOT assays. 
Positive responses are indicated by filled  squares according to the key on the right hand side.
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It may be that the NF54 strain of TRAP preferentially induced IL-10 T cell responses, 
whereas other strains induce IL-4. There were more IL-10 responses (n = 7) to the NF54 
strain, than IL-4 responses (n = 5), but the donor numbers were too small to assess for 
significance. Another possible reason for the high levels of IL-10 induction in the single 
strain study was that this study was performed during the high malaria transmission 
season (June/July 1988), whereas the variant study was performed during a low 
transmission period (September 1999). High levels of IL-10 induction by malaria epitopes 
is a recognised phenomenon during episodes of malaria transmission (Winkler et a l, 1998, 
Winkler et al., 1999).
Two donors (K8 and K12) gave entirely Th2 biased responses to TRAP variants, and 3 of 
the 11 donors for whom all 3 cytokines were tested were Thl biased (donors K13, K21, 
K22) (Table 5.15). For three of the donors IFN-y was produced to certain variants, and IL- 
4 to another variant of the same epitope (donors K9, K10, K14). For example donor K10 
produced IFN-y to tp37x and 37z, and IL-4 to tp37y. Similarly, donor K14 produced IFN- 
y to tp43x and IL-4 to tp43y. There were no cases of IL-10 production to one variant and 
IFN-y to another. Thus, I could find no TRAP variant CD4 T cell regions that might 
behave as altered peptide ligands in a similar manner to that described for CS in chapter 4. 
The conserved peptide tp2 induced an IFN-y and IL-10 response in the same donor (K7). 
Another donor produced IL-4 and IL-10 to the conserved epitope tp47 (Kl). This dual 
induction of different cytokines by the same conserved CD4 T cell epitopes illustrates the 
complexity of malaria T cell immunity.
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5.4
DISCUSSION
Thrombospondin related adhesive protein (TRAP) is thought to play a role in protection 
at the pre-erythrocytic stage of malaria infection, and might be a useful component of 
malaria vaccines. In this chapter I examined CD4 T cell reactivity to TRAP in detail, since 
no CD4 T cell epitopes had been identified for the antigen. I have identified 52 novel 20mer 
epitopes (21 in exposed Gambians, 48 in exposed Kenyans), denoted tp, spanning the 
length of the antigen, which can induce rapid IFN-y production in naturally exposed 
donors. A further 10 novel IFN-y inducing epitopes (3 in Gambians, 10 in Kenyans), 
denoted tv, were identified in these 2 studies, having been selected on the basis of a high 
predicted binding to certain HLA class II haplotypes. Thus, from 64 peptides I have 
identified 62 novel epitopes, 16 (26%) of which are conserved worldwide (Table 5.1). The 
screening for multiple peptide responses in one simple assay thus facilitates epitope 
mapping for malaria, and may also be utilised for other infectious diseases. Sixteen of the 
tp epitopes, and one of the tv responses, were shown to be CD4 T cell mediated. Two of 
the tp responses (tp5 and tp6) were dual CD4 and CDS T cell epitopes, which is 
consistent with the fact that they both contain a previously identified HLA A2 restricted 
CTL epitope called tr29 (Aidoo et a l, 1995).
It is interesting that the epitopes were spread along the length of the molecule, unlike CS 
where regions of immunodominance arise in certain polymorphic areas of the antigen 
(Good et al, 1988d). This suggests that multiple regions of the antigen can be processed 
and presented to T cells in vivo. This is quite unusual, since generally only certain regions 
of an antigen are immunogenic. This data suggested that TRAP may be under less immune 
selection pressure than CS protein, which is further supported by the fact that it is less 
polymorphic than CS protein. Furthermore, this data supports the incorporation of the 
entire TRAP antigen into a pre-erythrocytic malaria vaccine, since the antigen contains so 
many T cell epitope regions.
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Adult Kenyans showed significantly increased T cell reactivity to TRAP compared to 
Gambians, but comparable reactivity to two immunodominant CD4 epitope regions of CS 
(Th2R and Th3R). The high reactivity levels observed in naturally exposed Kenyans 
suggested that a vaccine bearing one or two strains of TRAP might be sufficient to induce 
immune responses in most Kenyan donors, although this may not be the case for 
Gambians The T cell repertoire of IFN-y responses to TRAP derived peptides in these 2 
populations was quite different, and this is an important consideration in the design of 
vaccines for use in naturally exposed donors. The possible reasons for differences in 
reactivity rates and repertoire are numerous, and include technical differences in the assays, 
or real differences. The assays were all performed by myself or under my supervision, 
using the same methods, and the same peptides and batch tested serum. This therefore 
minimises the possibility of technical differences, but cannot rule it out. T cell repertoire 
differences with decreased reactivity in Kenyans and increased reactivity in Gambians was 
observed for IFN-y ELISPOT responses to another malaria antigen, MSP-1, in parallel 
studies (Lee et a l, 2000). This further suggested that the differences observed in this study 
were not technical in nature.
There are many non technical reasons for differences in reactivity between the Gambian 
and Kenyan adults. These include different HLA types of the 2 populations, different 
parasite exposure, and different strains and seasonality. Class II HLA typing confirmed 
considerable disparity between the 2 populations (Table 5.11), and typing of many of the 
responders failed to show common HLA types for donors giving the same TRAP epitope 
responses. This suggested that the TRAP epitopes are recognised through more than one 
HLA type, which may in part explain why so many responses were seen across the whole 
antigen. This further supports TRAP as an excellent malaria vaccine candidate, since 
disparity in HLA distributions in different malaria endemic regions of the world is a major 
obstacle in malaria vaccine design. It remains to be seen whether high levels of T cell 
reactivity to TRAP occur in other malaria endemic regions of the world.
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In The Gambia the entomologie inoculation rate (EIR) is low frequency with an individual 
receiving an average of 5 infective bites / year (Greenwood et a l, 1987, Gupta et a l, 1994). 
In Kilifi, Kenya the parasite prevalence is -50%, and the EIR ranges from 0-60 infective 
bites per year depending on where on the coast the individual lives (Mbogo et a l, 1995) 
(low to moderate transmission in North Kilifi, high transmission in South Kilifi). The 
seasonality is also quite different between the 2 countries. There is one long wet season in 
The Gambia between August and November when the majority of malaria episodes occur. 
In Kilifi, transmission occurs most of the year, with peak periods occurring with the rains 
from June to August and December to January (Mbogo et a l, 1995). Thus, the reactivity 
differences observed in this study might be explained on the grounds of the differences in 
parasite exposure. The Gambian samples were taken during the low transmission period, 
and thus IFN-y ELISPOT T cell responses to TRAP might be expected to be low given 
that the ELISPOT is thought to reflect recent memory events (Chapter 3). The sampling in 
Kenya took place during a high transmission period when ELISPOT T cell responses might 
be expected to be higher. These broad conclusions are complicated by the fact that malaria 
induced immunosuppression of T cell responses is also well recognised (Ho et a l, 1986, 
Theander et al, 1986, Riley et a l, 1988a, Hviid et a l, 1991b), although in this study it is 
the more highly exposed Kenyans that exhibit higher reactivity.
An analysis of responses to polymorphic T cell epitope variants of TRAP, derived from 
10 naturally occurring strains, showed that for approximately 35% of positive responses 
there was some cross-recognition with variants of the same epitope. This was comparable 
to the degree of cross-recognition of T cell variants within 2 immunodominant CS T cell 
epitope regions. In only one instance did a donor respond to all the variants tested for a 
particular TRAP T cell epitope (K3 to the 4 tp31 variants tp31, 31x, 31y, 31z). There are 
several publications detailing the TRAP variant strains present in infected West Africans 
(Robson et a l, 1990, Robson et a l, 1998), but only limited data for East African Ugandans 
(Robson et a l, 1998), and no published data for Kenyans. Preliminary typing data for 
Kenyan donors in this study showed that the strains were similar to those present in The 
Gambia, but certain differences in frequencies and some new polymorphisms were
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observed (K. Robson, personal communication). Interestingly, over 50% of Kenyan donors 
had mixed infections with more than one parasite strain, which should increase the 
likelihood of a donor recognising more than one T cell epitope variant at a time. The cross­
recognition of variant T cell epitopes by individual donors in this study was probably 
mediated by different T cell clones, that are each capable of recognising different epitopes 
within the same region, rather than truly cross-reactive T cell clones which recognise 
multiple variants of a T cell epitope through the same TCR. However, certain of the 
variants tested have never been identified in Africans eg the tp43x RNI polymorphism (aa 
426-428) (Table 5.3) appears to be exclusively South East Asian and was not found in the 
Kenyan samples (K. Robson, personal communication). The IFN-y ELISPOT T cell 
responses seen for 3 Kenyan donors (K9, 10, 14) to tp43x (Table 5.12) might therefore be 
truly cross-reactive with T cells which recognise another variant T cell epitope for the 
same region to which the donors had been exposed. The other possibility is that the strains 
are present in Kenya, but have not been identified to date, or that positive responses are 
due to cross-reactivity with another immunogen to which the T cells have been primed 
(Zevering et a l, 1992).
I found double the number of IL-10 compared to IL-4 reactivity in Kenyans (63% vs 33%) 
to the NF54 strain of TRAP, although this did not reach significance probably because of 
the small sample size. There was also increased IL-10 reactivity to TRAP in Kenyans 
compared to Gambians which again failed to reach significance on adjusting for small 
sample size. One possible explanation for the high IL-10 reactivity in the Kenyan study 
was that it was performed during the malaria season (June/July), whereas the Gambian 
study was performed during the dry season when malaria transmission rates were low. The 
preferential induction of IL-10 is one immunological mechanism by which the parasite 
might suppress the host immune response during peak transmission periods, and may in 
part be responsible for malaria induced immunosuppression of T cell responses. Indeed, a 
study of malaria infected children in Gabon observed many IL-10 producing CD4 and CD8 
T cells (Winkler et a i, 1998, Winkler et a l, 1999). When the TRAP peptides from 10 
variant strains were tested for Th2 reactivity in adult Kenyans, the IL-10 and IL-4
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response rate was comparable (47% of donors gave IL-4 and 55% IL-10 responses). This 
study was performed after the peak malaria transmission period in Kilifi, which may 
explain the reduced level of IL-10 induction. In certain donors variant TRAP peptides from 
the same T cell epitope region were found to induce either IFN-y or IL-4. For no epitope 
region was there a differential induction of IFN-y and IL-10 in the same donor by variant 
peptides, and thus no evidence that TRAP polymorphic variants employ the same APL 
immune evasion strategy described for CS variants in chapter 4. However, the high level of 
IL-10 reactivity induced by TRAP in Kenyans during the malaria transmission season 
suggested that preferential induction of this immunosuppressive cytokine might play a role 
in the well recognised immunosuppression of malaria.
In summary, this study demonstrated that TRAP represents a significant target for 
protective IFN-y T cell responses in naturally exposed Gambians and Kenyans, which may 
be susceptible to boosting by vaccination. A number of conserved epitopes have been 
identified in the 2 populations, and these may represent particularly useful components of 
a future malaria vaccine. High levels of IL-10 were induced in those donors tested by 
ELISPOT during the peak malaria transmission season. Differences in T cell reactivity to 
TRAP were observed between East and West Africans in terms of the absolute number of 
responders, although precursor frequency levels were comparable. Studies aimed at 
understanding differences in T cell reactivity to malaria vaccine candidate antigens in 
different malaria endemic populations are essential if the goal of developing an effective 
malaria vaccine effective in these different populations is to be achieved.
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CHAPTER 6
TRAP T CELL RESPONSES BY IFN-y ELISPOT ASSAY: 
ADULTS COMPARED TO CHILDREN AND ANALYSIS 
FOR CORRELATES OF PROTECTION
6.1
INTRODUCTION
In the previous chapter I demonstrated differences in T cell reactivity to TRAP between 
East African (Kenyan) and West African (Gambian) adults. The Kenyans had a 
significantly greater rate of T cell reactivity to TRAP, but not to CS protein. The 
repertoire of responses to a panel of overlapping peptides was also different between the 2 
populations, although the numbers of specific responder cells (per 106 PBMC) were 
comparable for both TRAP- and CS-specific T cell responses. These apparent population 
differences might be real, or may be due to technical differences, and these possibilities 
were explored in the discussion.
The many non-technical variables that complicate a comparison between 2 populations 
include HLA differences, differences in parasite exposure and strains, and different malaria 
seasonality. Differences in reactivity between East and West Africa might suggest that the 
increased reactivity observed in Kenyans was a consequence of the increased exposure to 
malaria in these individuals compared to Gambians. If this is the case then the fact that 
reactivity to CS protein was comparable between the 2 populations might reflect negative 
regulatory factors affecting reactivity to CS protein, but not TRAP. Indeed, I have 
demonstrated CS protein variant epitope antagonism at the CD4 effector T cell level.
Children are the main target population for malaria vaccine programmes, and it is thus 
important to understand the nature of their T cell immunity in response to natural 
exposure, and the type of responses that are to be boosted by vaccination. I therefore 
undertook to assess TRAP reactivity in children, and to compare reactivity with adults in
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order to further understand the nature of development of immunity to TRAP. No studies 
have directly compared T cell responses to pre-erythrocytic antigens between adults and 
children. Any differences between subgroups could not be attributed to technical 
discrepancies, HLA variation, or different parasite strain prevalence, thus ruling these 
variables out.
Throughout this thesis I have utilised the IFN-y ELISPOT assay to measure T cell 
responses to malaria derived peptides. I have suggested that the IFN-y ELISPOT is a more 
clinically relevant assay than proliferation, since the Thl type cytokine IFN-y is thought 
to be protective at the pre-erythrocytic stage of infection. Indeed, there is evidence in 
animals that IFN-y ELISPOT responses correlate with protection (Plebanski et a l, 1998). 
In humans, the candidate vaccine RTS,S has been shown by IFN-y ELISPOT to induce 
CD4 T cell responses to CS protein, and these are thought to be relevant in protection 
(Lalvani et a l, 1999). The ELISPOT is a rapid and simple technique for use in field studies, 
and can be used to screen for multiple peptide responses at a time.
Despite the possibility that IFN-y ELISPOT responses might be protective, no study has 
assessed for a protective association between IFN-y ELISPOT responses and the 
subsequent development of malaria in naturally exposed donors. Since I observed such high 
levels of reactivity to TRAP in Kenyan adults, I proposed to investigate whether IFN-y 
ELISPOT responses to TRAP correlated with protection. If protective IFN-y ELISPOT 
responses were found, then this assay might provide a simple method of assessing both the 
levels of protective immunity in the population, and monitoring T cell responses during 
malaria vaccine trials. The assay could also be used for assessing immunity to other 
infectious diseases where IFN-y is thought to play a protective role.
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6.2
STUDY DESIGN 
6.2.1
Rationale
6.2.1.1
Adults vs Children
Protective immunity at the pre-erythrocytic stage of malaria infection is probably the 
cumulative effect of responses to hundreds or even thousands of pre-erythrocytic antigens. 
Development of pre-erythrocytic immunity from childhood to adulthood is poorly 
understood, and there is a notable paucity of studies comparing T cell responses 
throughout different age groups. A comprehensive comparison of children and adults might 
increase our understanding of the development of pre-erythrocytic immunity, and the 
nature of protection enjoyed by lifelong exposed adults. It is not known if young children 
have IFN-y ELISPOT responses to T cell epitopes, or at what age such responses might 
first be seen. It was also unknown whether the repertoire of T cell responses would vary 
between age groups, or whether the entire population would have a comparable T cell 
repertoire given their similarity in exposure rates and HLA type. To address these 
questions a cross-sectional analysis of IFN-y ELISPOT responses to selected T cell 
epitopes from TRAP was performed in a cohort of donors ranging from infants to old age.
6.2.1.2
Analysis for Protection
The ELISPOT is a relatively new tool for use in field studies, and no large scale assessment 
of ELISPOT responses have looked for protection against the subsequent development of 
malaria. There is good evidence supporting a protective role for TRAP in animal studies, 
and some evidence for a protective role in humans (reviewed in Chapter 1). I therefore 
aimed to assess whether IFN-y ELISPOT responses to selected TRAP T cell epitopes 
were protective. Donors tested by IFN-y ELISPOT in a cross-sectional bleed were 
subsequently followed up prospectively in the field, and assessed for the development of
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malaria. Analysis for protective IFN-y ELISPOT T cell responses to TRAP was then 
performed.
6.2.1.3
One Year Repeat ELISPOT Assays
I proposed in chapter 3 that the ex-vivo ELISPOT detects circulating effector T cells 
(Tem). If this is correct one would predict that responses will change frequently over time 
according to recent exposure. No study has assessed for changes in IFN-y ELISPOT T cell 
responses over time in malaria exposed donors, and in fact there is little data regarding such 
changes with time for any disease. Results from a malaria vaccine trial suggest that OS- 
specific IFN-y ELISPOT T cell responses decline after 1 month in malaria naïve donors 
(Lalvani et a l, 1999). A selected number of donors in this study were therefore re-tested in 
identical IFN-y ELISPOT assays after 1 year to see whether responses were maintained, or 
whether they changed after 1 year of natural exposure.
6.2.2
Study Site and Volunteers
Two hundred and seventeen donors aged between 1 month and 81 years (57% females, 
43% males) were recruited from Ngerenya district in Northern Kilifi (Figure 6.1). The 
people were predominantly Giriama ethnicity, and were mainly farmers of maize and 
cassava for home consumption, and cashew and coconut cash crops. The cross-sectional 
bleed took place at Kilifi District Hospital (Figure 6.1) between 31st August and 11th 
September 1998. This represents a period of lower transmission following the peak 
transmission intensity period from June to August (Mbogo et a l, 1995). Ngerenya district 
is an area of moderate malaria transmission with an entomologie inoculation rate (EIR) of 
10 (range 3-15) infectious bites per person / year (C. Mbogo, personal communication)
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Figure 6.1
/ Ngerenya 
District Indian Ocean
Kilifi
District
Hospital
Figure indicating the Ngerenya district study area in Northern Kilifi. 217 donors were recruited from  
households in Ngerenya, and followed up weekly in the field. The cross-sectional bleed took place at 
Kilifi District Hospital (indicated).
6.2.3
Peptides
Fourteen tp TRAP peptides were selected for the cross-sectional analysis, and were 
chosen according to a number of criteria: all those with a frequency of >9% in the pilot 
study of Kenyan adults (Chapter 5, Table 5.6); and those of particular interest such as 
highly conserved (tp23), highly polymorphic (tp43), or containing a domain of proposed 
functional significance (tp30) (Table 6.1, 6.2). Peptides tp4, tp5 and tp6 were pooled and 
tested as one condition, as were peptides tp30 with tp31; and tp37 with tp38. This gave 
10 P/TRAP conditions for testing in the donors (Table 6.1). Fifty one percent of the adults 
in the pilot study responded to one or more of these 10 TRAP conditions. Seven of the 10 
TRAP conditions were known to be CD4 T cell epitopes, and one (tp4-6) elicited CD4 or 
CDS T cell responses in depletion studies. Two were conserved sequences worldwide (tp2 
and tp23), and 6 conserved in Africa (tp2, tpl4, tp23, tp40, tp51) (Table 6.1).
Table 6.1
CONDITON M C D 4 / CD8 WORLDWIDE AFRICA RESPONSE IN GAMBIANS
tp 2 1 1 - 3 0 ND conserved conserved No
t p 4 - 6 3 1 - 7 0 CD4 & CD8 variant variant Yes
tp1 4 1 3 1 - 1 5 0 CD4 variant conserved Yes
t p 2 3 2 2 1 - 2 4 0 CD4 conserved conserved Yes
t p 3 0 - 1 2 9 1 - 3 2 0 CD4 variant variant No
t p 3 7 - 8 3 6 1 - 3 9 0 CD4 variant variant Yes
t p 4 0 3 9 1 - 4 1 0 ND variant conserved Yes
t p 4 3 4 2 1 - 4 4 0 CD4 variant variant Yes
t p 4 7 4 6 1 - 4 8 0 CD4 variant variant Yes
tp51 5 2 6 - 5 4 5 CD4 variant conserved No
The 14 TRAP peptides selected fo r  testing in the 217 donors were made up into 10 conditions, 3 o f  which 
were peptide pools.
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T able 6.2
EPITOPE FREQ NOTES
tp 2 9% C o n s e rv e d , m ostly  s ign al s eq u e n c e , pred ic ted  p -s h e e t ( a a l -2 0 /2 8 -3 0 )
t p 4 1 2% S -S  a a 4 3  to 5 5 , p -s h e e t  ( a a 3 1 -3 3 /4 8 -5 0 )
t p 5 9% A -like  dom ain  (beg ins a a 4 8 ), S -S  a a  4 3  to 5 5 , p -s h e e t (a a 4 8 -5 3 ) ,  C T L  e p ito p e  tr2 9  (a a 5 1 -5 9 )
t p 6 12% In A -like  dom ain , S -S  a a 5 5 , p -s h e e t (a a 5 1 -5 3 ) , C T L  ep ito pe  tr29  (a a 5 1 -5 9 , L L M D C S G S I)
t p l  4 9% a -h e lix  (a a 1 3 6 -1 4 3 )
t p 2 3 7% H igh ly  conserved  reg ion , end  A -like  dom ain  (a a 4 8 -2 4 1 ) , S -S  a a 2 3 4 , a -h e lix  a a 2 3 7 -2 4 0
t p 3 0 7% C onta in s  proposed  a d h e s iv e  dom ains  E P L D V  (a a 2 9 1 -2 9 5 )  and  R O D  (a a 3 0 7 -3 0 9 )
tp 3 1 9% C onta in s  R O D  cell recognition seq u en ce
t p 3 7 9% C onta in s  P N P  rep ea ts
t p 3 8 9% P red ic ted  a -h e lix  (a a 3 8 1 -3 8 7 )
t p 4 0 9% P red ic ted  a -h e lix  (a a 3 9 9 -4 0 5 )
t p 4 3 5% H igh ly  po lym orphic
t p 4 7 9% C o n s e rv e d  across  m ost s tra ins
t p 5 1 14% C o n s e rv e d  in A frica , tra n s m e m b ra n e  (a a 5 1 2 -5 4 0 ) ,  a -h e lix  ( a a 5 1 1 -5 1 2 ) , p -s h e e t (a a 5 1 5 -5 1 9 )
Details o f  the 14 TRAP tp peptides chosen fo r  the cross-sectional analysis o f  ELISPOT responses in 217 
Kenyan donors. The frequency at which they were positive in the study o f  65 Kenyan adults is given, since 
the peptides were selected on the basis o f  this pilot study (see Chapter 5, Table 5.7). The amino acid 
sequences fo r  each peptide can be found  on Table 5.1 (Chapter 5).
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6.2.4
Follow up for Malaria
Active follow up was performed weekly by a team of field workers. Each household was 
visited, and the temperature of each trial participant was recorded. A history was taken 
regarding fever and any other clinical symptoms over the preceding week. Those with a 
history of fever, or a temperature of >37.5°C on the day of the visit, were referred to the 
clinic and had duplicate finger prick blood smears performed (thick and thin films). All data 
was entered into a computer database using Fox-Pro software.
6.2.5
Statistical Methods 
6.2.5.1
Age Group Comparisons
There were only small numbers of responders in each year group, so in certain cases the 
donors were divided into larger age groups: 0-3 years (n = 47), 4-6 years (n = 46), 7-9 
years (n = 49), 10-14 years (n = 33), >15 years (n = 42). The rationale behind these 
subdivisions was that most episodes of clinical malaria in Northern Kilifi occur in the first 
3 years of life (0-3 years), the clinical infection rate falls to almost zero by 6 years of age 
(4-6 years) (Gupta et a l, 1999). The next group was again 3 years (7-9 years), the next 
pre-adulthood (10-14 years), and the final group was the adults (>15 years). All these 
groups contained approximately the same number of donors, and from an immunological 
point of view might be expected to behave differently. For some of the protection analyses 
the donors were divided into 3 groups only: 0-6 years, 7-15 years, >15 years ie peak 
malaria, pre-adulthood, and adults.
The number of responders in the different age groups were compared using standard chi 
squared analysis. Comparisons of the magnitude of the T cell responses (specific cells / 106 
PBMC) by age were performed using student’s t-tests assuming unequal variances with 
age as a continuous variable, and student’s t-tests were used to compare between particular 
age groups.
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6.2.S.2
Analysis for Protection
Statistical analysis for protection was performed by Amanda Ross, the statistician in 
Kilifi, since the data is stored on a data base in Kilifi and is confidential at present. 
Analysis was performed using the STATA version 6 (STATA Corporation, TX, USA) 
computer programme. The endpoints for the analysis were chosen before the analysis 
began. Analysis beyond 6 months was deemed unlikely to correlate with protection since 
the ELISPOT is most likely a function of recent memory, rather than long term memory 
(see Chapter 3). Indeed, there is evidence that malaria specific ex-vivo ELISPOT responses 
wane after 1 month (Lalvani et a l, 1999).
Many episodes of parasitaemia in this population were likely to be asymptomatic, and a 
minimum parasitaemia cut off is regarded as more likely to detect only clinically relevant 
cases. There is much debate surrounding this ideal cut off, and the value is likely to be 
specific to the malaria endemic area in question. Parasitaemias of between 400 and 20,000 
parasites/pl have been proposed in previous studies (Beadle et a l, 1995, Famert et a l, 
1999), and >10,000 parasites/pl was selected for this study as likely to detect clinically 
relevant episodes. The analysis for protection was therefore carried out for the following 3 
parameters:
Number of donors with parasitaemia over 2 months (any parasitaemia and >104/pl)
Number of donors with parasitaemia over 6 months (any parasitaemia and >104/pl)
A delay in time to first parasitaemia (any parasitaemia and >104/pl)
Fisher’s exact tests were used to compare the proportions of donors with at least one 
episode of parasitaemia who had specific TRAP epitope T cell responses with those who 
did not have the response (Results 6.3.4 and 6.3.5). The mean total SFU values were 
compared for those who subsequently did and did not have an episode using two sample t- 
tests (see Results 6.3.6).
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Kaplan-Meier estimates of the proportion of donors remaining episode free were plotted 
against time following the cross-sectional analysis of TRAP ELISPOT responses. Log-rank 
tests were used to compare survival experience for those donors with particular TRAP T 
cell epitope responses to those without (Results 6.3.4 and 6.3.5). Maentel-Haenzel tests 
for homogeneity were used to assess whether there was evidence of a significantly different 
effect of having a TRAP response in different age groups (Results 6.3.5).
The relationship between total SFU and time to first parasitaemia appeared to be non 
linear, thus total values were divided into 4 categories (< 0, 0-49, 50-99, > 100) to look for 
Kaplan-Meier survival, rather than assessed as a continuous variable (Results 6.3.6). Cox’s 
proportional hazards were used for analysis of total SFU and time to first episode of 
parasitaemia. The estimated effect of each total SFU category was presented as an 
estimated hazard ratio for an individual in each category compared to the baseline group 
(those with total SFU <0). It was assumed for this analysis that the effect of total SFU 
remained constant with time. A hazard ratio <1 meant that the hazard was less than the 
baseline category, and >1 meant greater than the baseline group. Differences in time to first 
episode between the categories were investigated using a likelihood ratio test, both 
univariately and after adjusting for age.
6.3
RESULTS
6.3.1
Constant Response Rate to TRAP T Cell Epitopes Maintained from 1 Year to 
Adulthood Despite Continuous Malaria Exposure
The 217 donors were tested in an overnight IFN-y ELISPOT assay for reactivity to the 10 
peptide conditions described above (Table 6.2), except for 68 donors in whom tp30-31 
was not tested. A positive IFN-y ELISPOT T cell response was assigned using the 
statistical table (described in Methods) which gives a >95% confidence that the response is 
a true positive (p < 0.05) compared to the background response. A total of 41.9% (91/217) 
of the donors gave a positive response to one or more of the 10 conditions, and
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surprisingly only 44.2% (96/217) of the donors gave a positive PPD response (Table 6.3). 
The results for each of the 217 donors are tabulated in an appendix at the end of this 
chapter.
A year by year comparison of the number of donors responding to one or more peptides 
showed that the response rate was more or less constant throughout all age groups (Figures 
6.2A and B). There was a notable dip in the 5 year olds in whom only 16.7% (2/12) 
responded, followed by the peak response rate of 70% (7/10) in the 6 year olds. 
Comparing these 2 groups suggested that the difference in proportion of responders was 
statistically significant (%2 = 6.42, p = 0.03), however this is a subgroup analysis 
comparing the 2 extremes over each year group, and hence is more likely to be a chance 
finding. Twenty nine (2/7) of the less than one year olds gave a positive peptide T cell 
response, which was lower than the average response rate of 42.4% (89/210) seen for the 
remaining donors, although this difference was not significant (%2 = 0.53, p = 0.7). This 
was not surprising given that only 7 donors were in the <1 year age group. It was 
interesting that by one year of age the frequency of TRAP specific T cell responses was 
38.5% (5/13), a level which was then maintained more or less constant throughout all age 
groups (Figure 6.2B). Thus, despite continuous and repeated exposure to malaria 
throughout life, the frequency of donors responding did not appear to increase with 
exposure throughout life. This is consistent with the theory (suggested in Chapter 3) that 
ex-vivo ELISPOT responses detect effector memory T cells (TEM), which are indicative of 
recent exposure. Thus, all donors from the same region would have the same parasite 
exposure, and might be expected to have comparable response rates regardless of age.
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F igure 6.2
A.
Number of Responders No. Tested
25 No. Positive
Age in Years
% Donors Responding to a tp Peptide
100
2 80 - o
o 60 
Q
‘B 40
Age in Years 14 20 40 81
^  ^ COW™  0 / 'fe -  -
response rate was more or less constant throughout all age groups (Figure 6.2A and B), and the dip in 5 
year olds and peak in 6 year olds probably arose by chance.
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6.3.2
T Cell Precursor Frequency Levels to TRAP Epitopes in Children and Adults
The ELISPOT assay is quantitative, and gives a value for the number of cells present in the 
well capable of producing cytokine (as spot forming units or SFU / well) in response to the 
peptide(s) added to the well. A precursor frequency of specific cells per 106 PBMC can 
thus be calculated for each donor to each condition tested. The precursor frequency levels 
for all positive responses in this cross-sectional study averaged 26.6 ±1.4 SE / 106 PBMC 
(range 13 to 143 SFU / 106 PBMC). This value was comparable to those found in the 
Gambian (28.2 ±1.2 SE / 106 PBMC) and Kenyan (33.6 ±2.1 SE / 106 PBMC) studies 
detailed in chapter 5. There was no significant difference in precursor frequency levels for 
any of the age groups (p = 0.53), and even the <1 year olds averaged 30 ±10 SE SFU / 106 
PBMC for all positive TRAP T cell responses observed (Figures 6.3 A-C). There was no 
significant difference in PPD precursor frequency level by age as a continuous variable (p = 
0.3), although the <1 year olds all failed to respond to PPD (Figures 6.4 A-C), despite the 
fact that approximately half should have received BCG vaccination at birth (T. Mwangi, 
personal communication).
Selecting only positive responses introduces a bias in the comparison between groups since 
only those responses above a certain cut off are recorded positive (those with a >95% 
probability of being a true positive, see Methods). If all the SFU’s / 106 PBMC are 
averaged for all wells, differences in precursor frequency were apparent between the age 
groups (Figures 6.3 D-E). The average across all age groups was 4.7 ±0.5 SE / 106 PBMC, 
and there was no significant difference by age taken as a continuous variable (p = 0.3). 
However, the <1 year olds had a lower value than the other age groups (Figure 6.3D), and a 
comparison with all other donors showed that responses were significantly lower (p = 
0.01). A lower level in the <1 year olds would make sense immunologically since immunity 
is developing for the first time in this age group.
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Figure 6.3
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across all wells whether positive or negative (D-E).
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Figure 6.4
A.
Mean PPD Positive Responses
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Precursor frequency fo r  positive PPD IFN-y responses only (A-C), and responses across all wells whether 
positive or negative (D-E).
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The average SFU to TRAP peptides declined from 6 years of age, to reach a nadir in the 9 
year olds (Figure 6.3D). Comparing the 9 year olds to all other donors suggested a 
significantly lower response rate in these donors (p = 0.04), but the significance was 
unlikely to be real since this was a non hypothesis driven subgroup analysis, and was 
probably a chance effect due to the small numbers in each group. Indeed, a broader 
subgroup analysis across the 5 age categories in Figure 6.3E showed no significant 
difference between age groups (p = 0.11), even though the 7-9 year olds still had lower 
levels. By 10 years of age the values had returned to the average level, and were then 
maintained constant throughout the adult groups (Figure 6.3D). Thus the lower precursor 
frequency levels observed in children compared to adults (Figure 6.3F) was accounted for 
by certain age subgroups, and probably the only significant difference was the lower levels 
in <1 year olds. The average PPD values for all wells were not significantly different when 
compared across age groups (p = 0.77), although the < 1 year olds again gave a lower value 
than observed for all other age groups (Figure 6.4D), although this was not significant.
6.3.3
Differences Between Adults and Children in Repertoire of T Cell Responses to 
TRAP
The nature of development of pre-erythrocytic immunity to malaria in naturally exposed 
individuals is far from understood. There is no data on pre-erythrocytic T cell responses in 
children assessed by ELISPOT, or indeed T cell reactivity to TRAP in childhood. I was 
therefore interested to see at what age the first IFN-y ELISPOT T cell responses to TRAP 
would first be detected. I also wanted to assess whether naturally exposed donors would 
give a different repertoire of T cell responses with increasing age, or if the repertoire would 
remain constant in all age groups.
The earliest age at which a T cell response was seen in this study was 2 months old (donor 
N2 to tp4-6) (Chapter 6 Appendix), indicating that by 2 months a child’s immune system 
is capable of developing a potentially protective T cell response to the pre-erythrocytic 
antigen P/TRAP. I assessed for differences in repertoire of responses for the different age
175
groups. In a comparison of number of responders to each of the 10 TRAP conditions, tp4- 
6 was the most frequently positive in most age groups (Table 6.3). This was hardly 
surprising given that this condition consisted of a pool of 3 separate TRAP 20mers, 
whereas most of the other conditions contained one 20mer only. Thus, in the comparison 
of responses, for those conditions that consisted of >1 epitope in a well (tp4-6, tp30-l, 
tp37-8) the number of responders was divided by the number of epitopes added to the 
well to make the comparison with the other wells valid. Thus, tp4-6 responders were 
divided by 3, since there were 3 pooled tp epitopes added to the well.
A year by year comparison to age 10 suggested that the immunodominant T cell responses 
in childhood were similar between groups (Table 6.4A). Thus, tp23 and tp51 were most 
commonly positive. The predominant adult response was to tp4-6, although tp51 was 2nd 
and tp23 3rd (in addition to a number of other epitopes) (Table 6.4A). Separating the 
donors into larger age groups gave a similar picture to that described above, with tp23 and 
tp51 playing a prominent role as immunodominant responses, and tp4-6 emerging as 
dominant in adulthood (>15 year olds) (Table 6.4B). The peptide pool tp30-l was 
generally the least commonly recognised in most groups (Table 6.4B).
In the overall analysis for all age groups tp23 was the most frequently recognised and tp 5 1 
was second. This focus of responses on tp23 and tp51 was particularly interesting since 
both are conserved in Africa, and the former is highly conserved worldwide. They might 
thus be particularly useful vaccine components, since they would elicit cross-strain 
immunity. Some functional predictions have been made for these epitopes (Table 6.1), 
although the precise structure of TRAP remains unknown. The adult bias towards tp4-6 is 
also of particular interest since 2 of the constituent peptides, tp5 and tp6, contain the 
conserved CTL epitope tr29. In depletion studies it was found that tp4-6 can elicit both 
CD4 and CDS IFN-y ELISPOT responses, even in the same donor (Chapter 5, Figure 
5.5D). It has long been thought that CD8+ cytotoxic T cells play a vital role in protective 
immunity at the pre-erythrocytic stage of infection (reviewed in Chapter 1).
176
Table 6.4
A. Commonest Epitopes by Age
PCE EPITOPE NO. TESTED FREQUENCY
< i y t p 5 1 7 1
i y t p 5 1 1 3 2
2y tp23, 30-1, 43, 51 9 1
3y tp23 1 8 3
4y tp23 24 3
5y tp14, 40, 47 1 2 1
6y tp14, 23, 47, 51 1 0 2
7y tp43 1 9 2
8y tp23 1 2 2
9y tp2, 43, 51 1 8 1
1 Oy tp43 1 5 2
1 1 -1 4y tp2, 23, 40 1 8 2
15 -20y tp51 1 4 2
21 -40y tp43 1 3 2
41-81 y tp4 -6 1 5 1.7
B. Epitope Recognition Pattern by Age Group
A3E 1ST 2ND LEAST
0 -3 y tp23, 51 tp2, 4-6, 43, 47 tp14, 40
4 -6 y tp14, 23 tp51 t p 3 0 - 1
7 - 9 y tp2, 23, 43 tp 5 1 tp30-1, 37-8
1 0 -1 4y tp2, 40, 43 tp23, 47 t p 3 0 - 1
>15y tp 4 -6 tp51 tp40, 47
All tp23 tp51 t p 3 0 - 1
Pilot tp51 tp 4 -6 tp43
Repertoire o f  T  cell responses to TRAP peptides varies between adults and children. NB Where there is 
more then one peptide p er condition (tp4-6, tp30-31, tp37-38) the number o f  responders is divided by the 
number o f  peptides.
I l l
This focusing o f the adult TRAP responses on a CTL containing T cell epitope region 
might be o f significance since it is the adults that are semi-immune to malaria. It is possible 
that a bias towards CDS T cell epitope regions might be a more generalised phenomenon, 
and this would need to be confirmed in a much larger study.
6.3.4
No Individual T Cell Epitope Response to TRAP Correlated With Protection
The analysis for protection was carried out to 27 weeks (just over 6 months) after the 
cross sectional bleed. Donors seen less than 20 times out o f a possible 27 home visits (n = 
13) were considered inadequately followed up, and were excluded from the study (Table 
6.5A). Thus, 204 (94%) o f the 217 donors recruited to the study were analysed for 
correlates o f protection (Table 6.5B). The first question was whether IFN-y ELISPOT 
responses to any o f the 10 individual TRAP conditions tested (Table 6.5C) correlated with 
protection against the subsequent development o f  parasitaemia. I f  an individual epitope 
was found to be protective, this would be an ideal vaccine candidate. Analysis was 
performed for whether having a positive T cell epitope response by IFN-y ELISPOT to 
each o f  the 10 conditions significantly decreased the likelihood o f  having an episode o f 
parasitaemia over 2 months (10 weeks) and 6 months (27 weeks) o f follow up (Table 
6.6A), but no evidence for a protective effect was found (2 months p = 0.06-0.99, 6 
months p = 0.14-0.99) (see Statistical M ethods, 6.2.5).
M any episodes o f  parasitaemia in this population were likely to have been asymptomatic, 
and thus analysis for donors who had parasitaemias >104/p l over 2 and 6 months was also 
performed (Statistical M ethods 6.2.5). Again, there was no evidence o f a significantly 
reduced number o f episodes over 2 or 6 months in those individuals that had any o f the 
individual tp responses (2 months p = 0.16-0.99, 6 months p = 0.14-0.99) (Table 6.6B). 
Kaplan-M eier analysis to 8 months was used to assess the effect o f having a TRAP 
response on time to first parasitaemia (any parasitaemia and >104/pl) following the cross- 
sectional ELISPOT measurements. During that time 51% (104/204) o f donors had >1 
episode o f parasitaemia, and 28% (58/204) had >1 episode o f parasitaemia >104/pl.
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T able 6.5
A. Frequency of Field Visits
No. Visits Frequency Percent
4 - 1 0 7 3.2
1 1 -19 6 2.8
20 2 0.9
21 3 1.4
22 8 3.7
23 9 4.2
24 8 3.7
25 28 12.9
26 53 24.4
27 93 42.8
Total 217 1 00
B. Ages of Donors Analysed for Protection
Age Category Starting No. Excluded Remaining Percent
0-3 years 47 2 45 21.2
4-6 years 46 5 41 20.7
7-9 years 49 2 47 25.1
10-14 years 33 1 32 13.8
>15 years 42 3 39 19.2
Total 217 1 3 204 1 00
C. Frequency of tp Responses
217 Donors 204 Donors
Freq Percent Freq Percent
tp2 1 2 5.5 1 1 5.4
tp4 -6 34 15.7 33 16.2
tp1 4 9 4.2 8 3.9
tp23 1 6 7.4 1 6 7.8
t p 3 0 - 3 1 1 1 7.4 1 0 7.3
tp37 -38 1 4 6.5 1 2 5.9
tp40 7 3.2 6 2.9
tp43 1 2 5.5 1 2 5.9
tp47 8 3.7 8 3.9
tp 5 1 1 5 6.9 1 3 6.4
The 204 Ngerenya donors that were seen more than 20 times out o f  a possible 27 home visits (A) were 
considered adequately fo llow ed up, and were analysed fo r  correlates ofprotection.
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T able 6.6
A. Any Parasitaemia and Individual tp Responses
TRAP
CONDITION
2 MONTHS 
p-value
6 MONTHS 
p-value
tp2 0.99 0.55
tp4 -6 0.49 0.99
tp 1 4 0.06 0.14
tp23 0.75 0.43
t p 3 0 - 3 1 0.18 0.51
tp37 -38 0.72 0.77
tp40 0.14 0.99
tp43 0.14 0.38
tp47 0.68 0.14
tp51 0.48 0.99
B. Parasitaemia >104/yvl and Individual
TRAP 2 MONTHS 6 MONTHS
CONDITION p-value p-value
tp2 0.6 0.55
tp4 -6 0.32 0.99
tp l  4 0.16 0.14
tp23 0.99 0.43
t p 3 0 - 3 1 0.5 0.51
tp37-38 0.31 0.77
tp40 0.45 0.99
tp43 0.31 0.38
tp47 0.16 0.14
tp 5 1 0.35 0.99
Ngerenya donors were analysed over 2 and 6 months fo r  whether any o f  the 10 individual TRAP tp
abfecW Æl/SP0 7  corre/aW  m/A pro/ecnbM. were /awW 6y
F isher’s Exact Test.
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Statistical analysis gave significant p-values for the tp l4  and tp47 responses (p = 0.05 and 
0.01 respectively), which suggested that having either o f these responses significantly 
decreased the time to first parasitaemia (Table 6.7). Thus, rather than seeing a protective 
effect, the only statistically significant values suggested a more rapid progression to first 
parasitaem ia for those who had that response. These results should however be interpreted 
with caution, since all tests were univariate, and no adjustments were made for the effect o f 
other tp responses. In addition, this analysis involved multiple significance testing, and 
thus the chance o f a false positive result is much greater than 5%. The effect for tp l4  and 
tp47 was lost in the analysis for parasitaemia > 104/ j l i1 only (Table 6.7).
There was therefore no evidence that individual TRAP specific T cell responses provided a 
protective effect against the likelihood o f having an episode over 2 months or 6 months, or 
in delaying the onset o f the first episode o f parasitaemia. One factor complicating this 
analysis was that there was no run in period to this study where parasitaemias were 
monitored, nor were donors treated and cleared o f parasites before the study period. In 
retrospect this may well have been the thing to do. Therefore I do not know when each 
donor had their last episode o f parasitaemia or clinical malaria prior to commencing the 
study. I do know that 48% (104/217) o f donors were parasitaemic at the time o f testing, 
comprised o f 39.3% (35/89) tp responders and 63.9% (69/108) non responders. Thus, 
those with a positive ELISPOT response to TRAP in this study were significantly less 
likely to be parasitaemic at the time o f testing than those with no response (%2 = 11.81, p 
= 0.006), and conversely those with parasitaemia were less likely to have positive 
ELISPOT responses.
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Table 6.7
Time to First Parasitaemia and Individual tp Responses
TRAP
CONDITION NO.
ANY PARASITAEMIA 
NO. WITH EPISODE p-value
PARASITAEMIA >104///1 
NO. WITH EPISODE p-value
tp2 Neg 1 93 98 0.72 57 0.17
Pos 1 1 6 1
tp 4 -6 Neg 171 86 0.81 49 0.81
Pos 33 1 8 9
tp1 4 Neg 1 96 98 0 . 0 5 * 56 0.99
Pos 8 6 2
tp23 Neg 1 88 94 0.29 51 0.16
Pos 1 6 1 0 7
t p 3 0 - 1 Neg 1 28 58 0.62 28 0.53
Pos 1 0 5 3
tp37 -8 Neg 1 92 98 0.87 54 0.57
Pos 1 2 6 4
tp40 Neg 1 98 101 0.67 57 0.60
Pos 6 3 1
tp43 Neg 1 92 96 0.19 53 0.25
Pos 1 2 8 5
tp47 Neg 1 96 97 0 . 0 1  * 55 0.39
Pos 8 7 3
tp 5 1 Neg 191 98 0.99 53 0.35
Pos 1 3 6 5
Analysis fo r  time to f ir s t parasitaemia fo r  donors responding to the 10 individual TRAP tp conditions 
detected by IFN-y ELISPOT fa iled  to show any significant protective effect fo r  having a tp response. The 
significant values fo r  tp l4  and tp47 indicated that they cause a more rapid progression to parasitaemia. 
This effect was lost fo r  the analysis fo r  parasitaemia >104/pl. Log-rank survival test values given.
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6.3.5 Those Donors With a TRAP Response, Compared to Those Without, Were No 
More Likely to be Protected
Since no individual tp epitope response correlated with protection, the next analysis 
addressed whether simply having an IFN-y ELISPOT T cell response to any o f the 10 
TRAP conditions correlated with protection when compared to those donors who had no 
response. This analysis was performed for those donors who were tested by all 10 TRAP 
conditions only (n = 138), since 66 donors were not tested for the tp30-31 TRAP peptide 
pool. No significant protective effect was provided by having a TRAP specific T cell 
response, compared to not having one, in decreasing the chance o f  having an episode o f 
parasitaemia (any or >104/pl) over 2 or 6 months (p-values 0.06-0.99) (Tables 6.8 A-D). 
M aentel-Haenzel tests for homogeneity suggested that there was no evidence o f a different 
effect in the different age categories (p-values 0.13-0.99). Kaplan-M eier analysis suggested 
that having any TRAP tp response did not slow time to first parasitaem ia (any or >104/pl) 
(Figures 6.5A and B). The log-rank test comparing time to first episode for those with a tp  
response compared to those with no response, further confirmed that there was no 
evidence that the presence o f a response to >1 o f the 10 TRAP conditions correlated with 
protection (any parasitaemia: p = 0.77 unadjusted / p = 0.28 stratified by age; parasitaemia 
>104/pl: p = 0.89 unstratified / p = 0.70 stratified).
6.3.6 Summed Response to the 10 TRAP Conditions (Total SFU) for Each Donor 
Failed to Correlate with Protection
Since no individual TRAP responses correlated with protection, I wondered whether the 
summed TRAP response to all 10 ELISPOT wells for each donor (total SFU value) would 
correlate with protection, since this gives a value for the total response to epitopes 
spanning approximately half o f the TRAP antigen. Thus, for each donor, the number o f 
spots for each well were added together, after subtracting the background negative well 
value for each peptide response. This gave a total precursor frequency for each donor for 
all 10 TRAP conditions tested. The high background responses for certain donors resulted 
in an overall negative total SFU value where the background response was greater than the 
TRAP specific responses.
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T able 6.8
A. tp Response vs No tp Response: 2 Months Any Parasitaemia
WITH tp RESPONSE 
n FREQ PARA 2m %
WITHOUT tp RESPONSE 
n FREQ PARA 2m % p-value
0-6 y 
7-14 y 
>15 y 
All
2 2 9 41 % 
1 8 4 22% 
1 7 0 0% 
5 7 13 23%
30 7 23% 
3 5 1 3 %
1 6 0 0% 
81 8 10% 0 . 0 5 *
Maentel-Haenzel test for homogeneity of tp response effect: p = 0.13
B. tp Response vs No tp Response: 2 Months Parasitemia >104/ // I
WITH tp RESPONSE 
n FREQ PARA 2m %
WITHOUT tp RESPONSE 
n FREQ PARA 2m % p-value
0-6 y 
7-14 y 
>15 y 
All
n >104 2m %
2 2 3 14% 
18 2 11% 
1 7 0 0% 
5 7 5 9 %
n >104 2m %
3 0 3 10% 
3 5 1 3%
1 6 0 0% 
8 1 4 5%
p-value
0.49
M-H test for homogeneity: p = 0.46
C. tp Response vs No tp Response: 6 Months Any Parasitaemia
WITH tp RESPONSE 
n FREQ PARA 6m %
WITHOUT tp RESPONSE 
n FREQ PARA 6m % p-value
0-6 y 22 1 7 77% 30 1 3 43%
7-14 y 1 8 6 33% 35 1 6 46%
>15 y 1 7 0 0% 1 6 1 6%
All 57 23 40% 81 30 37% 0.73
M-H test for homogeneity: p = 0.99
D. tp Response vs No tp Response: 6 Months Parasitaemia >104/ / / l
WITH tp RESPONSE WITHOUT tp RESPONSE
n FREQ PARA6m % n FREQ PARA6m % p-value
0-6 y 22 9 41% 30 9 30%
7-14 y 1 8 5 28% 35 6 17%
>15 y 1 7 0 0% 1 6 0 0%
All 57 1 4 25% 81 1 5 19% 0.40
M-H test for homogeneity: p = 0.42
Analysis o f  those who had a TRAP tp response by IFN-y ELISPOT compared to those who had none fa iled  
to show a significant protective effect.
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Figure 6.5
A. TRAP tp Peptide Response Vs No tp Response Any Parasitaemia
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B. TRAP tp Peptide Response Vs No tp Response Parasitaemia >104///l
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Kaplan-Meier plots fo r  those donors who did or did not have a tp TRAP peptide response.
The total SFU values ranged from -165 to 255, and were normally distributed (mean 45 +/- 
5 SE / 106 PBM C) (Figure 6.6A). A plot o f total SFU by age did not show any obvious 
association except that very low values rarely occurred after 20 years o f  age (Figure 6.6B).
Figure 6.6 
A. Total SFU distribution for 217 donors
40 -
20  -
-2ÔÔ
Total SFU
B. Total SFU by Age
Age in Years
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Analysis o f whether greater total SFU values, and thus more T cells capable o f responding 
to the 10 TRAP conditions, protected against the development o f parasitaemia over 2 and 
6 months was performed (Tables 6.9A and C). There was no significant difference in the 
total SFU values for those donors who developed parasitaemia, and those who did not (2 
months p = 0.11; 6 months p = 0.57). Analysis for total SFU and the development o f 
parasitaemia >104/pl over 2 and 6 months also failed to show a significant protective effect 
(2 months p = 0.78; 6 months p = 0.69) (Tables 6.9B and D). Thus, there was no evidence 
to suggest that higher total SFU values were associated with a decrease in the number o f 
donors with an episode o f parasitaemia over 2 or 6 months, and adjusting for age had no 
effect on this result (not shown).
The relationship between the total SFU value and the time to first episode appeared to be 
non-linear, and thus the total SFU values were divided into 4 groups for analysis: <0, 0-49, 
50-99, >100. Kaplan-M eier analysis for each o f these 4 categories for time to 1st 
parasitaemia, and parasitaemia >104/pl (Figures 6.7A and B). Cox’s proportional hazards 
were used to analyse for time to first episode. The estimated effect o f each total SFU 
category was given as a hazard ratio (see Statistical M ethods 6.2.5). No significant effect 
was found for any o f the total SFU categories and protection against the subsequent 
development o f parasitaemia (any parasitaemia p = 0.32; parasitaemia >104/pl p = 0.26) 
(not shown). The estimates o f the hazards ratios were adjusted for age category to look for 
an effect o f age, but none was found (any parasitaemia p = 0.46; parasitaemia >104/jil p = 
0.68) (not shown).
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T able 6.9
A. Total SFU and Any Episode in 2 Months
ANY EPISODE IN 2 MONTHS NO EPISODE IN 2 MONTHS
n MEAN TOT SFU SE n MEAN TOT SFU SE p-value
0-6 y 33 52.4 15.5 53 46 9.7
7-14 y 1 0 87.5 9.4 69 29.6 6.8
>15 y 0 NA NA 39 57.8 10.0
All 43 60.5 12.3 161 41.8 5.0 0.11
B. Total SFU and Parsitaemia >104///l in 2 Months
ANY EPISODE IN 2 MONTHS NO EPISODE IN 2 MONTHS
n MEAN TOT SFU SE n MEAN TOT SFU SE p-value
0-6 y 1 4 41.0 27.2 72 49.9 8.6
7-14 y 5 74.8 17.1 74 34.4 6.6
>15 y 0 NA NA 39 57.8 10.0
All 1 9 49.9 20.6 1 85 45.3 4.8 0.78
C. Total SFU and Any Episode in 6 Months
ANY EPISODE IN 6 MONTHS NO EPISODE IN 6 MONTHS
n MEAN TOT SFU SE n MEAN TOT SFU SE p-value
0-6 y 53 55.0 11.7 33 37.9 11.0
7-14 y 38 43.7 9.9 41 30.7 8.3
>15 y 1 -88 .0 ND 38 61.6 9.5
All 92 48.7 8.0 1 12 43.3 5.6 0.57
D. Total SFU and Parasitaemia >10%/l in 6 Months
ANY EPISODE IN 6 MONTHS NO EPISODE IN 6 MONTHS
n MEAN TOT SFU SE n MEAN TOT SFU SE p-value
0-6 y 36 50.3 13.7 50 47.1 10.6
7-14 y 1 5 48.9 19.1 64 34.8 6.6
>15 y 0 NA NA 39 57.8 10.0
All 51 49.0 11.1 153 44.7 5.1 0.69
Analysis fo r  whether the magnitude o f  the total SFU  value to all 10 TRAP tp conditions measured by IFN- 
y ELISPOT showed no protective effect over the ensuing 2 and 6 months o f  follow up.
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\Figure 6.7
A. Total SFU Any Parasitaemia
1.00  -
0.75 -
100+
0.50 -
0.25 -
0.00  -
time in months
B . Total SFU Parasitaemia >104///l
1.00  -
0.75 -
0.50 -
100+
0.25 -
50-99
0.00  -
time in months
Kaplan-Meier plots fo r  those donors who did or did not have a tp TRAP peptide response.
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6.3.7
E L ISPO T  R esponses O ver 1 Year
I suggested in chapter 3 that ex-vivo ELISPOT responses reflect recent memory, or 
effector T cell (TEM), responses. It is not known how long such memory responses persist 
in individuals, and no study has assessed for the change in malaria specific ELISPOT 
responses in naturally exposed donors over time. Thus, 69 o f the 217 donors tested by 
IFN-y ELISPOT assay in August / September 1988, were re-tested to exactly the same 
conditions in September 1999. Surprisingly, the response pattern had entirely changed over 
the one year period, and only 4 o f the 75 positive T cell responses to TRAP detected by 
ELISPOT in 1998 were still present in 1999 (donors N23, N62 & N142) (Table 6.10). 
Even those responses that were very high in 1998 (marked with an asterisk) were no longer 
present on re-testing in 1999, and conversely the high values in 1999 were not present on 
testing in 1998. In the 1998 analysis, tp23 was the most frequently recognised epitope, 
being positive 20.6% (14/68) donors, and tp51 was second in 14.7% (10/68) o f donors. In 
1999 the response rates to tp23 and tp51 were 5.9% (4/68) and 1.5% (1/66 tested) 
respectively. The most frequently positive response in 1999 was to tp2 (9/68, 13.2% of 
donors), all but one o f which occurred in children (<15 years o f  age). Thus, once again the 
most frequently recognised epitope was conserved. Since tp2, tp23 and tp51 are all 
conserved epitopes then the fact that the repertoire has changed over the year cannot be a 
result o f  exposure to different parasite strains, since all strains will carry the same 
conserved regions. The change must be a result o f other factors. The number o f adult 
donors that responded in this study was too small (4/68) to draw any conclusions 
regarding T cell repertoire differences in adults.
IFN-y ELISPOT responses to /ÿTR A P T cell epitopes were therefore not retained over a 
one year period. I do not know how long such T cell responses persist in malaria exposed 
individuals, and this will require a longitudinal follow up study with repeated testing. The 
short lived nature o f  these responses may be the reason that no correlates o f protection 
were found in this study.
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cFigure 6.8
1998 1999
D ono r A g e
N g2 2 m
N g4 5 m
N g7 7 m
N g 1 4 1 V
N g 1 6 1 y
N g 2 6 2 y
N g 2 7 2 y
N g 2 8 2 y
N g 2 9 2 y
N g 3 8 3 y
N g 3 9 3 y
N g 4 0 3  y
N g 4 2 3 y
N q 4 4 3 y
N g 5 9 4  y
N g 6 0 4  y
N g 6 2 4  y
N g 6 3 4  y
N g 6 4 4  y
N g 6 5 4  y
N q 6 6 4 y
N g 7 8 5 y
N g 8 5 6 y
N g 9 2 6 y
N g 9 3 6  y
N g 9 9 7 y
N g l  0 7 7  y
N g 1 0 8 7 y
N g l  10 7 y
N g l  12 7 y
N g 1 2 0 8 y
N g 1 2 1 8 y
N g 1 2 2 8 y
N g 1 2 3 8 y
N g 1 2 8 9 y
N g 1 3 7 9  y
N g 1 3 8 9  y
N g l  3 9 9 y
N g 1 4 2 9 y
N g 1 5 3 1 0 y
N g 1 5 4 l O y
N g l  5 5 l O y
N g 1 6 0 11 y
N g 1 6 1 11 y
N g 1 6 7 1 2 y
N g 1 8 7 1 9 y
N g 1 8 8 1 9 y
N g 1 8 9 2 0 y
N g 1 9 3 2 4 y
N g 2 0 1 3 7 y
N g 2 0 8 5 3 y
N g 2 1 2 6 2 y
N g 2 1 3 6 2 y
N g 2 1 7 8 1  y
2 4 - 6  1 4  2 3  3 0 - 1  3 7 4 7  5 1
a
2 4 - 6  1 4  2 3  3 0 - 1  3 7 - 8  4 0  4 3  4 7  5 1
* '
m
"Fô" ND ND
*
m * "
m
M . W A
m
Y //,
* * *
m l\D W ND ND"
Repeat IFN-y ELISPOT testing after 1 year led to a complete change in the pattern o f  responses fo r  each 
donor. * indicates very high ELISPOT responses (p<0.01).
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It is possible that any protective effect afforded by T cell responses detectable by ex-vivo 
ELISPOT is very short lived ie up to a month, although a delay in time to first 
parasitaemia might have been expected in this study in the younger age groups if  that were 
the case.
The response rate in 1999 o f 36.8% (25/69) was much lower than the response rate o f 
70.6% (48/68) in the same donors the previous year. The probable explanation for this is 
selection bias, since predominantly TRAP responders were selected from the 1998 cohort 
in order to address the question o f whether responses were maintained. The overall 
response rate in the 1998 study o f 41.9% (91/217) was comparable to the rate o f 36.8% 
obtained in 1999. The positive PPD response rate o f 46.4% (32/69) in 1999 was 
comparable to the 40.6% (28/69) who were positive in 1998, with 4 new cases arising in 
the 0-1 year old donors (age in 1998). The PPD batches used were different for the 2 
studies, and the unexpectedly low reactivity rate o f 50% was even observed for the adults 
tested. Thus, a PHA response was tested in 1999 as a second positive control and 100% o f 
donors gave a positive response, confirming that the assay was working for all donors. The 
magnitude o f positive responses (precursor frequency level) seen on re-testing in 1999 
could not be compared to 1998 because o f the significantly higher background levels in 
1999
The 69 donors that were re-tested in 1999 were followed up weekly throughout the year 
preceding the analysis. The number o f malaria episodes seen in the preceding 12 months 
for the whole group was 2.3 0.2 SE for all parasitaemias, and 1.4 0.2 SE for parasitaemia 
>104/pl. As expected the majority o f cases occurred in the younger age groups (0-6 years). 
Since it is believed that ex-vivo ELISPOT responses detect recent memory, I looked for a 
statistical association between the presence o f  a positive ELISPOT response in 1999 and 
episodes o f parasitaemia (any and >104/pl) in the preceding 1 to 5 months. There was no 
evidence to suggest that those donors who had a positive TRAP IFN-_ ELISPOT response 
in 1999 were more likely to have had an episode o f  parasitaemia (any or >104/pl) in the 
previous months than those who did not (_2 analysis 0.04-1.86; p-value range 0.17-0.85).
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Thus, the presence o f a TRAP IFN-_ ELISPOT response to >1 o f  the 10 conditions was 
not significantly associated with parasitaemia in the 5 months prior to ELISPOT testing.
6.4
DISCUSSION
The development o f pre-erythrocytic immunity in naturally exposed donors is far from 
understood. No study has comprehensively compared immune responses in adults and 
children for TRAP, or indeed any other pre-erythrocytic antigen. Thus, IFN-y ELISPOT 
responses were assessed to 14 TRAP epitopes spanning half the molecule for 217 Kenyan 
donors aged between 2 months to 81 years. All donors were from a single study area called 
Ngerenya in Northern Kilifi, and thus had similar HLA types, comparable rates o f parasite 
exposure, and bed net usage.
Forty two percent o f donors overall responded to one or more o f the 10 TRAP T cell 
conditions tested in the study. A response rate o f  28.6% was observed for the <1 year 
olds, and the reactivity rate o f  38.5% in the one year olds was similar to the reactivity 
levels observed in adults. Thus the overall response rate o f  approximately 40% was 
established by one year o f age, and was comparable to the reactivity in adults despite the 
fact that the latter had experienced continuous and repeated lifelong exposure to malaria. 
The precursor frequency level for positive T cell ELISPOT responses to TRAP epitopes 
was also constant, even in the <1 year olds. This may not be a valid comparison since only 
those wells reaching a certain threshold were considered positive. Indeed, when the 
responses for all wells were averaged, the lower level observed in the <1 year olds was 
significantly different to the rest o f the donors. A decline in levels was also observed from 
7 to 9 years, but was not statistically significant. It is easy to understand why the <1 year 
olds would have lower T cell precursor frequencies, since immunity is ju st beginning to 
develop in them as a result o f exposure in the first year o f  life. It is useful to know that 
children as young as one year develop T cell responses to TRAP that might be susceptible 
to boosting by vaccination.
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The T cell repertoire differences between adults and children were interesting, since the 
predominant childhood responses focused on two conserved CD4 T cell epitopes (tp23 
and tp51) in 1998, and on another highly conserved epitope (tp2) upon re-testing in 1999. 
The immunodominant epitope in the adults was tp4-6, even after allowing for the fact that 
this consisted o f 3 individual epitopes tp4, tp5, and tp6. The conserved HLA A2 
restricted CTL epitope tr29 is contained with tp5 and tp6, and it is possible that the adults 
focused their responses on the CTL epitope within these peptides. CD4 and CDS T cell 
depletion studies were not performed as part o f this study, but I do know that this peptide 
pool can elicit both CD4 and CDS T cell responses, even in the same donor. A future 
study might address whether adults and children do indeed focus on different conserved 
regions within TRAP, and whether adults preferentially select conserved CTL epitope 
regions. The focus o f T cell reactivity towards conserved T cell epitope regions within 
TRAP found in this study was completely different to CS, where the immunodominant T 
cell epitopes are all concentrated in polymorphic regions within the carboxy terminus o f 
the antigen (reviewed in Chapter 1). This might suggest that TRAP is a more suitable 
vaccine candidate than CS, since conserved regions will provide cross-strain protection.
Analyses for correlates o f  protection for T cell responses to pre-erythrocytic antigens have 
been disappointing. Two studies hinted at protection mediated by a single 
immunodominant CD4 T cell epitope region o f CS (Hoffman et a l, 1989b, Riley et a l, 
1990), and one study showed protection to a peptide determinant in LSA-1 (Luty et al, 
1999). M ost studies have focused on lymphoproliferative responses to a few peptide 
determinants, but given the evidence that the IFN-y ELISPOT might detect protective 
responses, I speculated that it might provide correlates o f protection in malaria exposed 
Kenyans. Since reactivity to TRAP was so high in Kenyans, I investigated whether IFN-y 
ELISPOT T cell responses to TRAP derived peptides correlated with protection for the 
217 Kenyan donors assayed in 1998. IFN-y ELISPOT responses probably detect recent 
memory / effector memory T cells (Chapter 3) and I predicted that a protective effect 
beyond 6 months was highly unlikely. Thus, the 204 donors who were followed up
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adequately were analysed for correlates o f protection over 2 months, and 6 months, in 
addition to time to first parasitaemia.
The analysis assessed for the presence o f a significant protective effect by any o f the 10 
individual TRAP conditions; total response across all 10 wells (total SFU); and whether 
having any ELISPOT response to TRAP compared to none at all was protective. 
Unfortunately, none o f the analyses showed a protective effect for TRAP specific IFN-y 
ELISPOT T cell responses. The possible reason(s) for this lack o f protection are 
numerous. The IFN-y ELISPOT assay may not measure T cell responses that are 
protective against malaria. There is evidence from vaccine trials that malaria specific T cell 
responses measured by ex-vivo ELISPOT responses wane after one month (Lalvani et a l, 
1999), and in this study cultured ELISPOT responses were shown to be more durable. 
Perhaps cultured responses are more important in protective immunity than the overnight 
unstimulated ex-vivo responses. Indeed, a study o f  naturally exposed Gabonese children 
showed that cultured (day 6) IFN-y production to peptides derived from the liver stage 
antigen (LSA-1) were associated with significantly delayed first reinfections and 
significantly lower rates o f reinfection in those children admitted with mild malaria (Luty et 
a l, 1999), and this is the only human study linking IFN-y production with protection at 
the pre-erythrocytic stage in naturally exposed donors. The ex-vivo ELISPOT responses 
may be too short lived to have found a significant protective effect in the study in this 
chapter. However, if  a protective effect did exist it might have manifested in a delay in time 
to first parasitaemia in the younger age groups.
The pow er for detecting a protective effect for TRAP responses in this study was 
determined retrospectively, since I did not know at the onset o f  the trial how many donors 
would respond, and what proportions would respond in the different age groups. For the 
individual peptide analysis estimates in the region o f 25% power have been made, and thus 
increasing the number o f  donors might have improved the chances o f  seeing protection. 
None o f  the results stand out as being close to protective, and in certain cases the trend 
went in the ‘w rong’ direction eg the presence o f a tp l4  or tp47 response decreased time to
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first parasitaemia. In these latter cases, increasing the number o f donors and power would 
have been insufficient to demonstrate protection.
I may not have chosen the optimal end points for the analysis. For example, it is possible 
that parasitaemias >104/pl were not the best cut o ff to analyse for, and that a value o f 
>103/p l might have been better. Alternatively, the analysis may have shown protection if 
analysis was for the first 6 weeks, rather than 10 weeks, o f follow up. Further analyses 
may show a protective effect, although the p-value o f such an effect would have to be 
highly significant for it to be convincing, since the multiple analyses performed thus far 
increase the likelihood o f a false positive result. Further studies would then be required to  
confirm any significant protective effect found on re-analysis o f this data. Another 
possibility that could explain the lack o f protection is that TRAP specific T cell responses 
are not protective in humans. This seems unlikely given that TRAP has such an im portant 
functional role at the pre-erythrocytic stage o f  infection, including sporozoite motility and 
hepatocyte invasion (Müller et a l, 1993, Sultan et a l, 1997) (reviewed in Chapter 1). 
Moreover, high levels o f  protection against subsequent malaria challenge can be achieved in 
mice immunised with constructs expressing the whole o f TRAP (Schneider et a l, 1998).
The development o f pre-erythrocytic immunity to malaria is far from understood, and is 
likely to be a complex response to multiple B cell and T cell (CD4 and CDS) epitopes to 
multiple antigens. The data in this chapter provides some insights into the nature o f the 
development o f  pre-erythrocytic immunity, and further illustrates the complexity o f T cell 
immunity at this stage o f infection. A child o f 2 months o f  age was capable o f mounting an 
IFN-y T cell response to TRAP, and by one year o f age the levels o f reactivity were 
comparable to those seen in adults, both in terms o f absolute numbers o f responders and 
precursor frequency levels achieved. Differences in T cell repertoire between adults and 
children were observed, and further investigation o f this may provide an insight into w hy 
adults, but not children, enjoy a state o f partial immunity. The fact that a protective effect 
was not observed for IFN-y ELISPOT T cell responses to TRAP in this study does not
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mean T cell responses to this antigen are not protective. This assay still warrants further 
analysis for protective correlates, as do T cell responses to TRAP.
197
6.5
APPENDIX
Sum m ary o f  A ll E L ISPO T  R esponses in C ross-Sectional B leed
I FN- y  ELISPOT R e s p o n s e s  TRAP Pept ides by Age  for Donors  Ngl  - Ng217
DONOR AGE t p 4 - 6 t p 2 3 t p 3 0 - 1 t p 3 7 - 8 t p 4 0 t p 4 3 t p 4 7 PP D
TTgT p <  0 .0 5
p < 0 .01Ng2  2 m
Ng3 4 m
Ng 4  5 m
Ng5  5 m 
Ng 6  7 m
Ng 7  9 m NT
Ng8 NT
Ng9  
N g 1 0
Ng 1 2
l= # lNg1 3 
Ng 1 4
Ng 1 7
N g 1 8 NT
N g 2 0 W
N g 2 2
TTg23
NT
N g 3 6 NT
N g 4 4 N T
N g 4 7 NT
Positive responses are indicated by filled in squares. A positive score was allocated according to the 
statistical table in Methods (Section 2.16.1)
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Responses to tp TRAP Peptides by Age continued:
DONOR AGE t p 2 t p 4 - 6 t p 1 4 t p 2 3 t p 3 0 -1 t p 3 7 - a t p 4 0 t p 4 3 tp47 t p 51 PP D
N g 4 8 4 NT'
N g 4 9 4 NT
N g 5 0 4 NT
Ng 5 1 4
Ng.52 4
N g 5 3 4 NT
N g 5 4 4 NT
N g 5 5 4 N T
N g 5 6 4 NT
N g 5 7 4
N g 5 8 4
N g 5 9 4 NT
N g 6 0 4
Ng 6 1 4 NT
N g 6 2 4
N g 6 3 4
N g 6 4 4 N T
N g 6 5 4 N T
N g 6 6 4
N g 6 7 4
N g 6 8 4
N g 6 9 4
N g 7 0 4
Ng 7 1 4
N g 72 5 NT
N g 7 3 5 NT
N g 7 4 5 NT
NS75 5 NT
N g 7 6 6
N g 7 7 5
Ng78 5N g 7 9 5
N g 8 0 5 N T
Ng 8 1 5 NT
—DLS.82 5 NT
N g 8 3 5
N g 8 4 6 I
N g 8 5 6
N g 8 6 6 ________
HN g 8 7 6
N g 8 8 6 I
HN g 8 9 6
N g 9 0 6
Ng 9 1 6CMo>O)
z 6
I N g 9 3  I 6 I I
Positive responses are indicated by filled  in squares. A positive score was allocated according to the 
statistical table in Methods (Section 2.16.1)
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R esponses to tp TRAP Peptides by Age continued:
DONOR AGE PPDt p 4 - 6 t p 2 3 t p 3 0 - 1 t p 3 7 - 8 t p 4 0 t p 4 3 t p 4 7 t p 5 1
N g 9 4
N g 9 5
N TN g 9 8  
N g 99  
\lg 1 0 0
NT
02
03
0 4
N g l  05
Ng NT
2 5 NT
2 7 NT
2 8
Ng1  3 0
3 4
HZ
Ng1 3 6
N g 1 3 7 NT
N g 1 42
Positive responses are indicated by filled  in squares. A positive score was allocated according to the 
statistical table in Methods (Section 2.16.1)
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Responses to tp TRAP Peptides by Age continued:
DONOR AGE t P 2 t p 4 - 6 t p l  4 t p 2 3 t p 3 0 - 1t p 3 7 - 8 t p 4 0 t p 4 3 t p 4 7 t p 5 1 PPD
N g 1 4 3 i 0
Ng1 4 4 1 0
Ng 1 4 5 i 0
Ng1  4 6 1 0
Ng1  4 7 1 0
Ng 1 4 8 1 0
N g 1 4 9 1 0
N g l  5 0 1 0
N g l  51 1 0 NT
N g 1 5 2 1 0
N g 1 53 1 0
N g 1 5 4 1 0
_____
■
N g 1 55 1 0 □
Ng 1 56 1 0 ■
Ng J  5 7 1 0 ■
Ng1 58 1 1
N g 1 59 1 1 NT
N g 1 6 0 1 1 $ 5 ^
N g l  61 1 1 NT
N g 1 62 1 2
N g 1 63 1 2 NT
N g 1 64 1 2
Ng 1 6 5 1 2 8880
Ng1  66 1 2 NT
N g 1 6 7 1 2
Ng1 6 8 1 2
N g 1 6 9 1 3 NT
N g l  70 1 3
Ng 1 71 1 4
Ng1  7 2 1 4
N g 1 7 3 1 4 NT
N g l  7 4 1 4
Ng 1 7 5 1 4 NT
Positive responses are indicated by filled  in squares. A positive score was allocated according to the 
statistical table in Methods (Section 2.16.1)
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R esponses to tp TRAP Peptides in Adults:
DONOR AGE t p 2  
N g 1 7 6  1 5 ___
PPDt p 4 - 6 t p 1 4 t p 2 3 t p 3 0 - 1 t p 3 7 - 8 t p 4 0 t p 4 3 t p 4 7 t p 5 1
EfI p < 0 .0 5
p <  0 .01N g 1 77
Ng 1  7 8
N g 1 7 9
Ng 1 80  
Ng1 81 NTT
N g 1 82  
Ng 1 83  
N g l  8 4 N T
Ng1 95  3 0 
N g 1 9 6  3 1  
N g 1 9 7  3 2 
Ng1 9 8  3 3 
N g l 9 9  3 5
N g 2 0 0  3 5 
N g 2 0 1  3 7  
N g 2 0 2  3 8 
N g 2 0 3  4 2 
N g 2 0 4  5 0
mimmi
i ^ i
I M i l
N g 2 0 5  5 0
N g 2 0 6
5 2
N g 2 1 3 6 2 
N g 2 14  6 3
NT
N g 2 1  5
N g 2 1 6 6 7
N g 2 1 7 | 81
Positive responses are indicated by filled  in squares. A positive score was allocated according to the 
statistical table in Methods (Section 2.16.1)
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CHAPTER 7
CONCLUDING REMARKS
Throughout this thesis I have attempted to further elucidate the nature o f naturally 
acquired T cell immunity at the pre-erythrocytic stage o f malaria infection. The main 
purpose o f this goal is to use the information to optimise the design o f  pre-erythrocytic 
stage malaria vaccines. Immunisation o f animals and humans with irradiated sporozoites 
induces sterile heterologous protection against malaria challenge (Nussenzweig et ah, 1969, 
Clyde et a l, 1973, Clyde et âl., 1975, Rieckmann et al., 1979), and the hope is that this 
protective effect can be mimicked by developing vaccines that stimulate anti-sporozoite 
and anti-liver stage immunity. The effect o f irradiated sporozoites is likely to be mediated 
by responses to hundreds or thousands o f  T and B cell epitopes, however if  a handful o f  
protective T cell epitopes can be identified in key pre-erythrocytic antigens, then boosting 
T cell responses to artificially high levels might provide protection.
7.1 
Insights Into Malaria T Cell Non-Responsiveness
One unusual factor o f  pre-erythrocytic stage T cell immune responses in naturally exposed 
healthy donors is the widespread nonresponsiveness to malaria antigens and epitopes 
(Good et a /.,4988d, Riley et a l, 1988b, Doolan et al., 1993, Doolan et al.t 1994, Plebanski 
et a l, 1997a). This is observed in adults as well as children, despite the former having been 
repeatedly and continuously exposed to malaria throughout life. Such nonresponsiveness is 
malaria specific, since T cell responses to recall antigens such as PPD are generally 
preserved, apart from during episodes o f  acute malaria infection (Ho et a i, 1986). Indeed, 
the immunosuppression observed during malaria infection seems to be a separate entity 
from the generalised malaria nonresponsiveness seen in healthy donors (Ho et a l, 1988, 
Theander et a l, 1986, Riley et a l, 1988a, Chemtai and Okelo, 1989, Hviid et a l, 1991b, 
Hviid et a l, 1991a). A  variety o f immunological mechanisms have been proposed to cause 
this phenom enon including T cell tolerance induction in the neonate (Pombo et a l, 1988),
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peripheral T cell anergy, ‘original antigenic sin* (Good et al., 1993), and the induction of 
immunosuppressive activated T cells (Riley et ah, 1989, Mshana et ah, 1990, Theander et 
a l,  1993).
7.1.1
Use o f 3 T Cell Assays
The studies upon which these broad conclusions of T cell nonresponsiveness are based 
employed the lymphoproliferation assay when assessing for CD4 T cell reactivity (Good 
et a l, 1988d, Riley et a l, 1988b, Doolan et a l, 1994). Few of the studies of pre- 
erythrocytic antigens assessed for the release of cytokines in parallel to 
lymphoproliferation, but when they have the results have been contradictory. Thus, Riley 
and colleagues found no correlation between IFN-y release (by ELISA) and proliferative 
responses to CS protein in Gambian children (Riley et a l, 1990). By contrast, Doolan and 
colleagues found a positive correlation between IFN-y production (by ELISA) and 
proliferation in a study of CD4 T cell responses to CS protein" in adults from Papua New 
Guinea (Doolan et a l, 1994).
The ELISPOT assay is a relatively new tool, and is a rapid and simple way to assess for 
IFN-y responses to multiple epitopes in the field. It has never been used in field studies of 
natural T cell immunity, and I wondered whether it would detect the same responses as 
lymphoproliferation assays. Another T cell assay was also developed for my study 
whereby cells were first re-stimulated in vivo with pools of peptides, and then tested by 
an overnight ELISPOT assay for IFN-y release (cultured ELISPOT). T cell responses to 8 
peptides spanning the main T cell epitope regions of CS protein were assessed by all 3 
assays (proliferation, ex-vivo ELISPOT, cultured ELISPOT) in adult Gambians. 
Surprisingly, none of the 3 assays correlated suggesting that the 3 assays detect different T 
cell subsets. The simultaneous use of 3 assays markedly increased the T cell reactivity 
level compared to that detectable by one assay alone. Therefore, one reason for the T cell 
nonresponsiveness observed by many groups may be that many reactive memory T cells 
are missed by using one T cell assay alone.
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7.1.2
Different Memory T Cell Subsets
I proceeded to confirm that, as expected, the ex-vivo ELISPOT and proliferative assays 
were mediated by CD45RO+RA" memory T cells. I also found that CD45RB"1" cells play a 
significant role in mediating ex-vivo ELISPOT responses. I further demonstrated that ex- 
vivo ELISPOT responses were mediated by a putative CCR7" effector memory (TEM) T 
cell population, whereas cultured ELISPOT responses were generated by a CCR7+ central 
memory (TCM) T cell population, indicating that the two IFN-y assays detect the different 
memory T cell subsets first proposed by Sallusto and colleagues (Sallusto et a i, 1999).
Depletion from PBMC of cells expressing the T cell activation marker CD38 (Malavasi et 
a l, 1994) led to a significant increase in lymphoproliferative responses to the recall antigen 
PPD in many donors tested. This effect was more marked the lower the starting 
proliferative response, and was not apparent if the initial PBMC proliferative response 
was high. This suggested that CD38+ cells actively suppress lymphoproliferation in an 
antigen specific manner in certain donors. I went on to demonstrate that CD4+38+ T cells 
can actively suppress the proliferation of CD4+38" T cells to PPD and the gluten derived 
coeliac allergen GIQ; and CD38+ PBMC can inhibit responses of 38" PBMC to PPD, TT 
and GUI. The inhibitory effect required cell-cell contact since it did not occur when the 
inhibitory cells were added across transwells. Thus, the release of the classic inhibitory 
mediators EL-10 and TGFP could not explain the inhibitory effect of these CD38+ T cells. 
These findings are in agreement with those of Read and colleagues in the murine model who 
identified an CD38+CD45RB,0WCD4+ T cell subset which inhibits proliferation of CD38" 
CD4+ T cells by a mechanism requiring cell-cell contact (Read et a l9 1998). I demonstrated 
for a malaria exposed donor that proliferative responses to an immunodominant Th2R 
malaria CD4 T cell epitope were enhanced by CD38+ cell depletion of PBMC. Thus, 
CD38+ T cells may be inhibitory in malaria, and may play a role in malaria specific T cell 
nonresponsiveness. This will need to be explored in future studies.
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7.2
Significance of Antigenic Polymorphism
African P. falciparum is estimated to have arisen from a single ancestral strain some 25-60 
thousand years ago (Rich et a l, 1998), and throughout this time has developed numerous 
mechanisms for evading the host immune response. The immune selection pressure caused 
by the malaria parasite is enormous considering that it is responsible for maintaining a 
variety of harmful genetic disorders (sickle, thalassaemia, G6PD deficiency) because the 
heterozygous state is protective against malaria (Allison, 1954, Flint et al, 1986, Ruwende 
et ai, 1995). Indeed, it also has a profound influence on the maintenance of MHC 
polymorphism in Africans (Hill et al, 1991, Hill et a l, 1992b, Hill et al, 1992a).
7 .2 .1
Lack o f Cross-Recognition
CS protein was the first pre-erythrocytic antigen to be discovered, and there was initially 
great optimism that it might be an ideal vaccine candidate. One caveat is that the main T 
cell epitope regions are highly polymorphic (de la Cruz et a l, 1988b, Good et al, 1988c, 
Good et al, 1988d, de Groot et al, 1989), and there was evidence that there is limited 
cross-recognition of polymorphic variants in naturally exposed populations (de la Cruz et 
al, 1988a, de la Cruz et a l, 1989, Udhayakumar et a l, 1994, Zevering et a l, 1994). I have 
demonstrated in a study of Gambian adults that there is indeed limited cross-recognition of 
the naturally occurring variants of the immunodominant epitope Th2R of CS protein.
7 .2 .2
Altered Peptide Ligand Antagonism
The phenomenon of altered peptide ligand antagonism (APL) is a recognised 
immunoevasion strategy employed by the HIV (Klenerman et a l, 1994) and hepatitis B 
(Bertoletti et a l, 1994) viruses, and more recently recognised for a CTL epitope region 
within CS protein of malaria (Gilbert et a l, 1998). I found that APL also operates for a 
CD4 T cell epitope region within the Th2R immunodominant domain of CS protein. This 
is the first demonstration of APL for naturally occurring CD4 T cell epitope variants for
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any infectious pathogen. The mechanism involved the switching of a single CD4 T cell 
clone from production of the protective cytokine IFN-y induced by one variant, to the 
immunosuppressive cytokine EL-10 induced by the antagonist. This is therefore another 
means by which malaria immunosuppression might arise, and helps explain how variant 
parasites escape host immune responses. The effect is not only at the effector T cell stage, 
since the dual presentation of APL variants at the time of T cell priming can prevent the 
generation of memory T cells altogether, and thus generate functionally naïve hosts 
(Plebanski et al, 1997b, Plebanski et al, 1999). This therefore represents a form of 
tolerance induction / anergy, although the mechanism is quite distinct.
7 .3
TRAP as a Vaccine Candidate
The use of circumsporozoite protein as a vaccine Candidate is therefore fraught with 
problems, mainly in relation to it’s extensive polymorphism in immunodominant T cell 
epitope regions. One way to overcome this problem is to use only conserved epitopes 
within CS protein, however few have been identified (Nardin et al, 1989, Aidoo et al, 
1995, Chatteijee et a l, 1995). It is thus felt that alternative less polymorphic pre- 
erythrocytic vaccine candidates should be sought. TRAP is one such alternative, although 
no CD4 T cell epitopes had been identified for TRAP, and the nature of natural T cell 
immunity to TRAP was not known. I therefore carried out a detailed analysis of T cell 
responses to TRAP in naturally exposed Africans, in order to assess it’s potential as a pre- 
erythrocytic vaccine candidate.
7 .3 .1
CD4 T Cell Epitopes
I first screened Gambian and Kenyan adults for the presence of CD4+ T cell epitope 
regions within TRAP, and was surprised to find that they were distributed along the entire 
length of the molecule, with no obvious regions of immunodominance. Moreover, 65% of 
Kenyan adults responded to one or more epitope within TRAP, although reactivity in The 
Gambia was somewhat lower at 32%. The fact that TRAP stimulated responses to
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peptides along it’s entire length in multiple naturally exposed donors supports the use of 
the whole antigen in a vaccine construct.
7 .3 .2
Variant Cross-Recognition
TRAP is regarded as less polymorphic that CS protein, however numerous non 
conservative point mutations do arise along the length of the antigen (Robson et al, 1990, 
Robson et a l, 1998). The effect that these have on T cell immune recognition was not 
known. I therefore assessed for cross-recognition for a number of naturally occurring 
variants of commonly recognised TRAP T cell epitopes in Kenyan adults. Disappoint­
ingly, there was no more cross-recognition than was observed to polymorphic variants of 
CS protein and thus single strain vaccination will not provide heterologous protection for 
polymorphic epitope regions. However, I identified 16 T cell epitopes within TRAP that 
are conserved for all sequences so far typed, and there was a tendency for conserved 
regions to be the most frequently recognised in the cross-sectional analysis of 217 
Kenyans. These conserved epitopes might thus be incorporated into a multi-epitope 
vaccine which could provide cross-strain protection if these epitopes are indeed protective.
7 .3 .3
Correlates o f Protection
Few studies of pre-erythrocytic T cell immunity to malaria antigens have found correlates 
of protection. There are 2 studies hinting at a protective effect for proliferative responses 
to the immunodominant Th2R CD4 T cell epitope region of CS protein (Riley et a l, 1990, 
Hoffman et a l, 1989b), and one study that found correlates of protection for cultured IFN- 
Y responses to LSA-1 (Luty et a l, 1999).
Since EFN- y is the cytokine by which T cells mediate their protective, I assessed for the 
protective efficacy of IFN-y TRAP responses assessed by ex-vivo ELISPOT assay in 217 
Kenyan donors. This is the, first study using the IFN-y ex-vivo ELISPOT assay to assess 
for correlates of protection, but unfortunately no protection was found. Donors were
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analysed for a protective association for time to first parasitaemia, and number of episodes 
of parasitaemia over 2 and 6 months. The reasons for a lack of protection include the 
possibilities that CD4 T cell responses to TRAP are not protective, that ex-vivo ELISPOT 
responses are not protective, or that I asked the wrong questions or failed to assess enough 
donors. All these issues are discussed in the previous chapter, and will need to be 
addressed in future studies.
Since I now know that ex-vivo ELISPOT, cultured ELISPOT and proliferation assays 
detect different memory T cell subsets, then the former 2 assays both need to be analysed 
carefully for correlates of protection. Proliferative responses to TRAP have also yet to be 
analysed for protective efficacy in malaria exposed donors. Perhaps the combined 
responses to different T cell assays will be more likely to correlate with protection, since it 
will give an overall picture of reactivity to the immunogens being assessed. Thus, future 
field studies for protection might consider using all 3 T cell assays.
7 .3 .4
East vs West Africans
One problem in the development of T cell inducing malaria vaccines is that different 
populations exhibit widely varying HLA types, particularly in Africa (Hill et a l, 1992a). 
All T cell responses are HLA restricted to a greater or lesser extent, and therefore any 
vaccine construct must contain sufficient epitopes to cover the broad range of HLA types 
in the population(s) to be vaccinated. I investigated what effect disparity in HLA types 
might have on the nature of T cell responses to TRAP, by performing similar studies in 2 
African populations, The Gambia in West Africa and Kenya in East Africa. I found that 
the repertoire of T cell responses for the 2 populations was different. Repertoire 
differences between East and West Africans were also observed to both CS protein and the 
blood stage antigen MSP-1 (Lee et a l, 2000), suggesting that HLA differences may well 
have influenced the T cell repertoire to these malaria antigens.
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The number of donors reacting to TRAP varied between the 2 countries being higher in the 
Kenyan study (62% reactivity) carried out in a region of higher malaria transmission 
compared to The Gambian response rate (32% reactivity). Interestingly, the reactivity rate 
to CS was comparable between the 2 populations, suggesting that CS protein might be 
susceptible to certain negative regulatory influences that do not affect TRAP responses. If 
it is true that TRAP responses are less easily suppressed in vivo this would be another 
good reason to use TRAP in malaria vaccines. The magnitude of response in terms of T cell 
precursor frequency levels were comparable between East and West Africa to all antigens 
tested, but were low as is typical for malaria T cell responses. It therefore seems that when 
responses were stimulated they were of a similar magnitude.
7 .3 . 5
Adults vs Children
The repertoire differences observed above between 2 populations may not simply be 
explained by differing HLA types since subgroups within the same Kenyan population 
(adults and children) also gave a different repertoire of T cell responses, despite being of 
the same ethnic group and HLA distribution. The fact a child as young as 2 months of age 
had a T cell responses to TRAP in my study is encouraging since these potentially 
protective responses might be susceptible to boosting by vaccination. Indeed, by one year 
of age the rate of T cell reactivity to TRAP derived peptides was comparable to that 
observed in adults. Interestingly, the only group that had significantly lower precursor 
frequency levels was the under one year olds, and thereafter levels were comparable across 
all age groups. This suggested that a pre-erythrocytic vaccine might be suitable for very 
young children, which is encouraging since they are the main target population for malaria 
vaccination.
7 . 3 . 6
Th2 T Cell Responses
Few studies have comprehensively assessed Th2 T cell reactivity to pre-erythrocytic 
antigens. EL-4 and IL-10 ELISPOT assays were thus used to assess for Th2 type T cell
2 1 0
responses to TRAP derived peptides in Gambians and Kenyans. No IL-10 reactivity was 
observed in the Gambians, but more than 60% of Kenyan adults produced EL-10 to pools 
of peptides spanning the whole of TRAP. This needs to be borne in mind for vaccines 
incorporating the whole of the TRAP antigen, since EL-10 is an immunosuppressive 
cytokine and may dampen protective responses at the liver stage of infection (I^ e Moine et 
al, 1999).
I could find no evidence that TRAP variant epitopes might use the same APL evasion 
strategy demonstrated for CS protein (ie differential induction of IFN-y and EL-10 by 
variants of the same region). If TRAP is not susceptible to APL, this could be one reason 
why CS protein specific T cell reactivity rates were lower than TRAP reactivity in Kenya. 
This will need to be investigated further since APL antagonism can occur by means other 
than IL-10 induction, including the differential secretion of EL-4 (Evavold and Allen, 1991). 
Indeed, EL-4 reactivity levels of 33% were observed to TRAP peptide pools in Kenyans. 
A 17% reactivity to the same TRAP peptide pools was observed in Gambians by ex-vivo 
EL-4 ELISPOT, although the donor numbers were too small to draw any firm comparative 
conclusions. The high levels of EL-10 reactivity to TRAP observed in the Kenyan study 
may be a reflection of the fact that the blood samples were obtained during a period of 
peak malaria transmission. Indeed, high levels of IL-10 induction has been documented in 
malaria infected children and adults in Gabon (Winkler et al, 1998, Winkler et al, 1999).
7 .4
Final Comments
Throughout this thesis I have studied T cell responses to two major pre-erythrocytic 
vaccine candidates, namely circumsporozoite (CS) protein and thrombospondin related 
adhesive protein (TRAP). I have identified a number of mechanisms that might explain the 
well recognised phenomenon of T cell nonresponsiveness in naturally exposed donors, 
which relate to CS protein in particular. I have carried out detailed studies of natural T cell 
immunity to TRAP, both in Kenya and The Gambia, and taken the opportunity to 
compare T cell responses to this antigen both between (Kenya vs Gambia) and within
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(adults vs children) populations. I looked for correlates of protection between ex-vzvo IFN- 
Y ELISPOT responses to TRAP and the subsequent development of malaria, but could find 
no protective effect. My findings illustrate the complexity of pre-erythrocytic stage T cell 
immunity in naturally exposed donors, and demonstrate that we still have a considerable 
way to go before we fully understand the nature of T cell immunity to this highly complex 
disease.
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